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Genomes of all organisms are continuously damaged by numerous 
exogenous and endogenous sources leading to different kinds of DNA lesions, 
which if not repaired efficiently may trigger wide-scale genomic instability, a hallmark 
of cancer development. To overcome this, cells have evolved a sophisticated 
sensory network called the DNA damage response (DDR) comprised of a large 
number of distinct protein complexes categorized as sensor, mediator, transducer 
and effector proteins that amplify the DNA damage signal and activate cell cycle 
checkpoint to initiate DNA repair or trigger apoptosis where the defect is beyond 
repair. This intricate signaling pathway is tightly regulated by modulating DDR 
factors recruitment, retention and dissociation from the sites of DNA damage in a 
spatiotemporal manner mediated by numerous reversible post-translational 
modification (PTMs) including phosphorylation, ubiquitination, SUMOylation, 
methylation, acetylation, poly(ADP-ribosyl)ation, and Neddylation. In this study, I 
examined the role of phosphorylation and ubiquitination in regulating the DDR 
signaling at the DNA damage sites.  
 DNA double-strand breaks triggers a phosphorylation-mediated signaling at 
the damage sites leading to histone ubiquitination in Lys63-linked manner that 
recruits BRCA1-A complex to the damage sites. The A complex is comprised of 
BRCA1, Rap80, NBA1, BRE, BRCC36 and the adaptor protein Abraxas, which has 
	 viii	
been shown previously to constitutively interact with BRCA1-BRCT (BRCA1 C-
terminal) domain through its C-terminal phosphorylated S406 residue. In this study, 
we found that DNA damage-induced Abraxas phosphorylation at neighboring S404 
residue induces stable BRCA1 dimerization through its BRCT domain. Both crystal 
structure and in vivo analysis confirmed that phosphorylation at Abraxas S404 
residue is essential for stable BRCA1-BRCT dimer formation and mutation in the 
S404 residue leads to impaired accumulation of BRCA1 to damaged chromatin. In 
addition, we found two germline mutations in the BRCA1-BRCT dimerization 
interface disrupt stable dimer formation both in vitro and in vivo.  
 Although phosphorylation has been shown to be the major PTM at the DSB 
sites, over the last decade, ubiquitination has also emerged as a key regulatory 
player in the DDR. Irradiation (IR)-induced DNA damage catalyzes Lys63-linked 
polyubiquitination of histones, H2A and H2A.X that leads to accumulation of BRCA1-
A complex to DSBs. In my second study, we sought to determine whether non-
lys63-linked ubiquitination also exists at the DSBs regulating the DDR pathway. My 
findings indicate that along with Lys63-linked ubiquitination, chromatin-bound 
proteins are also modified with Lys11-linked polyubiquitination at DNA damage sites 
in an ATM-dependent manner by Ube2S/Ube2C E2 conjugating and RNF8 E3 ligase 
enzymes and deubiquitinated by OTUD7B (Cezanne) enzyme. I further showed that 
histones H2A and H2A.X is modified with Lys11-linked polyubiquitination in a DNA 
damage-dependent manner that is essential for inhibiting transcriptional silencing at 
proximity to DSB sites to maintain genomic stability. Overall, my findings provide 
insights into how post-translational modifications regulate DDR factors dynamics at 
DSB sites and play a crucial role in maintaining genomic integrity.  
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CHAPTER 1 
OVERVIEW OF THE DNA DAMAGE RESPONSE 
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1.1 Introduction: 
 The genomic integrity of all organisms is continually threatened by DNA 
damage. The human genome regularly encounters and repairs a large number of 
DNA damage lesions, estimated at 104 to 105 lesions per cell per day (1, 2).  
Exogenous exposure to carcinogens, ionizing radiation (IR), or the ultraviolet light 
from the sun can all damage DNA. Additionally, many cellular processes generate 
endogenous sources of DNA damage. Reactive oxygen and nitrogen species 
generated during cellular metabolism, misincorporation of dNTPs during DNA 
replication, cytosine deamination, DNA alkylation, and abortive topoisomerase 
activities all generate DNA lesions that must be repaired faithfully (2-5). Unrepaired 
DNA can physically interfere with fundamental cellular processes such as replication 
and transcription. Moreover, improper repair of these lesions can lead to gene 
mutations, deletions, or translocations that, in turn, either inactivate tumor 
suppressor genes or activate oncogenes. Together, these events trigger wide-scale 
genomic instability, a characteristic hallmark of cancer development (6-8)  
 To combat the DNA lesions and maintain genome integrity, cells have 
evolved highly orchestrated sensory signaling cascades collectively called the DNA 
damage response (DDR) (Figure 1). The DDR senses DNA damage and initiates 
DNA repair. Distinct protein complexes categorized as sensors, mediators, 
transducers and effectors amplify the DNA damage signal, activate cell cycle 
checkpoints, and initiate repair or trigger apoptosis should the defect be irreparable  
	 3	
 Figure 1: Organization of cellular DNA damage response pathway. Cellular 
response to DNA damage from different sources involves sensing the damage 
signal, amplifying and transducing the signal to mediator proteins that regulate 
spatio-temporal organization of effector proteins to exert appropriate response 
that involves activation of a cell cycle checkpoint, transcriptional regulation, 
execution of DNA repair or induction of apoptosis in case of severe DNA 
damage. 
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(2, 4, 9). Recruitment, retention and dissociation of DDR factors to and from the sites 
of DNA damage are tightly regulated in a time-dependent manner to maintain 
cellular homeostasis. This is mainly mediated by numerous reversible post-
translational modifications (PTMs) (10-13).  
1.2 DNA repair pathways in mammalian cells 
 To counteract DNA damage, cells have developed lesion-specific repair 
mechanisms. In mammalian cells, these constitute 4 major repair pathways: base 
excision repair (BER), nucleotide excision repair (NER), mismatch repair (MMR) and 
double-strand break repair pathways (Figure 2) (1). In this thesis, I examine the 
complexity of DNA damage response signaling involved in irradiation (IR)-induced 
DNA double-strand breaks (DSBs) and how post-translational modifications play an 
essential role in regulating the DDR signaling.  
DNA double-strand breaks are one of the most cytotoxic lesions experienced 
by cells. If not properly repaired in a timely manner, DSBs may lead to a 
chromosomal deletion or translocation, triggering genomic instability and 
predisposing a cell to tumorigenesis (4, 5). Mammalian cells utilize two major repair 
pathways for DSB repair – non-homologous end joining (NHEJ) and homologous 
recombination (HR). In higher order vertebrates, NHEJ is the prevalent repair 
pathway choice. NHEJ operates throughout the cell cycle and is known to be 
inherently “error-prone”. Conversely, HR predominantly occurs during S and G2 
phases of the cell cycle as it requires the presence of the sister chromatid that is 
used as a homologous template for repair of the damaged DNA and is considered 
as an “error- free” repair pathway (14). 
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Figure 2: Types of DNA damage and DNA repair mechanisms. The 
figure illustrates sources of endogenous and exogenous DNA damages 
and relevant repair pathways repair the damaged DNA.  
 
Figure is adapted and modified with permission from (1) Cedric Blanpain, 
Mary Mohrin, Panagiota A Sotiropoulou, and Emmanuelle Passegue, DNA-
Damage Response in Tissue-Specific and Cancer Stem Cells. Cell Stem 
Cell 2011 8, 16-29 2011. License number 4092160106928. 
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1.3 Spatiotemporal dynamics of DDR factors at DNA damage sites: 
 One of the most notable features of the DNA damage response is the 
assembly and disassembly of chromatin regulators and DDR factors at damaged 
chromatin. This dynamic activity can be visualized by immunofluorescence as 
distinct nuclear ‘foci’ using antibodies. Although the focal accumulation of DDR 
proteins at damaged sites amplifies the damage signal, the functional significance of 
these foci in the DDR pathway still remains unknown (10). It is important to note that 
not all DDR factors assemble and dissociate from the damaged chromatin at the 
same time. Rather, the assembly and disassembly of DDR factors occur in a 
hierarchical fashion in a time-dependent manner. For example, while accumulation 
of NHEJ repair proteins at DSB sites is rapid but transient, HR proteins show 
delayed but persistent retention at damage sites, illustrating the different repair 
kinetics of these two major repair pathways (15). This careful spatiotemporal 
regulation of DDR factors at damaged chromatin is in large mediated by numerous 
reversible post-translational modifications (PTMs). PTMs not only promote the 
recruitment and dissociation of DDR factors, but also regulate their residence time at 
damage sites. In DSB repair, the role of phosphorylation in initiating the DDR 
signaling cascade has been described in much detail. However, recent years have 
witnessed the characterization of an unprecedented number of post-translational 
modifications at the sites of DNA damage including ubiquitination, SUMOylation, 
Neddylation, methylation, acetylation, and poly(ADP-ribosyl)ation (10). These 
findings depict more complex picture of the DNA damage response pathway at DSB 
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sites. In addition, findings of cross talk between these different modifications 
illustrate the intricacy of PTM signaling in the DDR (12, 16, 17)  
1.4 Activation of DNA damage response following DNA double-strand breaks 
 Activation of DDR signaling and the efficiency of DNA repair is largely 
dependent on chromosomal contexts, such as whether chromatin has an open or 
compacted structure at the sites of DNA damage. At densely packed chromatin 
regions, repair of damaged DNA is more difficult and takes a longer time to 
complete. Several DDR kinases play an essential role in altering chromatin structure 
to render damaged chromatin accessible to repair factors. In mammalian cells, 
members of the phosphatidylinositol-3-kinase-like kinase family (PIKKs) – ATM, 
ATR, and DNA-pkcs – act as the furthermost upstream kinases that transduce and 
amplify the DNA damage signal.  ATM and ATR appear to be the major kinases that 
phosphorylate hundreds of substrates preferentially at S/TQ (serine/threonine-
glutamine) sites to activate cell cycle checkpoints, chromatin remodeling, and initiate 
DNA repair (18). Although both ATM and ATR kinases share significant structural 
and functional similarity and have overlapping substrate proteins involved in the 
DNA damage response pathway, the activation of these two kinases requires 
different stimuli (19). While ATM is primarily activated in response to DNA double-
strand breaks, ATR is activated to a broad spectrum of DNA damaging signals 
including lesions generated by UV, cross-linking agents, and replication stress, in 
addition to DSBs. Recent genome wide analysis reveals that ATM and ATR function 
as master signal transducers in the DDR pathway, coordinating a large cellular 
signaling network to maintain genomic integrity. 
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 ATM is activated immediately after DSBs by the sensor protein complex, 
Mre11-Rad50-Nbs1 (MRN) (20-27). Following activation by MRN, ATM triggers DDR 
signaling by phosphorylating hundreds of downstream proteins (18, 28). One of the 
early events following ATM activation is the phosphorylation of histone variant 
H2A.X by ATM at Ser139 residue. The DSB-induced phosphorylation of H2A.X 
occurs immediately after DNA damage and spreads over megabases of chromatin 
flanking the damage site in both directions. H2A.X phosphorylation can be detected 
in cells as discrete “foci” following DSB induction by irradiation (IR) (29-31). 
Phosphorylated H2A.X (γH2A.X) directly recruits the mediator protein, MDC1 
(mediator of DNA damage checkpoint 1), which recognizes and binds 
phosphorylated H2A.X through its BRCT domain. MDC1 also forms IR-induced foci 
(IRIF) that extensively co-localizes with γH2A.X (32-34). Interestingly, MDC1 also 
interacts with ATM through its FHA domain. ATM-MDC1 interaction targets activated 
ATM to DSB flanking chromatin regions, thereby propagating ATM-mediated H2A.X 
and MDC1 phosphorylation at damaged chromatin to amplify the damage signal. In 
addition, MDC1 has been shown to regulate damage-induced cell cycle arrest 
checkpoint (35, 36).  
 γH2A.X-MDC1 acts a molecular platform that orchestrates the recruitment of 
additional DDR factors to the sites of DNA damage in a hierarchical manner (Figure 
3). Phosphorylated MDC1 binds and targets E3 ubiquitin ligase RNF8 to damage 
sites. RNF8 contains an FHA domain at its N-terminus and RING domain at its C-
terminus. RNF8 interacts with ATM-phosphorylated MDC1 via its FHA domain. 
Interestingly, RNF8 localization to damage sites is independent of its RING domain 
	 9	
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Phosphorylation-dependent ubiquitin signaling at DSB sites. DNA 
double-strand breaks induces a ATM-mediated phosphorylation-dependent 
ubiquitin signaling at DSB sites. Ubc13-RNF8-RNF168 enzymatic machinery 
catalyzes Lys63-linked ubiquitin chain that targets 53BP1 and BRCA1-A complex at 
damage sites to initiate repair. 
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but requires the FHA domain, indicating that a phosphorylation-dependent 
interaction with MDC1 is crucial for RNF8 accumulation to DSBs (37-39). RNF8 
recruitment to damaged chromatin is consistent with earlier observations of ubiquitin 
conjugation at IRIF. In addition to MDC1 binding, the RNF8 FHA domain also 
interacts with another E3 ligase, HERC2, forming an MDC1-RNF8-HERC2 complex. 
This complex facilitates RNF8 interaction with the E2 ubiquitin conjugating enzyme, 
Ubc13, to catalyze Lys63-linked ubiquitination at damaged chromatin (40). The 
RNF8-Ubc13 enzymatic machinery ubiquitinates chromatin-bound proteins, 
including histone H2A and H2A.X, with non-proteolytic Lys63-linked ubiquitin chains 
in a DNA damage-dependent manner. This ubiquitination triggers the recruitment of 
downstream DDR factors recruitment including 53BP1 and components of BRCA1-A 
complex to damaged chromatin. In addition, RNF8 depletion has been shown to 
result in G2/M checkpoint arrest and hypersensitivity to IR-induced DNA damage, 
indicating that RNF8-dependent ubiquitination at DNA damage sites is essential for 
cells to cope with DNA double-strand breaks (37-39, 41). Later studies 
demonstrated that RNF8-mediated Lys63-linked ubiquitin conjugates are recognized 
by MIU (42) domains of another E3 ligase, RNF168, triggering its accumulation at 
DSB sites. RNF168, in association with the Ubc13 E2 conjugating enzyme, then 
amplifies the Lys63-linked ubiquitin chain on histone H2A and H2A.X, along with 
other unidentified substrates. Lys63-linked ubiquitin chains on histone and other 
chromatin-bound proteins are also recognized by the Ubiquitin Interacting Motif 
(UIM) of Rap80, which subsequently mediates accumulation of 53BP1 and 
components of BRCA1-A complex to sites of DNA damage (43-45). Recruitment of 
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BRCA1 and 53BP1 at DNA damage sites regulates the balance and repair pathway 
choice between HR and NHEJ at the damage sites. More recently, the Mailand 
group has shown that H1-type linker histones, but not core histones, serve as the 
major substrate for Ubc13-RNF8-mediated Lys63-linked ubiquitination and that 
RNF168 recognizes Lys63 ubiquitinated histone H1 at damaged chromatin, 
emphasizing the essential role of Ubc13 and RNF8 in recruiting RNF168 to DSBs 
(46).  
1.5 Role of BRCA1-A complex in DSB repair 
 BRCA1-A complex, named after the adaptor protein Abraxas, consists of five 
different proteins: Rap80, Abraxas, NBA1, BRE, and BRCC36 (47-54). Abraxas 
mediates the interaction between BRCA1 and the other components of the A 
complex. The Abraxas-BRCA1 interaction is essential for Abraxas’s role in DNA 
repair and maintenance of genome stability (55). Our lab and others have previously 
shown that Abraxas interacts with BRCA1 through its C-terminal pSPTF motif, in 
which phosphorylated Ser406 (S406) binds to BRCA1 C-terminal (BRCT) domain. 
Deletion of the pSPTF motif or mutation of the S406 residue disrupts both Abraxas-
BRCA1 interaction and BRCA1 localization to DNA damage sites, thereby impairing 
efficient DNA repair (47, 49, 51). Abraxas knockout mice generated by our lab 
exhibit chromosomal instability and increased incidence of tumor development. 
Interestingly, a mutation in the phenylalanine residue of the Abraxas pSPTF motif 
(F409C) has been identified in human tumors (55), suggesting the importance of 
Abraxas-BRCA1 interaction in tumor suppression. Yet, it still remains unknown how 
Abraxas mediates BRCA1’s tumor suppression function. Of note, Abraxas S406 is 
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constitutively phosphorylated in presence and absence of DNA damage (47). 
Therefore, it is tempting to speculate that there may be an additional regulatory 
mechanism that modulates Abraxas-BRCA1 interaction upon DNA damage.  
1.6 Non Lys63-linked ubiquitination at DSB sites  
 Although Lys63-linked ubiquitination at damaged chromatin have been 
extensively studied, emerging evidence from different groups indicate that the 
ubiquitin landscape at DSB sites is much more complicated than previously 
anticipated and that additional linkage-specific ubiquitin chains (such as Lys6, 
Lys48, or Lys27-linked chains) exist at damaged chromatin. For instance, RNF168 
has recently been shown to catalyze Lys27-linked ubiquitination at DSB sites that is 
essential for the proper activation of DDR signaling and regulates the recruitment of 
53BP1, Rap80 and other DDR factors (56). In addition, RNF8 has been shown to 
interact with different E2 conjugating enzymes to catalyze different linkage-specific 
ubiquitin chain types. For example, recent findings have demonstrated that RNF8 
can catalyze both Lys63 and Lys48-linked ubiquitin chains by interacting with Ubc13 
and UbcH8 E2 enzymes, respectively (37-39, 57, 58). These findings depict that 
additional linkage-specific ubiquitin chain types exist at DSB sites to regulate 
efficient DDR signaling. Further study of different lysine residue-linked ubiquitination 
will therefore provide deeper understanding of the DDR signaling. 
1.7 Transcription silencing in response to DSBs 
 Given DNA damage occurs in the context of chromatin structure, it potentially 
interferes with transcription and therefore coordination between DNA repair and 
transcription machinery is crucial for genomic stability. This coordination involves 
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chromatin organization by chromatin modulators, histone chaperones, and DDR 
factors that induce transcriptional silencing in response to DNA damage (59). DNA 
damage-induced transcriptional silencing was initially identified in human fibroblast 
cells where RNA synthesis is significantly depressed in a rapid and transient manner 
following UV-induced DNA damage (60). Following studies have shown that UV-
irradiation induces local transcriptional silencing in damaged nuclei and recovery of 
transcription is dependent on nucleotide excision repair (NER) (60, 61). Interestingly, 
RNA synthesis is also inhibited at IR-induced DSB sites marked with γH2A.X foci 
(62). These findings were further confirmed by the Friedl group, who demonstrated 
that the repressive H3K27me3 mark is enriched at γH2A.X-marked DSB sites with 
concomitant exclusion of H3K4me3, which is associated with active transcription 
(63). Moreover, along with these repressive chromatin marks, several 
heterochromatin components (such as kap-1, HP1, suv39h1, and Polycomb group 
(PcG) that are known to be associated with transcription repression are enriched at 
DSBs (64, 65).  Findings from the Elledge group suggest that PARP-dependent 
chromatin remodeling also plays an integral role in transcriptional silencing at DSB 
sites (66). However, the mechanistic detail of how the transcriptional silencing is 
achieved in the vicinity of DSBs is still poorly understood. Using a reporter-based 
assay system, a recent study has shown that transcription at the damaged sites is 
inhibited in an ATM-dependent manner. ATM kinase plays an essential role in 
inhibiting transcription elongation-dependent chromatin decompaction. In addition, 
their findings indicate that ATM-dependent transcriptional silencing at damaged 
chromatin is associated with RNF8 and RNF168 activity in a manner independent of 
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Lys63-linked ubiquitination (67). However, whether additional linkage-specific 
ubiquitin conjugation exists at DSB sites that play an essential role in inducing 
transcriptional silencing still remains unknown. Further research is needed to provide 
meaningful insights into ubiquitin-dependent transcriptional silencing at DNA 
damage sites. 
1.8 Objective:  
 PTMs have emerged as key regulatory players in DDR signaling, In this 
thesis, I sought to explore two different PTMs, phosphorylation and ubiquitination, in 
the DDR pathway.  In my first study, I examined how DNA damage-induced 
phosphorylation of Abraxas protein induces stable dimerization of the tumor 
suppressor protein, BRCA1, essential for efficient recruitment of BRCA1 to damaged 
chromatin. This study gleans structural and functional insights into how Abraxas-
BRCA1 interaction is modulated in response to DNA damage in order to promote 
BRCA1 accumulation at damage sites for effective repair and maintenance of 
genomic stability. In my second study, I investigated the function of non-Lys63-linked 
ubiquitination in the DNA damage response pathway. I found that, in addition to 
Lys63-linked ubiquitination, chromatin-bound proteins are also modified by Lys11-
linked ubiquitination and that these Lys11-linked chains are essential for 
transcriptional silencing at the DNA damage sites. Findings from these studies 
provide mechanistic insights into the complexity of the DNA damage response 
signaling, deepening our understanding of how PTMs regulate the DDR pathway to 
prevent genomic instability. 
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2.1 Introduction  
 The tumor suppressor BRCA1 has emerged as the master regulator of the 
genome integrity.  Recent proteomic and genetic studies have revealed that BRCA1 
associates with large number of proteins in cells forming distinct BRCA1 complexes 
in vivo to exert its function in DNA damage repair, transcription, cell cycle regulation, 
replication as well as other signaling pathways to maintain genomic stability and 
function as a tumor suppressor (68, 69). The majority of the hereditary breast and 
ovarian cancer syndrome (HBOC) patients carry mutations in the BRCA1 gene and 
to a lesser extent in the BRCA2 gene (70). HBOC patients have a lifetime risk of 
developing breast and ovarian cancer of up to 60-80% and 20-40%, respectively 
(71). In addition to early onset of breast and ovarian cancer, HBOC patients also 
have a higher risk of developing pancreatic, fallopian tube, prostate and stomach 
cancer. More than 800 clinically relevant mutations have been identified to date in 
the BRCA1 gene indicating BRCA1 plays crucial role as a tumor suppressor to 
maintain genome integrity (72-74). BRCA1 associates with multiple repair proteins 
forming distinct subcellular complexes to exert its role as in various cellular signaling 
pathways including DNA damage repair, DNA replication, DNA end resection, 
transcription, and cell cycle regulation (75, 76). BRCA1 deficiency leads to defective 
S phase, G2-M and spindle assembly checkpoints as well as defective DNA repair 
that trigger genome instability in cells. In addition, BRCA1-associated tumors have 
shown further genetic alteration that includes loss of heterozygosity of tumor 
suppressor genes as well as activation of oncogenes (such as cyclin D1, c-Myc and 
ErbB2) (77-79). These findings collectively indicate that BRCA1 functions as a 
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master regulator in maintaining genome stability and tumor suppression. 
2.1.1 BRCA1 domain organization 
BRCA1 is a large protein of 1863 amino acids containing an N-terminal RING 
E3 ubiquitin ligase domain and two C-terminal BRCT domains (80) (Figure 4). The 
RING domain is a motif found in many E3 ubiquitin ligase enzymes and involved in 
mediating protein ubiquitination. The BRCA1 RING domain mediates stable 
association with BRCA1-associated RING domain protein 1 (BARD1) and BRCA1-
BARD1 heterodimer has been implicated in catalyzing Lys6-linked polyubiquitin 
chain that is recognized but not degraded by 26S proteasome (81-84). Although 
earlier studies indicated that BRCA1-BARD1 E3 ligase activity plays an essential 
role for BRCA1’s tumor suppressor function, a recent study using genetically 
engineered mouse model has shown that BRCA1 E3 ligase activity is not required 
for its function in homologous recombination-mediated repair and tumor suppression 
(85).  
The BRCT domains, each containing about 100 amino acid residues and 
arranged in a head-to-tail fashion, consist of three α-helices packed around four 
strands of β-sheet (86). BRCA1 BRCT domain has been characterized in regulating 
diverse biological processes by associating with multiple proteins forming distinct 
subcellular complexes. The BRCT domain directly interacts with phosphorylated 
proteins containing pSPxF (87) motif (68, 69). Using a knock-in mouse model, 
Shakya et al has recently shown that mutations in the BRCA1 BRCT domain that 
disrupt phosphoprotein recognition leads to tumorigenesis in mouse (85) 
emphasizing that BRCT interaction with pSPxF motif-containing proteins is 
	 18	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Domain organization of BRCA1. BRCA1 contains a RING 
domain at its N-terminus, a centrally located coiled-coil domain and two 
BRCT domains at its C-terminus. 
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essential for BRCA1’s tumor suppressor function. Many tumor-derived clinically 
relevant mutations have been identified in the BRCA1 BRCT domain. While some of 
these mutations have been shown to destabilize the BRCT structure or interfere with 
its binding to the pSPxF motif-containing proteins leading to cancer predisposition, 
the function of a large number of BRCT domain mutations still remains to be 
determined. To date, three pSPxF motif containing proteins, Abraxas, BACH1, and 
CtIP, have been shown to directly interact with BRCA1 BRCT domain forming three 
mutually exclusive protein complexes with specific functions, designated as A, B, 
and C, respectively named after the main adaptor protein in these complexes (68). 
Although how these three complexes transmit BRCA1 signal has been largely 
unknown, it appears that BRCA1 involvement in these complexes plays a major role 
in its tumor suppressor function.  
2.1.2 BRCA1-A complex 
 BRCA1-A complex consists of five different proteins: Rap80, Abraxas also 
known as CCDC98), NBA1 (also known as MERIT40), BRE (also known as 
BRCC45) and BRCC36 (47-54). Abraxas interacts with BRCA1 BRCT domain 
through its C-terminal pSPTF motif (p-S406) and thereby mediating BRCA1 
interaction with the A complex.  It is important to note that Abraxas does not only 
interact with BRCA1 but also bridges interaction with other members in the A 
complex. Therefore, Abraxas appears to serve as a central adaptor protein in the A 
complex.  
 As described in chapter 1, DNA damage induces ATM-dependent signaling 
cascade at the damaged chromatin. One of the earliest events in the DDR activation 
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is phosphorylation of histone H2A.X (γH2A.X) by ATM kinase. This leads to 
phosphorylation-dependent downstream signaling cascade that culminates with 
ubiquitination of histone H2A and H2A.X in Lys63-linked manner by Ubc13 
conjugating enzyme and RNF8/RNF168 E3 ubiquitin ligases (37-39, 41, 43, 45). The 
Lys63-linked polyubiquitin chain is recognized by the Ubiquitin Interacting Motif 
(UIM) of Rap80 that interacts with Abraxas and subsequently, the BRCA1-A 
complex is localized to the damaged sites. It is important to note that NBA1 and BRE 
interaction is essential for the integrity of the A complex (88). In addition, BRCC36 in 
the BRCA1-A complex contains catalytically active MPN+/JAMM domain, a domain 
found in zinc metalloprotease deubiquitinating enzymes (DUBs) (89) and cleaves 
Lys63-linked polyubiquitin chain at DSB sites (90, 91). Importantly, the BRCA1-A 
complex shares significant similarity with the lid of the 19S proteasome regulatory 
complex, which cleaves the polyubiquitin chain of substrates and facilitates entry into 
the proteasome core for proteolytic degradation (53). Since BRCC36 has 
deubiquitinating activity only towards Lys63-linked polyubiquitin chain, it appears 
that the BRCA1-A complex assembly at the DNA damage sites serves as a DUB 
complex to facilitate DUB activity of BRCC36 (53).  
2.1.3 Abraxas-BRCA1 interaction is essential for tumor suppression and 
maintaining genome stability 
 Mass-spec-based analysis from our lab and others identified Abraxas as a 
BRCA1- BRCT interacting protein. Abraxas co-localizes with BRCA1 and is essential 
for BRCA1 recruitment to IR-induced DSB sites. Both in vitro and in vivo biochemical 
analysis confirmed that Abraxas interacts with BRCA1 BRCT domain through its C-
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terminal pS406PTF motif in which Ser406 phosphorylation is essential for BRCT-
Abraxas interaction. Deletion or S406A mutation in the motif impairs BRCA1 
interaction with Abraxas resulting defective BRCA1 localization to IR-induced DSB 
sites. Abraxas deficient cells showed hypersensitivity to IR and UV-induced DNA 
damages. Moreover, in consistent with BRCA1’s function in homologous 
recombination (HR)-mediated DNA repair and cell cycle regulation, Abraxas 
deficient cells also showed defects in HR repair and G2-M checkpoint (47, 49). 
Because Abraxas interacts with BRCA1 and this interaction is essential for BRCA1’s 
function in maintaining genome stability, our lab has generated Abraxas knockout 
mouse to examine whether Abraxas functions as a tumor suppressor in vivo. We 
found that Abraxas knockout mice exhibit chromosomal instability and increased 
tumor incidence developing lymphomas and tumors of other origins. Furthermore, 
bioinformatics analysis of human tumors from TCGA and COSMIC databases 
revealed Abraxas gene expression is lost/reduced in multiple types of cancers 
including breast and ovarian cancer. Along with copy number loss or reduced 
expression, this analysis identified somatic mutations of Abraxas in endometrial, 
lung, colon, liver, kidney and leukemia (Figure 5). Of note, among 26 mutations 
found in Abraxas gene, six mutations were found to generate C-terminal pSPTF 
motif truncated products that cannot bind to BRCA1 protein highlighting the 
importance of this motif in interacting with BRCA1. Collectively, these findings 
suggest that Abraxas is a bona fide tumor suppressor and highlight the importance 
of Abraxas-BRCA1 interaction in DNA repair and maintaining genome stability (55). 
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 reduced life span exhibiting decreased disease-free survival
(Figure 6A). Pathologic analysis of the tissue slides from the
end-stage mice revealed a clear increase in the tumor incidence
in Abraxas+/! and Abraxas!/!mice. From the mice we analyzed,
over 60% of Abraxas!/! nullizygous and Abraxas+/! heterozy-
gous mice developed cancer including lymphoma and other
types of tumors (Figure 6B). Although tumors were detected
in some Abraxas+/! or Abraxas!/! mice as early as 8 months
of age, the mean age of Abraxas!/! and Abraxas+/! mice that
developed tumor was 17 and 24 months, respectively. Tumors
developed in Abraxas+/! and Abraxas!/! mice were primarily
lymphoma and a few cases of solid tumors in lung and liver (Fig-
ure 6C). Lymphoma prominently involved the spleen and lymph
nodes including the mesenteric and cervical lymph nodes (Fig-
ure S6). The majority of the lymphomas developed in Abraxas+/!
and Abraxas!/! mice were found to infiltrate various nonlym-
phoid organs, including liver, lung, kidney, and intestine (Fig-
ure 6D). The majority of the lymphomas appeared to be B cell
lymphoma indicated by B cell marker B220-positive staining in
immunohistochemistry (IHC) and B220 and immunoglobulin (Ig)
M double-positive staining in flow cytometry analysis of tumor
cells (Figure S6). To investigate whether tumor formation in
Abraxas+/! mice is attributed to haploid insufficiency, we per-
formed microdissection to isolate tumor cells and analyzed the
Abraxas genotype by PCR and Abraxas expression by western
blot. The tumor samples analyzed appeared to retain the wild-
type allele and expression of Abraxas indicating the remaining
wild-type allele is expressed (Figure S7), suggesting that hap-
loinsufficiency of Abraxas leads to tumorigenesis in mice.
Together, these data indicate that Abraxas is a tumor suppressor
in mice.
Indication of Loss of Abraxas/FAM175A Function in
Human Tumors
Because knockout ofAbraxas leads to spontaneous tumordevel-
opment in mice, we investigated whether Abraxas is also critical
for tumor suppression in human. To this end, we analyzed the
Abraxas expression level, gene copy number alteration, and
somatic mutation status in various human tumors in the TCGA
(http://cancergenome.noih.gov/) and COSMIC (Forbes et al.,
2010) database. Reduced Abraxas gene expression is observed
in multiple types of cancers (bladder, breast, cervical, head and
neck, renal papillary, endometrial, and thyroid) compared to
those from autologous normal tissues (Figure 7A). Gene copy
number loss of the Abraxas locus at chromosome 4q21 is
frequently found in ovarian, breast (especially basal subtype),
lung, and colon cancers, which involves the loss of whole chro-
mosome 4q arm (Figure 7B; Table S1). In addition, copy loss of
Abraxas correlated well with reduced Abraxas expression in
ovarian and breast cancer (Figure 7C), suggesting loss of gene
copy number is one of the major mechanisms to downregulate
Abraxas expression in these tumors. Furthermore, somaticmuta-
tions of Abraxas are found in endometrial, colon, lung, liver, kid-
ney cancers, and in leukemia (Tables S1 and S2) with the highest
mutation rate found in endometrial cancer (2.5%). Despite the
low mutation frequency, the distribution of mutation sites in the
Abraxas gene displays a remarkable pattern indicative of tar-
geted inactivation by human tumors. Among all 26 nonsynony-
mous mutations found in Abraxas, five nonsense mutations and
one frameshift insertion were found to generate truncated or
abnormal protein products that lack the pSPxF motif and inca-
pable of binding to the BRCA1 protein. Structural and biochem-
ical analysis of BRCA1 BRCT domains bound to optimized
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Figure 6. Abraxas+/! and Abraxas!/! Mice
Exhibit an Increased Susceptibility to Tumor
Formation
(A) Disease-free survival analyzed by the Kaplan-
Meier method (p < 0.0001). Amatched cohort of 33
Abra1+/+, 45 Abra1+/!, and 31 Abra1!/!mice were
monitored over 30 months for spontaneous tumor
development.
(B) Spontaneous tumor incidence in Abraxas+/+,
Abraxas+/!, and Abraxas!/! mice. From the mice
we analyzed, one out of six Abraxas+/+mice (17%),
14 out of 21 Abraxas+/!mice (67%), and seven out
of 11 Abraxas!/! mice (64%) developed tumor.
(C) Summary of the spontaneous tumor spec-
trum. Pathologic analysis revealed that one
Abraxas+/+mouse developed tumor that is most
likely histocytic sarcoma; among 14 Abraxas+/!
mice that developed tumor, two mice developed
both lymphoma and liver tumor, one mouse
developed lung adenocarcinoma, liver tumor, and
lymphoma, and one mouse developed histocytic
sarcoma; seven Abraxas!/! mice developed
lymphoma.
(D) Lymphoma in spleen, lymph node, and
lymphoid infiltrates to nonlymphoid organs.
Representative histological images (H&E staining)
of detected tumors are shown.
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lines. Untreated Abraxas!/! MEFs showed a nearly 3-fold in-
crease of spontaneous single chromatid breaks compared to
wild-type cell lines (Figures 5A and 5B), suggesting an intrinsic
defect in genome stability in Abraxas!/! cells. When treated
with 2Gy IR, braxas!/! cells displayed amore severe deficiency
in maintaining genome stability. IR-treated Abraxas!/!MEFs ex-
hibited a significant increase in the percentage of cells containing
chromosomal abnormalities compared to WT cells. In addition,
whereas chromosomal aberrations in WT cells are mostly single
breaks and very rarely fusions and radial structures, IR-treated
Abraxas!/! MEFs manifested multiple breaks per metaphase
as well as significant incr ases in chr mosomal fusion ev nts
and radial structures (Figures 5C and 5D). Thus, loss of Abraxas
results in the accumulation of both spontaneous and IR-induced
chromos mal defects. In a dition, DAPI staining f Abraxas!/!
MEFs displayed an increased incidence of abnormal nuclear
morphology in Abraxas!/! cells compared to WT. Nuclear frag-
mentation and micronuclei were more frequently observed in
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Figure 5. Abraxas-BRCA1 Interaction Is
Critical for Maintaining Genomic Stability
(A and B) Abraxas!/! cells displayed increased
spontaneous DNA breaks. Primary Abraxas+/+
MEF cells were used in the metaphase spread
analysis for spontaneous DNA breaks. Represen-
tative image and the percentage of cells containing
at least one DNA break are shown. Quantified data
are based on >300 metaphases per sample from
three replicate analyses.
(C and D) Abraxas!/! cells displayed increased
severity of chromosomal aberrations, consisting of
multiple DNA breaks, fusions, and radial struc-
tures, in response to IR. Metaphase spread anal-
ysis was carried out with primary early passage
Abraxas+/+ and Abraxas!/!MEF cells treated with
2 Gy IR. Percentage of normal and abnormal
metaphase was quantitated. Normal metaphase
contains no breaks. Abnormal metaphase con-
tains a single break, more than two breaks, a
fusion, a radial structure, or a combination of
breaks and fusion/radial structures (complex). The
percentage of ach ty of abnormal metaphase
was also calculated. Quantified data are based
on >40 metaphases per sample. Error bars
represent SD.
(E) Mutants of Abraxas failed to rescue g no e
instability of the Abraxas!/!MEF cells. Metaphase
spread analysis was carried out in immortalized
Abr xas!/! MEFs complemented with empty
vector, wild-type or mutants of Abraxas 4 hr after
treated with 2 Gy IR. Metaphases consisting
‘‘single break,’’ ‘‘multiple breaks (>1),’’ or ‘‘other’’
(chro osomal aberratio s of fusion/radial, or a
combination of breaks and fusion/radial structure)
were quantified. Quantified data are based on >40
metaphase per sample.
Abraxas-deficient cells, which also sug-
gest elevated levels of chromosomal
breaks and defects (Figure S5).
We then tested whether the interaction
of Abraxas and BRCA1 is important for
Abraxas tomaintain genome stability (Figure 5E). The IR-induced
chromosome aberrations in Abraxas-null cell were greatly
reducedwhen the null cells were complemented with expression
of WT Abraxas but not with the S404A mutant that is defective in
int racting with BRCA1. In addition, mutants that disrupt the
formation of the BRCA1-A complex also failed to reduce the
chromosome aberrations asmuch as theWT Abraxas. Together,
these result indicate that t e interaction f Abraxas with
BRCA1, as well as the formation of the BRCA1-A complex, is
critical for Abraxas’ function in maintaining genome stability.
Abraxas Suppresses Tumor Dev lopment in Mice
Because Abraxas interacts with BRCA1 and is critical for main-
taining genome stability, we examined whether Abraxas plays
a tumor suppressor role in mice. We monitored survival and
tumor development in a cohort of Abraxas+/+, Abraxas+/!, and
Abraxas!/! mice during organismal aging. Compared to WT
mice, Abraxas+/! and Abraxas!/! mice had a significantly
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lines. Untreated Abraxas!/! MEFs showed a nearly 3-fold in-
crease of spontaneous single chromatid breaks compared to
wild-type cell lines (Figures 5A and 5B), suggesting an intrinsic
defect in genome stab lity in Abraxas!/! cells. When treated
with 2Gy IR,Abraxas!/! cells displayed amore severe deficiency
in maintaining genome stability. IR-treated Abraxas!/!MEFs ex-
hibited a significant increase in the percentage of cells containing
chromosomal abnormalities compared to WT cells. In addition,
whereas chromosomal aberrations in WT cells are mostly single
breaks and very rarely fusions and radial structures, IR-treated
Abraxas!/! MEFs manifested multiple breaks per metaphase
as well as significant increases in chromosomal fusion events
and radial structures (Figures 5C and 5D). Thus, loss of Abraxas
results in the accumulation of both spontaneous and IR-induced
chromosomal defects. In addition, DAPI staining of Abraxas!/!
MEFs isplayed an increased incidence f ab ormal nuclear
orphology in Abrax s!/! cells compared to WT. Nuclear frag-
mentation and micro uclei were more frequ tly observed in
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Figure 5. Abraxas-BRCA1 Interaction Is
Critical for Maintaining Genomic Stability
(A and B) Abraxas!/! cells displayed increased
spontaneous DNA breaks. Primary Abraxas+/+
MEF cells were used in the metaphase spread
analysis for spontaneous DNA breaks. Represen-
tative image and the percentage of cells containing
at least one DNA break are shown. Quantified data
are based on >300 metaphases per sample from
three replicate analyses.
(C and D) Abraxas!/! cells displayed increased
severity of chromosomal aberrations, consisting of
multiple DNA breaks, fusions, and radial struc-
tures, in response to IR. Metaphase spread anal-
ysis was carried out with primary early passage
Abraxas+/+ and Abraxas!/!MEF cells treated with
2 Gy IR. Percentage of normal and abnormal
metaphase was quantitated. Normal metaphase
contains no breaks. Abnormal metaphase con-
tains a single break, more than two breaks, a
fusion, a radial structure, or a combination of
breaks and fusion/radial structures (complex). The
percentage of each type of abnormal metaphase
was also calculated. Quantified data are based
on >40 metaphases per sample. Error bars
represent SD.
(E) Mutants of Abraxas failed to rescue genome
instability of the Abraxas!/!MEF cells. Metaphase
spread analysis was carried out in immortalized
Abraxas!/! MEFs complemented with empty
vector, wild-type or mutants of Abraxas 4 hr after
treated with 2 Gy IR. Metaphases consisting
‘‘single break,’’ ‘‘multiple breaks (>1),’’ or ‘‘other’’
(chromoso al aberrations of fusion/radial, or a
combination of breaks and fusion/radial structure)
were quantified. Quantified data are based on >40
metaphases per sample.
Abraxas-deficient cells, which also sug-
gest levated levels of chromosomal
breaks and defects (Figure S5).
We then tested whether the interaction
of Abraxas and BRCA1 is important for
Abraxas tomaintain genome stability (Figure 5E). The IR-induced
chromosome aberrations in Abraxas-null cell were greatly
reducedwhen the null cells were complemented with expression
of WT Abraxas but not with the S404A mutant that is defective in
interacting with BRCA1. In addition, mutants that disrupt the
formation of the BRCA1-A complex also failed to reduce the
chromosome aberrations asmuch as theWT Abraxas. Together,
these results indicate that the interaction of Abraxas with
BRCA1, as well as the formation of the BRCA1-A complex, is
critical for Abraxas’ function in maintaining genome stability.
Abraxas Suppresses Tumor Development in Mice
Because Abraxas interacts with BRCA1 and is critical for main-
taining genome stability, we examined whether Abraxas plays
a tumor suppressor role in mice. We monitored survival and
tumor development in a cohort of Abraxas+/+, Abraxas+/!, and
A r !/! mi during organismal aging. Compared to WT
mice, Abraxas+/! and Abraxas!/! mice had a significantly
812 Cell Reports 8, 807–817, August 7, 2014 ª2014 The Authors
phosphopeptides has revealed that the phenylalanine residue in
the pSPxFmotif is essential for the recognition of thismotif by the
BRCT domains (Rodriguez et al., 2003; Shi zaki et l., 2004; Wil-
liams et al., 2004). The finding of an amino acid mutation of
phenylalanine (F409C) in the pSPxF motif located at the very C
terminus of Abraxas in one endometrial tumor also highlights
the importance of Abraxas binding to BRCA1. Notably, th
same R252* nonsense mutation within the coiled-coil domain
was found twice in two endometrial tumor samples. Another
seven mutations were found inside the MPN domain, which is a
domain critical for the formation of the BRCA1-A ompl x. In
addition, seven missense mutations were gathered around a
small region including a bipartite nuclear localization signal
(NLS) (Table S2). A germline mutation of Abraxas (R361Q) in
familiar breast cancer patients in this region was previously re-
ported to disrupt nuclear localization of Abraxas (Solyom et al.,
2012). Taken together, our cancer genomics data analyses
str ngly argue that Abraxas is a bona fide tumor suppressor
gene in human a d Abrax s-BRCA1 int raction is likely to be
important for the role of Abraxas in tumor suppression.
DISCUSSION
Abraxas interacts with BRCA1 and is required for accumulation
of BRCA1 to DNA damage sites playing important roles in the
DNA damage response (Kim et l., 2007; Liu et al., 2007; Wang
et al., 2007). In vivo study of this gene is necessary to further
understand its role in DNA repair and tumor suppression. In addi-
ion, assessing the clinical relevance of this gene in human can-
cer patients will pr vide invaluable insights to the function of
this gene in tumor suppression. In this study, we demonstrate
Abraxas is essential for DNA repair and tumor suppression in vivo
in mouse. In addition, reduced expression, gene copy loss, and
mutation of Abraxas are also observed in multiple types of
human tumor including breast and ovarian canc r.
Analysis from a number of mous models for BRCA1 inactiva-
tion has indicated that BRCA1 is essential for embryonic devel-
opment and conditional inactivation of BRCA1 in mammary
and ovarian tissues predisposes to tumor (Dine and Deng,
2013). Abraxas-null mice are viable and born at expected Men-
delian ratios, indicating that Abraxas gene, unlike BRCA1, is
not essential for embryonic development and thus is not likely
to play a major role in BRCA1’s function in embryonic develop-
ment. Imp rtantly, Abraxas is essential for tumor suppre sion.
Both Abraxas-null and heterozygous mice are tumor prone
with over 60% tumor incidence developing lymphomas and
other tumors. The tumor-suppressing function of Abraxas is
likely due to it role in DNA r pair. Ability to efficiently repair
damaged DNA is crucial for cells to maintain chromosomal sta-
bility and prevention of cancer. Our study showed that Abraxas
not only is involved in the IR-induced double-strand break repair,
but also plays a role in the crosslink repair. As a result, compared
to WT cells, Abraxas!/! ells displayed increased spontaneous
breaks and IR-induced chromosome aberrations including mul-
tiple breaks, fusions, and radial structures. In addition, lack
of Abraxas in mice results in hypersensitivity of mice to IR and
MEF cells o DNA-damaging agents such as IR, MMC, and
PARPi. Repair of DNA crosslinking lesions require Fanconi
Figure 7. Compromise of Abraxas Function in Human Cancers
by Reduced Gene Expression, Copy Number Loss, and Somatic
Mutation
(A) Downregulation of AbraxasmRNA expression in multiple tumors. Box plots
of logged RNaseq RSEM were made for multiple cancers. BLCA, bladder;
BRCA, breast; CESC, cervical; HNSC, head and neck; KIRC, renal clear cell;
KIRP, renal papillary; LIHC, liver; LUAD, lung adenocarcinoma; LUSC, lung
squamous carcinoma; PRAD, prostate; THCA, thyroid; UCEC, endometrial
cancer.
(B) Copy number loss of Abraxas/FAM175A locus (4q21) in ovarian cancer and
basal breast cancer, but not in luminal A breast cancer. Cumulative gene copy
number alterations were drawn from SNP6 data to show frequency of gene
copy number changes on each chromosome. Pink/green, copy number gains/
losses; the red line marks the position of Abraxas gene on chromosome 4
(chr4).
(C) Correlation of reduced Abraxas expression level with copy number loss in
breast and ovarian cancer.
(D) A graphical summary of nonsilent somatic mutations of Abraxas gene
identified in human tumors. Each triangle represents a mutation identified from
an individual tumor.
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Figure 5: Abraxas is required for tumor suppression nd geno  st bility. 
A. Abraxas -/+ and Abrax s -/- mi e exhibit increased incidence of tumor 
susceptibility. B. Abraxas -/- MEFs (right) exhibit increased spontaneous breaks 
compared to Abraxas +/+ MEFS (left). C. R duced Abraxas RNA expression 
in multiple tumors. D. Copy number loss of Abrax s in ovarian and basal bre st 
cancer but not in luminal breast cancer. 
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2.1.4 Role of Abraxas phosphorylation in regulating Abraxas-BRCA1 
interaction 
Abraxas pSPxF motif at the C-terminus contains phosphorylated S406 
residue that mediates interaction with BRCA1 and mutation in this residue (S406A) 
abrogates this interaction. Interestingly Abraxas S406 is constitutively 
phosphorylated even in absence of DNA damage. This raises the question of “how 
BRCA1 BRCT-Abraxas interaction is regulated in presence of DNA damage?” To 
address this, we analyzed the C-terminal sequence of Abraxas adjacent to the 
pS406PTF motif. Sequence analysis of the Abraxas C-terminal revealed that an 
additional Ser residue (S404) located adjacent to S406 in the pSPxF motif. Given 
the close proximity of this Ser404 residue to Ser406 in the pSPxF motif, we reason 
that this residue may regulate BRCA1 BRCT-Abraxas interaction. Mass-spec 
analysis of BRCA1-BRCT domain showed that double-phosphorylated Abraxas 
peptide containing phosphorylated S404 and S406 (pS404pS406) bound to BRCT 
and was enriched significantly upon IR-induced DNA damage, while the singly 
phosphorylated pS406 containing peptide bound to BRCT domain but was not 
enriched after IR (47). These findings indicate that while constitutive S406 
phosphorylation is required for interaction with BRCA1, S404 phosphorylation may 
have some additional functional significance in regulating interaction with Abraxas. 
To gain further insights into Abraxas-BRCA1 interaction our lab generated an 
antibody that can specifically recognize doubly phosphorylated S404S406. The 
pS404pS406 specific antibody can detect Abraxas in control cells but not in Abraxas 
KO HEK293T cells. The double phosphorylation of Abraxas is abrogated in cells 
	 25	
 
Figure 6: IR-induced Abraxas phosphorylation at S404 and S406 is ATM 
dependent A. Abraxas domain organization and C-terminal sequence 
containing phosphorylated S404 and S406 residues indicated as P. B. 
Double phosphorylation at S404 and S406 residues in response to IR in 
parental and Abraxas KO 293T cells. Cells were lysed 1 hour post-IR and 
analyzed by doubly phosphorylated S404S406 antibody. C. IR-induced 
Abraxas double phosphorylation is abolished in Abraxas S406A, S404A and 
S404AS406A double mutants. D. DNA damage-induced phosphorylation of 
Abraxas occurs immediate after IR. Western blot analysis was performed at 
indicated time-points with pS404pS406 antibody and pS406 antibody. . E. 
IR-induced Abraxas phosphorylation occurs in a dose-dependent manner. 
Results were obtained by Dan Su, Ph.D., Wang Lab. 
 
the hydrophobic interface, and the two domains are further
linked by extra helix aL (Figures 2A and 2E). The pSPTF motif
from Abraxas binds to the BRCT domains in a similar two-anchor
mode using pS406 and F409. Residues P407 and T408 do not
makemajor interactions with the BRCT domains. The phosphate
group of Abraxas S406 interacts with the side chains of BRCT
K1702 andS1655, aswell as themain chain of G1656 (Figure 2B).
The sid chai of F409 in Abraxas inserts into the BRCT hydro-
phobic pocket created by L1701, F1704, N1774, M1775, and
L1839 (Figure 2C). As F409 is the terminal residue for Abraxas,
an extra salt bridge is present between the main chain carboxyl
group of F409 with the BRCT domain residue R1699 (Figure 2D).
This extra interaction was seen in previous structures using tet-
rapeptides pSPTF (Campbell et al., 2010).
A notable difference between BRCT-Ab2p and BRCT-Ab1p_
short structure is the conformation of the Y403S404R405 region
(Figures 2E–2G). Extra electron density corresponding to the
phosphate group of pS404 and the side chain of Y403 is
observed only in BRCT-Ab2p. Unlike pS406, the pS404 phos-
phate group is oriented away from the BRCT domains into the
solvent region, thus avoiding contact with G1656, L1657, and
T1658 (Figure 2G). In BRCT-Ab2p, the Y403 side chain is posi-
tioned to interact through a hydrophobic interaction with BRCT
P1659 at the N terminus of BRCT1 a1. The extra interaction
could explain the increased proximity of a1 toward the N termi-
nus of the Abraxas phosphopeptide in BRCT-Ab2p compared to
BRCT-Ab1p_short (Figure S3A). Superimposition of all available
BRCA1 BRCT related crystal structures also showed that a1
movement toward the phosphopeptide is most prominent in
BRCT-Ab2p (Figure S2B). It indicates that one of the roles of
pS404 is to fix the side chain of Y403, which is conserved in
higher organisms (Figure 2I), such that a trans peptide bond
can form and collision is avoided. Superimposition of the
BRCT/Abraxas structures with the BRCT/Bach1 (PDB: 1T29)
(Shiozaki et al., 2004) and BRCT/CtIP structures (PDB: 1Y98)
(Varma et al., 2005) shows similar pSPxF-motif binding. How-
ever, compared to Bach1 and CtIP, the N-terminal sequence
of Abraxas in both BRCT-Ab1p and BRCT-Ab2p structures exits
B
E
F G
C
D
A Figure 1. IR-Induced Double Phosphoryla-
tion of Abraxas C Terminus S404 and S406
Is ATM Dependent
(A) Abraxas-domain boundary and C-terminal
sequence containing a serine residue (S404) next
to the BRCA1-binding pSPxFmotif (high-lighted in
blue). The phosphorylation of S404 and S406 is
indicated as P.
(B) Double phosphorylation of S404 and S406
residues at the Abraxas C terminus in response to
IR in 293T cells and 293T/Abraxas KO cells. The
lysates from cells treatedwith 10Gy IR followed by
incubation at 37!C for 1 hr were used for western
blot with anti-pS404pS406 antibody (‘‘*’’ non-
specific band).
(C) IR-induced double phosphorylation of S404
and S406 is abolished in Abraxas mutants (S404A,
S406A, or double mutant, DM) (‘‘*’’ non-specific
band). The FLAG- and HA-tagged Abraxas WT or
mutants were expressed in 293T cells. The lysates
from cells treated with 10 Gy IR and incubated at
37!C for 1 hr were used for immunoprecipitation
with anti-FLAG beads and western blot with anti-
bodies against pS404pS406, pS406, or HA.
(D) IR-induced double phosphorylation of S404
and S406 occurs immediately after IR treatment.
The time points were taken after cells were treated
with 4 Gy IR followed by incubation at 37!C.
(E) IR-induced phosphorylation occurs in a dose-
dependent manner.
(F) ATM regulates IR-induced phosphorylation.
The cells were incubated with ATM kinase inhibitor
KU55933 (10 mM) for 2 hr before exposure to 4 Gy
IR and subsequent incubation at 37!C for 1 hr.
(G) ATR is not involved in IR-induced double
phosphorylation. The ATR inhibitor VE-821 at
indicated concentrations was used for treating
cells for 2 hr before cells were exposed to 4 Gy IR
(see also Figure S1).
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expressing S404A, S406A as well as S404AS406A double mutant (Figure 6). We 
tested Abraxas phosphorylation status using the doubly phosphorylated antibody as 
well as previously generated phosphorylated S406 antibody. As shown in Figure 6, 
while the band intensity of pS406 antibody did not change after DNA damage; using 
pS404pS406 antibody we detected Abraxas band intensity increased in a time-
dependent manner up to 1 hour post-IR followed by gradual gradually decrease to 
the basal level at later time-points. Furthermore, we found that pS404pS406 band 
intensity increased in DNA dose-dependent manner. Since phosphorylation at S406 
did not change after IR treatment, these results indicate that phosphorylation at 
S404 is likely to be IR-induced (87). 
2.1.5 DNA damage-induced ATM-dependent phosphorylation of Abraxas at 
S404 
 Since the apical kinase ATM plays a crucial role in the IR-induced DNA 
damage response pathway that recruits BRCA1 and components of the BRCA1-A 
complex at the sites of DNA damage, we tested whether Abraxas phosphorylation at 
S404 is ATM-dependent. Cells treated with ATM inhibitor KU55933 showed 
complete disruption of S404 phosphorylation indicating IR-induced Abraxas 
phosphorylation at S404 is an ATM-dependent event (Figure 7). On the other hand 
inhibiting the cells with ATR appeared to have minimal effect on the IR-induced 
phosphorylation as detected by the pS404pS406 antibody (Figure7) (87). 
2.1.6 Crystal structure of BRCA1 BRCT domains in complex with single and 
double-phosphorylated Abraxas phosphopeptides 
 To mechanistically dissect the role of S404 phosphorylation in BRCT-Abraxas 
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interaction, we solved the crystal structure of BRCA1 BRCT domain with single 
(pS406) or double (pS404pS406) phosphorylated phosphopeptide. This work was 
done in collaboration with Dr. Tom Blundell’s lab, University of Cambridge, UK by Dr. 
Qian Wu (87). The crystal structures of BRCT with both single and double 
phosphorylated Abraxas phosphopeptides were solved at 3.5 Å resolution. 
Consistent with previously solved BRCT crystal structure with BACH1 and CtIP, the 
two BRCT domains of BRCA1 (BRCT1 and BRCT2) associate in a head-to-tail 
fashion. In each domain, a four-stranded parallel β sheet is surrounded by three α 
helices. The Abraxas pSPxF motif interacts with BRCT domains in a two-anchor 
mode where S406 and F409 of the pSPxF interact with residues in the BRCT 
domains (Figure 8).  
Importantly, the crystal structure data of BRCA1 BRCT with single 
phosphorylated S4046 (termed as BRCT-Ab1p) and double phosphorylated 
S404S406 (termed as BRCT-Ab2p) revealed unique differences in the conformation 
of Y403S404R405 region, which is located adjacent to the pSPTF motif in Abraxas. 
Extra electron density corresponding to the phosphate group of phosphorylated 
S404 and the side chain of Y403 was observed in the case of BRCT-Ab2p but not in 
the case of BRCT-Ab1p (Figure 8C & D). In addition, unlike BRCT-Ab1p, in the 
BRCT-Ab2p complex, we found that the pS404 is oriented away from the BRCT 
domain into the solvent region. The change in pS404 conformation fixes the side 
chain of Y403 that generates additional interaction with BRCT K1671 residue 
forming a hydrophobic interaction at the N-terminus of BRCT α1. Additionally, the 
negative surface region formed by the phosphate group of pS404 
	 28	 
Figure 7. ATM-dependent Abraxas phosphorylation. A. ATM –dependent 
Abraxas phosphorylation. Cells were treated with ATM inhibitor KU55933 (10 
uM) for 2 hours before IR treatment. Abraxas phosphorylation is detected with 
pS404pS406 antibody. B. ATR is not involved in IR-induced Abraxas double 
phosphorylation. Cells were treated with ATR inhibitor (VE-821) for 2 hours 
before IR treatment.  pS404pS406 antibody was used to detect 
phosphorylation status of Abraxas. 
 
Results were obtained by Dan Su, Ph.D., Wang Lab. 
 
 	
the hydrophobic interface, and the two domains are further
linked by extra helix aL (Figures 2A and 2E). The pSPTF motif
from Abraxas binds to the BRCT domains in a similar two-anchor
mode using pS406 and F409. Residues P407 and T408 do not
makemajor interactions with the BRCT domains. The phosphate
group of Abraxas S406 interacts with the side chains of BRCT
K1702 andS1655, aswell as themain chain of G1656 (Figure 2B).
The side chain of F409 in Abraxas inserts into the BRCT hydro-
phobic pocket created by L1701, F1704, N1774, M1775, and
L1839 (Figure 2C). As F409 is the terminal residue for Abraxas,
an extra salt bridge is present between the main chain carboxyl
group of F409 with the BRCT domain residue R1699 (Figure 2D).
This extra interaction was seen in previous structures using tet-
rapeptides pSPTF (Campbell et al., 2010).
A notable difference between BRCT-Ab2p and BRCT-Ab1p_
short structure is the conformation of the Y403S404R405 region
(Figures 2E–2G). Extra electron density corresponding to the
phosphate group of pS404 and the side chain of Y403 is
observed only in BRCT-Ab2p. Unlike pS406, the pS404 phos-
phate group is oriented away from the BRCT domains into the
solvent region, thus avoiding contact with G1656, L1657, and
T1658 (Figure 2G). In BRCT-Ab2p, the Y403 side chain is posi-
tioned to interact through a hydrophobic interaction with BRCT
P1659 at the N terminus of BRCT1 a1. The extra interaction
could explain the increased proximity of a1 toward the N termi-
nus of the Abraxas phosphopeptide in BRCT-Ab2p compared to
BRCT-Ab1p_short (Figure S3A). Superimposition of all available
BRCA1 BRCT related crystal structures also showed that a1
movement toward the phosphopeptide is most prominent in
BRCT-Ab2p (Figure S2B). It indicates that one of the roles of
pS404 is to fix the side chain of Y403, which is conserved in
higher organisms (Figure 2I), such that a trans peptide bond
can form and collision is avoided. Superimposition of the
BRCT/Abraxas structures with the BRCT/Bach1 (PDB: 1T29)
(Shiozaki et al., 2004) and BRCT/CtIP structures (PDB: 1Y98)
(Varma et al., 2005) shows similar pSPxF-motif binding. How-
ever, compared to Bach1 and CtIP, the N-terminal sequence
of Abraxas in both BRCT-Ab1p and BRCT-Ab2p structures exits
B
E
F G
C
D
A Figure 1. IR-Induced Double Phosphoryla-
tion of Abraxas C Terminus S404 and S406
Is ATM Dependent
(A) Abraxas-domain boundary and C-terminal
sequence containing a serine residue (S404) next
to the BRCA1-binding pSPxFmotif (high-lighted in
blue). The phosphorylation of S404 and S406 is
indicated as P.
(B) Double phosphorylation of S404 and S406
residues at the Abraxas C terminus in response to
IR in 293T cells and 293T/Abraxas KO cells. The
lysates from cells treatedwith 10Gy IR followed by
incubation at 37!C for 1 hr were used for western
blot with anti-pS404pS406 antibody (‘‘*’’ non-
specific band).
(C) IR-induced double phosphorylation of S404
and S406 is abolished in Abraxas mutants (S404A,
S406A, or double mutant, DM) (‘‘*’’ non-specific
band). The FLAG- and HA-tagged Abraxas WT or
mutants were expressed in 293T cells. The lysates
from cells treated with 10 Gy IR and incubated at
37!C for 1 hr were used for immunoprecipitation
with anti-FLAG beads and western blot with anti-
bodies against pS404pS406, pS406, or HA.
(D) IR-induced double phosphorylation of S404
and S406 occurs immediately after IR treatment.
The time points were taken after cells were treated
with 4 Gy IR followed by incubation at 37!C.
(E) IR-induced phosphorylation occurs in a dose-
dependent manner.
(F) ATM regulates IR-induced phosphorylation.
The cells were incubated with ATM kinase inhibitor
KU55933 (10 mM) for 2 hr before exposure to 4 Gy
IR and subsequent incubation at 37!C for 1 hr.
(G) ATR is not involved in IR-induced double
phosphorylation. The ATR inhibitor VE-821 at
indicated concentrations was used for treating
cells for 2 hr before cells were exposed to 4 Gy IR
(see also Figure S1).
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 and side chain E402 leads to cross interaction with BRCT K1671  (Figure 8E) (87). 
Collectively, these events promote stable dimerization of the BRCT-Ab2p complex 
involving α1 and β2 of the BRCT1 domain and the Ab2p (Figure 9A). α1 of the 
BRCT1 domain form hydrophobic interaction between α1 helices (α1- α1) and 
extensive hydrogen bonding between the two antiparallel β strands (β2- β2) (Figure 
9). At the dimerization interface, we found two of the α1 helices from each BRCT1 
domain form isologous interactions burying a hydrophobic patch formed by F1662, 
M1663 and Y1666 residues with hydrophobic side chains stacking on each other 
(Figure 9B). Importantly, two of three residues (F1662 and M1663) in the BRCT 
dimerization interface were identified as BRCA1 germline mutations  (F1662S and 
M1663K) in the Breast Cancer Information Core database (92) suggesting that 
mutations in these residues may disrupt the stable dimer structure and thereby 
impairs BRCA1’s role as tumor suppressor. 
2.1.7 BRCT-Ab2p complex forms a dimer in vitro 
 BRCA1 BRCT-Abraxas dimerization was examined in vitro by size-exclusion 
chromatography in collaboration with Dr. carol Robinson’s lab at the University of 
Oxford. The gel filtration analysis obtained from BRCT-Ab1p and BRCT-Ab2p 
complexes revealed that compared to the elution peak for BRCT-Ab1p complex, 
which aligns with BRCT-Bach1 and BRCT-CtIP complexes, the peak for BRCT-Ab2p 
complex shifted to the left of the BRCT-Ab1p suggesting a larger hydrophobic radius 
and a possible higher order complex. And according to the protein size markers, the 
size of BRCT-Ab2p appeared to be roughly double to that of the BRCT-Ab1p 
complex (Figure 10A). Moreover, measuring the exact molecular weight of peak 
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Figure 8. Crystal structure of BRCT in complex with single and doubl 
phosphorylated Abraxas phosphopeptide. A. Crystal structure of BRCT-
Abraxas pS406 complex (BRCT-Ab1p). The BRCT domains are in yellow and the 
Abraxas pS406 phosphopeptide is in wheat color. B Crystal structure of BRCT-
Abraxas pS406pS404 complex (BRCT-Ab2p). The BRCT is depicted in blue and 
pS404pS406 is denoted in cyan. C & D. Interface between BRCT and Abraxas 
phosphopeptide in BRCT-Ab1p (C) and BRCT-Ab2p complexes (D). The 2Fo-Fc 
electron density (s = 1.0) is shown for Abraxas phosphopeptides. E. Interaction 
between BRCT α1 helix and Ab2p.  
Crystal structure data was collected by collaborator Dr. Tom Blundell’s group, 
University of Cambridge. 
on the opposite side, close to the a1 of BRCT1 domain (Fig-
ure 2H). Interestingly, a similar side chain arrangement was
also seen in BRCA1 BRCT bound with ‘‘optimized peptide’’
(GAAYDIpSQVFPFAKKK) (PDB: 1T2V) (Williams et al., 2004)
(Figure S3C), in which the tyrosine residue (Y) at !3 position
(phosphorylated serine in pSxxF motif as 0 position) and nega-
tively charged residues glutamic acid (E) or aspartic acid (D)
at !2 position were shown more favored for interaction with
BRCA1 BRCT domains (Manke et al., 2003; Rodriguez et al.,
2003).
Dimerization of BRCT-Abraxas Complex in Crystal
Structures
There are eight copies of BRCT-Ab2p in the asymmetric unit
(ASU), and each BRCT-Ab2p appears to dimerize through the
same interface either within the ASU or between ASUs (Fig-
ure S2B). The dimerization of the 1:1 BRCT-Ab2p complex
results in a 2:2 BRCT/Abraxas complex dimer. Dimerization in-
volves a1 and b2 of the BRCT1 domain and the Ab2p (Figures
3A–3D) burying about 1,880 A˚2 area. In the dimer interface,
two of the a1 helices from each BRCT-Ab2p complex form isol-
ogous interactions burying a hydrophobic patch formed by
F1662, M1663, and Y1666 with aromatic side chains stacking
on each other (Figure 3B). Interestingly, BRCA1 germline muta-
tions of F1662 (F1662S) and M1663 (M1663K) have been identi-
fied in germline cancer patients as recorded in the Breast Cancer
Information Core database (Szabo et al., 2000). Extensive
hydrogen bonds also form between the two equivalent
antiparallel b2 strands (residues T1,675–L1,679) (Figure 3D). The
two-fold symmetry axis within the BRCA1/Abraxas dimer lies
perpendicular to the two b strands. The cross interaction be-
tween the two BRCT/Abraxas complexes is also mediated by
the ionic interaction between Abraxas and BRCT a1 of the oppo-
site BRCT/Abraxas complex. The negative surface patch, gener-
ated by the phosphate group of pS404 and side chain of E402 at
the N terminus of Ab2p peptide, leads to cross interaction with
A
B C D
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Figure 2. Crystal Structures of BRCT in Complex with Single and Double Phosphorylated Abraxas Peptide
(A) Crystal structure of BRCT-Ab1p_short. The BRCT domains are in yellow, and the Ab1p_short peptide is in wheat color.
(B–D) Show the detailed interactions between phosphopeptide and BRCT domains. The polar interaction is indicated in dashed lines.
(E) Crystal structure of BRCT-Ab2p. The BRCT is in blue, and the Ab2p peptide is in cyan.
(F andG) Show the interface betweenBRCT and Ab in both BRCT-Ab1p_short andBRCT-Ab2p structures. The 2Fo-Fc electron density (s = 1.0) is shown for Abs.
(H) Superimposition of BRCT-Ab2p, BRCT-Ab1p_short, BRCT-Bach1 (PDB code: 1T29), and BRCT-CtIP (PDB code: 1Y98). The BRCT domains are shown in a
gray surface representation. Ab2p, Ab1p_short, Bach1, and CtIP are in blue, yellow, green, and purple, respectively. The pSPxF motif is indicated in the image.
(I) Sequence alignment of Abraxas C terminus. The BRCT-binding motif is indicated by a blue line, and the black arrows indicate the half conserved residues (see
also Figures S2 and S3).
Molecular Cell 61, 434–448, February 4, 2016 ª2016 The Authors 437
on the opposite side, close to the a1 of BRCT1 domain (Fig-
ure 2H). Interestingly, a similar side chain arrangement was
also see in BRCA1 BRCT bound with ‘‘optimized peptide’’
(GAAYDIpSQVFPFAKKK) (PDB: 1T2V) (Williams et al., 2004)
(Figure S3C), in which the tyrosine residue (Y) at !3 position
(phosphorylated serine in pSxxF motif as 0 position) and nega-
tively charged residues glutamic acid (E) or aspartic acid (D)
at !2 position were shown more favored for interaction with
BRCA1 BRCT domains (Manke et al., 2003; Rodriguez et al.,
2003).
Dimerization of BRCT-Abraxas Complex in Crystal
Structures
There are eight copies of BRCT-Ab2p in the asymmetric unit
(ASU), and each BRCT-Ab2p appears to dimerize through the
same interface either within the ASU or between ASUs (Fig-
ure S2B). The dimerization of the 1:1 BRCT-Ab2p complex
results in a 2:2 BRCT/Abraxas complex dimer. Dimerization in-
volves a1 and b2 of the BRCT1 domain and the Ab2p (Figures
3A–3D) burying about 1,880 A˚2 area. In the dimer interface,
two of the a1 helices from each BRCT-Ab2p complex form isol-
ogous interactions burying a hydrophobic patch formed by
F1662, M1663, and Y1666 with aro atic side chains stacking
on each other (Figure 3B). Interestingly, BRCA1 germline muta-
tions of F1662 (F1662S) and M1663 (M1663K) have been identi-
fied in germline cancer patients as recorded in the Breast Cancer
Information Core database (Szabo et al., 2000). Extensive
hydrogen bonds also form between the two equivalent
antiparallel b2 strands (residues T1,675–L1,679) (Figure 3D). The
two-fold symmetry axis within the BRCA1/Abraxas dimer lies
perpendicular to the two b strands. The cross interaction be-
tween the two BRCT/Abraxas complexes is also mediated by
the ionic interaction between Abraxas and BRCT a1 of the oppo-
site BRCT/Abraxas complex. The negative surface patch, gener-
ated by the phosphate group of pS404 and side chain of E402 at
the N terminus of Ab2p peptide, leads to cross interaction with
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Figure 2. Crystal Structures of BRCT in omplex with Single and Double Phosphorylated Abrax s Pepti e
(A) Crystal structure of BRCT-Ab1p_short. The BRCT domains are in yellow, and the Ab1p_short peptide is in wheat color.
(B–D) Show the detailed interactions between phosphopeptide and BRCT domains. The polar interaction is indicated in dashed lines.
(E) Crystal structure of BRCT-Ab2p. The BRCT is in blue, and the Ab2p peptide is in cyan.
(F andG) Show the interface betweenBRCT and Ab in both BRCT-Ab1p_short andBRCT-Ab2p structures. The 2Fo-Fc electron density (s = 1.0) is shown for Abs.
(H) Superimposition of BRCT-Ab2p, BRCT-Ab1p_short, BRCT-Bach1 (PDB code: 1T29), and BRCT-CtIP (PDB code: 1Y98). The BRCT domains are shown in a
gray surface representation. Ab2p, Ab1p_short, Bach1, and CtIP are in blue, yellow, green, and purple, respectively. The pSPxF motif is indicated in the image.
(I) Sequence alignment of Abraxas C terminus. The BRCT-binding motif is indicated by a blue line, and the black arrows indicate the half conserved residues (see
also Figures S2 and S3).
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(A) Crystal structure of BRCT-Ab1p_short. The BRCT domains are in yellow, and the Ab1p_short peptide is in wheat color.
(B–D) Show the detailed interactions between phosphopeptide and BRCT domains. The polar interaction is indicated in dashed lines.
(E) Crystal structure of BRCT-Ab2p. The BRCT is in blue, and the Ab2p peptide is in cyan.
(F andG) Show the interface betweenBRCT and Ab in both BRCT-Ab1p_short andBRCT-Ab2p structures. The 2Fo-Fc electron density (s = 1.0) is shown for Abs.
(H) Superimposition of BRCT-Ab2p, BRCT-Ab1p_short, BRCT-Bach1 (PDB code: 1T29), and BRCT-CtIP (PDB code: 1Y98). The BRCT domains are shown in a
gray surface representation. Ab2p, Ab1p_short, Bach1, and CtIP are in blue, yellow, green, and purple, respectively. The pSPxF motif is indicated in the image.
(I) Sequence alignment of Abraxas C terminus. The BRCT-binding motif is indicated by a blue line, and the black arrows indicate the half conserved residues (see
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fractions eluted from size exclusion chromatography by using nano-electrospray 
mass spectrometry under native conditions showed while BRCT-Ab1p complex 
appeared to exist predominantly as a 1:1 monomer with a small fraction forming 2:2 
dimer, the BRCT-Ab2p was found to exist mostly as 2:2 complexes, indicating a 
much stable dimer formation. BRCT-Bach1 and BRCT-CtIP were detected as 1:1 
monomeric complexes similar to BRCT-Ab1p complex (Figure 10 B-E) (87). 
Collectively, these findings indeed confirm the crystal structure data that doubly 
phosphorylated Abraxas phosphopeptide induces stable dimerization of BRCA1 
BRCT-Abraxas complex. 
2.1.8 Abraxas S404 phosphorylation is essential for stable BRCA1 BRCT-
Abraxas complex dimerization 
 In order to corroborate functional significance of Abraxas S404 
phosphorylation in inducing stable dimerization, mutational analyses were performed 
using S404P and S404D mutants. Size exclusion chromatography with 
phosphomimetic S404D mutant revealed BRCT-Ab1p (S404D) can maintain 2:2 
dimer complex, while BRCT-Ab1p (S404P) led to the formation of 1:1 complex 
(Figure 11A). These findings highlight the functional significance of S404 
phosphorylation. In addition analysis of the N-terminal sequence of the pSPTF motif, 
which includes GFGEYS404RS406PTF, revealed while GFGE is not absolutely 
required for the dimer formation, the presence of this sequence stabilizes the dimer 
structure (data not shown). 
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Figure 9. Ab2p induces stable dimerization of BRCT-Ab2p complex. A. 
Simplified BRCT-Ab2p dimer interface containing three regions observed in 
BRCT-Ab2p crystal structure that contribute to formation of the dimer interface – 
N-terminal hydrophobic region of BRCT α1-α1 (B), Extensive hydrogen 
bonding by β2-β2 strands (C) and N-terminal region of Ab2p including the 
phosphorylated S404 interaction with BRCT α1 (D). E. Crystal structure of 
BRCT-Ab2p complex viewed from three different directions with a two-fold axis. 
In vitro data was collected by collaborators Dr. Tom Blundell’s group, University 
of Cambridge and Dr. Carol Robinson’s group, University of Oxford. 
 
Abraxas-Dependent BRCA1 Dimerization In Vivo
We tested whether BRCA1 forms dimers in vivo and whether the
stable dimer formation is dependent on Abraxas. We co-ex-
pressed differentially Myc- or FLAG-tagged BRCA1 full-length
protein in control (Ctrl) cells or Abraxas knockout (KO) cells. In
the co-immunoprecipitation experiment with lysates prepared
from cells treated with IR, immunoprecipitated FLAG-BRCA1 in-
teracts with Myc-tagged BRCA1, indicating that BRCA1 indeed
dimerizes in vivo. The dimerization was decreased in Abraxas
KO cells, indicating the dependency of dimerization on Abraxas
(Figure 6A). Similarly, a construct containing only the BRCA1-
BRCT domains also dimerizes when co-expressed in cells and
the dimerization is decreased in Abraxas KO cells (Figure 6B).
We then tested whether the germline mutations F1662S and
M1663K interfere with BRCA1 dimerization in vivo. We
compared the interaction of a Myc-tagged full-length BRCA1
and a HA-tagged wild-type BRCT fragment with that of the
F1662S or M1663K mutant of BRCA1 and a mutant BRCA1
BRCT fragment with three residues localized in the dimer
interface mutated (F1662S/M1663K/R1670E). Both the Myc-
immunoprecipitation (Figure 6C) and reciprocal HA- im-
munoprecipitation (Figure 6D) experiments showed that the
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Figure 4. Mutagenesis Studies of the Interface of BRCT-Ab2p Complex Dimer
(A) Simplified BRCT-Ab2p dimer interface containing three regions observed in BRCT-Ab2p crystal.
(B) Detailed interactions mediated through BRCT a1.
(C) Summary of BRCT and Abraxas mutants. The complexes tested are grouped into four and highlighted in different colors.
(D–G) Gel filtrations of BRCT and Abraxas mutants. The same color codes are used as in (C).
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Figure 10. Double phosphorylated Abraxas phosphopeptide induces 
dimerization of BRCT-Ab2p complex. A. Size exclusion chromatography of 
BRCT complex with Ab1p, Ab2p, BACH1 and CtIP phosphopeptides. The 
regions for dimer complex (2:2 complex) and monomer complex (1:1 complex) 
are high lined in yellow and gray shades. (B-E) The native mass spectra of 
BRCT-Ab1p (B), BRCT-ab2p (C), BRCT-Bach1 (D), and BRCT-CtIP  (E) 
complexes tested at 15 uM. 
In vitro data were collected by collaborators Dr. Tom Blundell’s group, University 
of Cambridge and Dr. Carol Robinson’s group, University of Oxford. 
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2.1.9 Germline mutation in the BRCT dimerization interface disrupts stable 
BRCT-Ab2p complex dimerization in vitro 
 The crystal structure data revealed that the BRCT dimerization involves α1 
and β2 of the BRCT1 domain forming hydrophobic interaction between α1 helices 
(α1- α1) and extensive hydrogen bonding between the two antiparallel β strands (β2- 
β2) (Figure 9). The α1- α1 dimerization interface consists of hydrophobic patch 
formed by F1662, M1663 and Y1666 amino acids with aromatic side chains stacking 
on each other (Figure 9B). As discussed in section 2.1.6, F1662 and M1663 
residues were identified as germline mutations as F1162S and M1663K in cancer 
patients (92). To understand whether α1- α1 interaction contributes more significantly 
than β2- β2 interaction in stabilizing the dimer interface, size-exclusion 
chromatography was carried out with mutants that disrupt the β2- β2 and α1- α1 
interaction. While the BRCT N1678A-Ab2p complex appeared to have minimal effect 
in destabilizing the dimer structure, the germline mutations F1662S and M1663K led 
to complete disruption of the dimer formation. BRCT Y1666A mutation did not 
appear to have much role in the stability of the dimer structure as the elution peak 
was detected between 2:2 and 1:1 complexes (Figure 11B). Collectively these 
results support our crystal structure results that F1662S and M1663K mutants 
disrupt the dimer stability indicating these residues likely play a crucial role in 
BRCA1’s tumor suppressor function (87).  
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Figure 11. Mutagenesis analysis of BRCT-Ab2p dimer Interface reveal the 
importance of S404 phosphorylation and residues of BRCA1 germline 
mutations for stable BRCT/Abraxas dimer formation. A. Gel filtration 
analysis of BRCT-Ab1p complex containing S404P or phosphomimetic mutant 
S404D or BRCT-Ab2p complex. B. Gel filtration analysis of BRCT-Ab2p 
complex containing BRCA1 BRCT mutations present in the dimerization 
interface. 
In vitro data were collected by collaborators Dr. Tom Blundell’s group, University 
of Cambridge and Dr. Carol Robinson’s group, University of Oxford. 
	
Abraxas-Dependent BRCA1 Dimerization In Vivo
We tested whether BRCA1 forms dimers in vivo and whether the
stable dimer formation is dependent on Abraxas. We co-ex-
pressed differentially Myc- or FLAG-tagged BRCA1 full-length
protein in control (Ctrl) cells or Abraxas knockout (KO) cells. In
the co-immunoprecipitation experiment with lysates prepared
from cells treated with IR, immunoprecipitated FLAG-BRCA1 in-
teracts with Myc-tagged BRCA1, indicating that BRCA1 indeed
dimerizes in vivo. The dimerization was decreased in Abraxas
KO cells, indicating the dependency of dimerization on Abraxas
(Figure 6A). Similarly, a construct containing only the BRCA1-
BRCT domains also dimerizes when co-expressed in cells and
the dimerization is decreased in Abraxas KO cells (Figure 6B).
We then tested whether the germline mutations F1662S and
M1663K interfere with BRCA1 dimerization in vivo. We
compared the interaction of a Myc-tagged full-length BRCA1
and a HA-tagged wild-type BRCT fragment with that of the
F1662S or M1663K mutant of BRCA1 and a mutant BRCA1
BRCT fragment with three residues localized in the dimer
interface mutated (F1662S/M1663K/R1670E). Both the Myc-
immunoprecipitation (Figure 6C) and reciprocal HA- im-
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Figure 4. Mutagenesis Studies of the Interface of BRCT-Ab2p Complex Dimer
(A) Simplified BRCT-Ab2p dimer interface containing three regions observed in BRCT-Ab2p crystal.
(B) Detailed interactions mediated through BRCT a1.
(C) Summary of BRCT and Abraxas mutants. The complexes tested are grouped into four and highlighted in different colors.
(D–G) Gel filtrations of BRCT and Abraxas mutants. The same color codes are used as in (C).
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2.1.10 Abraxas dimerization/oligomerization in cells is independent of BRCA1 
binding 
 The findings from this study led us to question whether Abraxas also forms a 
dimer in which the phosphorylated C-termini of Abraxas in complex with BRCA1-
BRCT could be in close proximity for dimerization. To test this, differentially tagged 
Abraxas molecules, either WT or S404A and S4046A, were immunoprecipitated and 
detected by western blot analysis. As shown in Figure 12A, both WT and S404A as 
well as S406A, mutant interact with differentially tagged counterpart suggesting that 
mutation in S404 or S406 does not disrupt Abraxas dimerization and that Abraxas 
dimerization is independent of its binding to BRCA1. To further examine the domain 
required for Abraxas dimerization, Abraxas truncation mutants were generated and 
tested for binding to its counterpart.  Importantly, we found that deletion of the 
coiled-coil domain in Abraxas disrupts its self-interaction with both WT or coiled-coil 
deletion mutant (Figure 12B). Taken together, these findings suggest that Abraxas 
dimerization/oligomerization occurs independently of BRCA1 BRCT dimerization 
through its coiled-coil domain. 
2.1.11 Objective 
 Although BRCA1 was cloned more than 20 years ago, the exact mechanism 
of how it functions as a tumor suppressor still remains to be determined. BRCA1 
BRCT domain serves as a phosphopeptide-binding module that recognizes pSPXF 
motif containing proteins including Abraxas, BACH1, and CtIP, forming three 
mutually exclusive complexes termed as A, B and C complex, respectively. The 
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Figure 6. Abraxas Promotes BRCA1 BRCT Dimerization In Vivo
(A) Abraxas-dependent BRCA1 dimerization in vivo. The differentially Myc- and FLAG-tagged BRCA1 full-length constructs were transiently transfected into
parental 293T (Ctrl) or Abraxas KO cells. The lysates from cells treatedwith 10Gy IR followed by 1 hr incubation at 37!Cwere used for FLAG-immunoprecipitation.
The intensity of individual bands was quantified by densitometric analysis using NIH ImageJ software. The normalized value (IPed_mycBRCA1/In-
put_mycBRCA1) was shown in the bar graph.
(B) Abraxas-dependent BRCA1-BRCT domains dimerization in vivo. The differentially Myc- and HA-tagged BRCA1-BRCT domains constructs were transiently
transfected into parental 293T (Ctrl) or Abraxas KO cells. The lysates from cells treated with 10 Gy IR followed by 1 hr incubation at 37!C were used for
HA-immunoprecipitation. The band intensity was quantified with NIH imageJ software. The normalized value (IPed_mycBRCT/Input_mycBRCT) was shown in
the bar graph.
(legend continued on next page)
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transfected into parental 293T (Ctrl) or Abraxas KO cells. The lysates from cells treated with 10 Gy IR followed by 1 hr incubation at 37!C were used for
HA-immunoprecipitation. The band intensity was quantified with NIH imageJ software. The normalized value (IPed_mycBRCT/Input_mycBRCT) was shown in
the bar graph.
(legend continued on next page)
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Figure 12. Abraxas dimerization/oligomerization in vivo is independent of 
binding to BRCA1. A. The differentially tagg d GFP- and HA-Flag-tagged WT or 
Abraxas mutants (S404A or S406A) were co-transfected in cells, irradiated (or 
untreated) followed by GFP immunoprecipitation and interaction between 
differentially tagged Abraxas mutants was analyzed by immunoblot using HA 
antibody. B.  Abraxas dimerizes/oligomerizes through the coiled-coil (CC) 
domain. The immunoprecipitation was carried out with lysates prepared from 
cells expressing HA-Flag-tagged WT Abra1 or ΔCC mutant and GFP-tagged 
WT or ΔCC mutant. 
Results were obtained by Dan Su, Ph.D., Wang Lab. 
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phosphopeptide binding ability of BRCA1 BRCT domain is essential for its tumor 
suppressor function and has been shown to harbor many clinically important breast 
and ovarian cancer mutations that lead to early onset of breast cancer in patients 
(Source: National Cancer Institute) (85, 93, 94). Therefore structural and functional 
analysis of the BRCA BRCT binding with pSPxF motif containing proteins is 
essential to understand the tumor suppressor function of BRCA1. Structural analysis 
of BRCA1-BRCT in complex with other pSPxF motif containing proteins, BACH1 and 
CtIP, has been solved previously providing a valuable structural framework into this 
interaction (94-97). However, a detailed structural analysis of BRCA1 BRCT-
Abraxas interaction still remains largely unknown. The interaction of Abraxas with 
BRCA1 is essential for BRCA1 recruitment to DNA damage sites and maintenance 
of genome stability. The significance of Abraxas pSPxF motif interaction with BRCA1 
BRCT in tumor suppression is exemplified by identification of an Abraxas mutation in 
tumor harboring F409C (55). In this study, we employed in vitro analysis to solve the 
crystal structure of BRCT-Abraxas complex that showed that phosphorylation at 
S404 residue induces stable dimerization of BRCT-Abraxas complex. Moreover, at 
the BRCT dimerization interface we found two germline BRCA1 mutations that 
destabilized the dimer structure in vitro. However, there are several questions that 
arise from these in vitro findings. First, “What is the functional significance of 
Abraxas S404 phosphorylation in terms of BRCA1 localization to damage sites?” 
Second, “Does BRCA1 dimerization occur in vivo through its BRCT domain?”  And 
third, “Does BRCA1 dimerization in vivo in Abraxas-dependent manner?”  
Addressing these questions will not only validate our in vitro findings of BRCT-
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Abraxas complex dimerization but will also provide insights into the functional 
significance of DNA damage-induced Abraxas S404 phosphorylation in regulating 
BRCA1 dimerization at the DNA damaged chromatin, deepening our understanding 
of Abraxas and BRCA1 tumor suppressor function to maintain genome stability. 
2.2. Materials and Methods  
2.2.1 Cell culture  
 All cell lines were maintained using standardized methodology in sterile 
condition. U2OS cells were grown in McCoy’s 5A medium (Corning) supplemented 
with 10% fetal bovine serum (FBS) and maintained at 370C with 5% CO2 
atmosphere. HEK293T cells were cultured in DMEM (Corning) supplemented with 
10% FBS. 
2.2.2 Generation of stable cell lines 
 To generate Abraxas knockdown cells complemented with WT or mutant 
Abraxas, U2OS cells were infected with retrovirus containing shRNAs against 
Abraxas followed by selection with puromycin (0.8 ug/ml) for 5 days. The Abraxas 
knockdown stable cell line was then complemented with expression of empty MSCV 
vector or expression constructs containing HA-tagged WT or mutant Abraxas, and 
selected with Blasticidin (9 ug/ml) 1 week for stable expression. Abraxas knockdown 
efficiency and complementation with HA-tagged Abraxas was confirmed by western 
blot with Abraxas and HA antibodies. 
2.2.3 Cell lysis and Western blot 
Cell lysis and western blot analyses were performed using established 
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methodology. Cells were lysed in NETN buffer (50 mM Tris-HCl, pH 8.0, 150 mM 
NaCl, 1 mM EDTA, 0.5% Nonidet P-40) with protease inhibitors (98) and protein 
phosphatase inhibitors, 1 mM NaF, and 1 mM Na3VO4. Cells were lysed on ice for 
atleast 30 minutes followed by brief sonication (Bioruptor) and centrifuged at 13,200 
rpm to remove cellular debris. Protein concentration was measured by Bradford 
assay and 50 µg protein lysate were used for western blot analysis. Samples were 
run in 10% SDS-PAGE gel and run at 90 volts for 2-3 hours in a Biorad Mini-
PROTEAN electrophoresis chamber using running buffer followed by transfer into 
nitrocellulose membrane using cold transfer buffer. The membranes were blocked 
with 4% milk for at least 20 minutes followed by incubation with primary and 
secondary antibodies. Blots were washed at least 4 times after each antibody 
incubation and developed using ECL-plus chemiluminescent detection reagent 
(Promega). 
2.2.4 Immunofluorescence 
 Abra1 shRNA knockdown cells complemented with empty vector, wild type or 
mutants of Abraxas were analyzed for BRCA1 IR-induced foci formation (IRIF). 
Following 10 Gy irradiation from a 137Cs source, cells were incubated at 370C for 2 
hours. Cells were then fixed with 3.6% formaldehyde for 10 min, permeabilized with 
0.5% Triton X-100 solution, and incubated with primary antibodies for 1 hr at 370C  
followed by appropriate Alexa 488-conjugated (green; Invitrogen) and Alexa 555-
conjugated (red; Invitrogen) secondary antibodies. At least 500 cells were counted 
for each cell type and cells containing more than 10 foci were counted as positive. 
All images were obtained with a Nikon TE2000 inverted microscope with a 
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Photometrics Cool- Snap HQ camera. Quantification of BRCA1 was performed using 
Imaris software (Bitplane). The DAPI channel was used to select the nuclei of the 
cells in the field, red and green channel were used for BRCA1 and γH2AX, 
respectively. For BRCA1 foci intensity measurement, foci were defined as particles 
bigger than 0.25 µM in diameter with an intensity cut-off value (1200) to eliminate 
background. At least 50 cells were counted and plotted using GraphPad Prism 
software. Statistical analysis was performed by student’s t-test or ANOVA with 
Tukey’s multiple comparisons test. p-value is as indicated.  
2.2.5 Coimmunoprecipitation  
 Cells were lysed in NETN buffer containing protease inhibitor and 
phosphatase inhibitor. For Flag IP, cell lysates were incubated with Flag beads (98) 
overnight with gentle agitation at 4oC. The beads were washed with NETN lysis 
buffer four times and eluted with 3X sample buffer for Western blot analysis. For 
analyzing Abraxas dimerization in vivo, GFP-tagged and HF- tagged Abraxas 
wildtype, S404A, S406A mutant or coiled-coil deletion mutant were transiently 
transfected to 293T cells. Two days after transfection, cells were either untreated or 
exposed to 10 Gy IR. 2 hr later, cells were collected for GFP- or Flag- IP and 
Western blot was probed with either antibodies against HA or GFP. For analyzing 
BRCA1 dimerization in vivo, Flag- or Myc-tagged BRCA1 full-length wild type or 
mutants, or HA- and Myc-tagged BRCA1 BRCT fragments were analyzed in a 
similar way.  
2.2.6 Clonogenic survival assay 
 Abra1 shRNA knockdown cells complemented with empty vector, wild type or 
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mutants of Abra1 were analyzed for cell survival in response to IR. Stable U2OS cell 
lines were seeded at low density in 10 cm dishes and irradiated with 4 Gy ionizing 
irradiation using a 137Cs source. The cells were then cultured at 37°C for 14 days to 
allow colonies to form. Colonies were stained with 2% methylene blue and 50% 
ethanol for 10 min. Colonies containing 50 or more cells were counted as positive 
and statistical data were analyzed by analysis of variance (99) with Tukey’s multiple 
comparisons test.  
2.2.7 Chromatin fractionation 
 Cells were irradiated at 10 Gy followed by 1 hr incubation at 370C. For total 
cell extracts, cells were lysed in NETN150 buffer containing protease inhibitor 
mixture and analyzed by Western blot. For chromatin fractionation, irradiated cells 
were washed in PBS and resuspended in Buffer A (10 mM Hepes pH 7.9, 10 mM 
KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 5 mM NaF, 1 mM Na3VO4 , 1 
mM dithiothreitol (DTT), and protease inhibitor mixture) containing 0.1% Triton X-
100, and incubated on ice for 5 min for permeabilization. The cytosolic fraction was 
then separated by centrifugation at 4000 rpm for 5 min at 4°C. The supernatant was 
discarded and the nuclei pellet was washed once with Buffer A and resuspended in 
Buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, protease inhibitor mixture) and 
incubated for 30 min on ice. The soluble nuclear fraction was separated by 
centrifugation at 4500 rpm for 5 min. The chromatin fraction pellet was washed with 
Buffer B and resuspended in 100 µl Laemmli sample buffer and sonicated for 10 sec 
before analysis.  
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2.3 Results 
2.3.1 Generation of Abraxas knockdown cells complemented with WT or 
mutant Abraxas 
 As discussed in section 2.1.5, while S406 is constitutively phosphorylated 
even in absence of DNA damage, we found DNA damage triggers ATM-dependent 
phosphorylation at S404 residue in DNA dose- and time-dependent manner (Figure 
13A). To dissect functional significance of S404 phosphorylation in the DDR 
pathway, I stably knocked down Abraxas in U2OS cells using retrovirus-encoding 
shRNAs targeting endogenous Abraxas. These cells were then complemented with 
shRNA-resistant HA-tagged WT, S404A or S406A mutants of Abraxas. The 
knockdown efficiency and complementation with above-mentioned constructs were 
confirmed by western blot analysis with Abraxas antibody (Figure 13B). Tubulin was 
used as loading control. 
2.3.2 Increased cellular sensitivity to IR-induced DNA damage of Abraxas-
deficient cells expressing mutants of Abraxas. 
Since S404 is phosphorylated in DNA damage-dependent manner that likely 
plays a role in stable BRCT-Abraxas dimerization in cells, I tested whether S404 
phosphorylation is critical for the function of Abraxas in response to IR. To test this I 
measured the cellular sensitivity of Abraxas knockdown cells expressing WT or 
mutant Abraxas. As shown in Figure 13, I found consistent with previous findings 
Abraxas depleted cells become hypersensitive to IR-induced DNA damage. 
Interestingly while complementing these cells with WT Abraxas can rescue the 
defects in cellular sensitivity, both S404A and S406A mutant expressing cells were  
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Figure 13. Abraxas phosphorylation at S404 and S406 are both essential for 
cellular resistance to IR. A. Abraxas stable knockdown cells complemented with 
vector, WT, S404A or S406A were generated as described in materials and method. 
Western blot analysis was performed with Abraxas antibody to confirm knockdown 
efficiency and expression of HA-Abra1 constructs. B. Increased cellular sensitity to 
IR-induced DNA damage in Abraxas-deficient cells expressing mutant Abraxas. 
Colony survival assay was carried out for cells treated with 4 Gy IR. The data 
represented means ± SD. 
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Figure 5. Phosphorylation of S404 and S406 Are Both Important for Cellular Resistance to IR and BRCA1 Accumulation at DNADamage Sites
(A) Generation of Abraxas knockdown U2OS cells complemented with expression of small hairpin (sh)RNA-resistant HA-taggedWT, S404A, or S406Amutants of
Abraxas.
(B) Increased cellular sensitivity to IR of Abraxas-deficient cells expressing mutants of Abraxas. The colony-survival assay was carried out for cells treated with
4 Gy IR. The data are presented as means ± SD. The data analyses are processed by ANOVA and the statistical significance was determined by Tukey’s multiple
comparisons test (*p < 0.02). There were three independent experiments that were performed (additional data are presented in Figure S5).
(C) Representative images of BRCA1 IRIF in Abra1 shRNA knockdown cells complemented with vector, WT, or mutants of Abraxas in response to 10 Gy IR
followed by 2 hr incubation at 37!C.
(D) The percentage of cells containingmore than ten BRCA1 IRIF foci was quantified. The data are presented asmeans ± SD. The data analyses are processed by
ANOVA and the statistical significance was determined by Tukey’s multiple comparisons test (*p < 0.0001). At least three independent experiments were per-
formed. More than 300 cells were counted for each experiment. Additional data for quantification at different time points post IR are presented in Figure S5.
(E) Quantification of the intensity of BRCA1 IR induced foci (IRIF). The data are presented as means ± SD (n > 50). The statistical analysis was carried out by
Student’s t test (*p < 0.0002).
(F) BRCA1 accumulation at damaged chromatin depends on both S404 and S406 residues. The Orc2 was used as a marker for chromatin-bound fraction. The
cells were treated with 10 Gy IR followed by 2 hr incubation at 37!C. The cellular fractionation was carried out and the chromatin fraction was analyzed (see also
Figure S5).
442 Molecular Cell 61, 434–448, February 4, 2016 ª2016 The Authors
inter ction/dimerization of BRCA1 a BRCT was decr ased
with mutation of the critical residues at the dimer interface
F 662S or M1663K. Thus, BRCA1 germline mutati ns interfere
with s able dimer formati n in vivo.
To understand dimerization of the BRCT/Abraxas complex
in vivo, we examined whether Abraxas forms a dimer in which
the phosphorylated C-termini of Abraxas in complex with
BRCT could be in close vicinity for dimerization. We expressed
both GFP-tagged Abr xas and HA-FLAG-tagged Abraxas in
cells a d tested whether the differ ntially tagged Abraxas mole-
cules interact with each other using the immunoprecipitation
assay. We found that wild-type Abraxas, as well as the S404A
A B
D
C
E F
Figure 5. Phosphorylation of S404 and S406 Are Both Important for Cellular Resistance to IR and BRCA1 Accumulation at DNADamage Sites
(A) Generation of Abraxas knockdown U2OS cells complemented with expression of small hairpin (sh)RNA-resistant HA-taggedWT, S404A, or S406Amutants of
Abraxas.
(B) Increased cellular sensitivity to IR of Abraxas-deficient cells expressing mutants of Abraxas. The colony-survival assay was carried out for cells treated with
4 Gy IR. The data are presented as means ± SD. The data analyses are processed by ANOVA and the statistical significance was determined by Tukey’s multiple
comparisons test (*p < 0.02). There were three independent experiments that were performed (additional data are presented in Figure S5).
(C) Representative images of BRCA1 IRIF in Abra1 shRNA knockdown cells complemented with vector, WT, or mutants of Abraxas in response to 10 Gy IR
followed by 2 hr incubation at 37!C.
(D) The percentage of cells containingmore than ten BRCA1 IRIF foci was quantified. The data are presented asmeans ± SD. The data analyses are processed by
ANOVA and the statistical significance was determined by Tukey’s multiple comparisons test (*p < 0.0001). At least three independent experiments were per-
formed. More than 300 cells were counted for each experiment. Additional data for quantification at different time points post IR are presented in Figure S5.
(E) Quantification of the intensity of BRCA1 IR induce foci (IRIF). Th data are pr s nt d as means ± SD ( > 50). The statistical analysis was carried out by
Student’s t test (*p < 0.0002).
(F) BRCA1 accumulation at damaged chromatin depends on both S404 and S406 residues. The Orc2 was used as a marker for chromatin-bound fraction. The
cells were treated with 10 Gy IR followed by 2 hr incubation at 37!C. The cellular fractionation was carried out and the chromatin fraction was analyzed (see also
Figure S5).
442 Molecular Cell 61, 434–448, February 4, 2016 ª2016 Th Authors
B A 
B 
	 45	
were unable to fully rescue the defect. These findings suggest that phosphorylation 
at plays a role in cellular resistance to IR-induced DNA damage.  
2.3.3 Abraxas phosphorylation is essential for efficient recruitment of BRCA1 
to DSB sites 
 Previous findings from our lab showed that Abraxas is essential for efficient 
recruitment of BRCA1 to DNA damage sites and BRCA1 localization is disrupted in 
Abraxas KO MEF cells (55). To test whether Abraxas phosphorylation plays any role 
in BRCA1 recruitment to DNA damage sites, I used Abraxas knockdown cells 
complemented with WT or S404A and S406A mutants of Abraxas. These cells were 
irradiated with IR (10 Gy) and immunostained two hours post IR treatment to 
examine whether IR-induced foci formation (IRIF) of BRCA1.  As shown in Figure 
14, the BRCA1 foci formation decreased significantly upon Abraxas depletion. While 
the defect can be rescued by expression of HA-tagged WT Abraxas; S404A or 
S406A mutants of Abraxas can only partially rescue the defect. Quantification of 
BRCA1 foci positive cells indicate that compared to WT Abraxas cells showed 
neither S404A or S406A mutant expressing cells can completely rescue the defects 
in BRCA1 IRIF. In addition, I measured the intensity of BRCA1 IRIF in these cells. 
Consistent with reduced foci positive cells, both S404A and S406A expressing cells 
showed decreased overall BRCA1 foci intensity compared to WT Abraxas 
expressing cells. 
2.3.4 BRCA1 accumulation at damaged chromatin requires both S404 and 
S406 phosphorylation of Abraxas 
To further validate the defects of BRCA1 localization to IR-induced foci in 
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Abraxas phosphorylation-deficient mutant expressing cells, I isolated chromatin 
fraction from Abraxas depleted cells complemented with WT or phosphorylation- 
deficient mutants (S404A, S406A or S404AS406A) 1-hour post-IR and analyzed for 
accumulation of BRCA1 to damaged chromatin by western blot analysis. 
Consistently, I observed that depletion of endogenous Abraxas impaired BRCA1 
loading onto damaged chromatin. While expression of WT Abraxas in Abraxas 
knockdown cells can rescue the defect, cells expressing S404A and S406A single 
mutants or S404AS406A double mutant of Abraxas failed to accumulate BRCA1 
onto damaged chromatin (Figure 15). This was not due to change in altered 
expression of BRCA1 in these cells since the total BRCA1 protein level was not 
affected in Abraxas knockdown cells or knockdown cells complemented with WT or 
mutant Abraxas as shown in the total cell lysate (Figure 15 bottom panel). Orc2 was 
used as a marker for chromatin fraction. Collectively, these results suggest that DNA 
damage-induced Abraxas S404 phosphorylation likely plays a crucial role in BRCA1 
accumulation to damaged chromatin. 
2.3.5 Abraxas-dependent dimerization of BRCA1 in vivo 
 Our crystal structure data revealed that BRCA1 BRCT dimerizes in presence 
of doubly phosphorylated Abraxas phosphopeptide through the BRCT1 domain 
(Figure 9). To test whether BRCA1 BRCT dimerizes in vivo and whether this 
dimerization depends on Abraxas, I co-expressed differentially Myc or Flag-tagged 
BRCA1 full-length constructs in 293T parental cells or Abraxas KO cells. These cells 
were irradiated, incubated at 370C for 1 hour and subjected to co-
immunoprecipitation analysis with Flag beads. To test whether Myc-tagged BRCA1 
	 47	
 
Figure 14. Abraxas phosphorylation at  both S404 and S406 are important for 
BRCA1 accumulation at DNA damage sites. A. Representative image of BRCA1 
BRCA1 IRIF in Abraxas knockdown cells complemented with vector, WT, S404A or 
S406A. Cells were irradiated at 10 Gy, incubated at 370C for 2 hours followed by 
immunofluorescence analysis with BRCA1 and γH2A.X antibodies. B. The percentage 
of cells containing more than 10 BRCA1 foci were counted and quantified. At 
least 300 cells were counted. The data represents means ± SD. C. 
Quantification of intensity of BRCA1 IRIF. The data represents means ± SD. 
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(A) Generation of Abraxas knockdown U2OS cells complemented with expression of small hairpin (sh)RNA-resistant HA-taggedWT, S404A, or S406Amutants of
Abraxas.
(B) Increased cellular sensitivity to IR of Abraxas-deficient cells expressing mutants of Abraxas. The colony-survival assay was carried out for cells treated with
4 Gy IR. The data are presented as means ± SD. The data analyses are processed by ANOVA and the statistical significance was determined by Tukey’s multiple
comparisons test (*p < 0.02). There were three independent experiments that were performed (additional data are presented in Figure S5).
(C) Representative images of BRCA1 IRIF in Abra1 shRNA knockdown cells complemented with vector, WT, or mutants of Abraxas in response to 10 Gy IR
followed by 2 hr incubation at 37!C.
(D) The percentage of cells containingmore than ten BRCA1 IRIF foci was quantified. The data are presented asmeans ± SD. The data analyses are processed by
ANOVA and the statistical significance was determined by Tukey’s multiple comparisons test (*p < 0.0001). At least three independent experiments were per-
formed. More than 300 cells were counted for each experiment. Additional data for quantification at different time points post IR are presented in Figure S5.
(E) Quantification of the intensity of BRCA1 IR induced foci (IRIF). The data are presented as means ± SD (n > 50). The statistical analysis was carried out by
Student’s t test (*p < 0.0002).
(F) BRCA1 accumulation at damaged chromatin depends on both S404 and S406 residues. The Orc2 was used as a marker for chromatin-bound fraction. The
cells were treated with 10 Gy IR followed by 2 hr incubation at 37!C. The cellular fractionation was carried out and the chromatin fraction was analyzed (see also
Figure S5).
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Figure 15. BRCA1 accumulation at damaged chromatin. Depends on both 
S404 and S406 phosphorylation. Abraxas-deficient cells expressing vector, 
WT or mut nt Abraxas (S404A, S406A or ouble mutant) were treated with 10 
Gy IR followed by 2-ho r i cubation t 370C. The cellular fractionation was 
carri d out and the chromatin fraction w s analyzed. Orc2 was used as loading 
control. Bottom panel: total cell lysates were analyzed to confirm BRCA1 protein 
was not affected in Abraxas knockdown cells and cells complemented with WT 
or mutant Abraxas. 
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interacts with its Flag-tagged counterpart, I performed immunoblot analysis with Myc 
antibody to detect BRCA1 dimerization. The findings indicate that BRCA1 indeed 
dimerizes in vivo and this dimerization decreased significantly in Abraxas KO cells 
indicating that BRCA1 dimerization occurs in an Abraxas-dependent manner (Figure 
16A). The Input western blot showed similar expression of BRCA1 constructs in both 
control and Abraxas KO cells confirming that the decreased BRCA1 dimerization in 
the KO cells was not due to reduced expression of any of the constructs. The band 
intensity of myc-BRCA1 was quantified by densitometric analysis using NIH ImageJ 
software. The normalized value (Immunoprecipitated myc-BRCA1 over Input) was 
shown in the bar graph. 
To further confirm whether this dimerization takes place through the BRCT 
domain of BRCA1, I performed a similar co-immunoprecipitation experiment with 
differentially Myc- or HA-tagged BRCT domain only constructs in 293T parental and 
Abraxas KO cells. In consistent with full-length BRCA1 dimerization, I found that a 
BRCA1 BRCT domain also dimerizes in vivo and this dimerization is also 
significantly impaired in Abraxas KO cells (Figure 16B). In sum, these findings 
validate our in vitro crystal structure findings that BRCA1 indeed dimerizes in vivo in 
Abraxas-dependent manner. 
2.3.6 BRCA1 germline mutations disrupt dimerization in vivo 
Our crystal structure data revealed that germline mutations in the BRCT dimerization 
interface, F1662S, and M1663K, disrupt the dimer stability. To test whether these 
mutations interfere BRCA BRCT dimerization in vivo, I compared the interaction of 
Myc-tagged full-length BRCA1 and HA-tagged wild-type BRCT fragment with that of 
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the F1662S or M1663K mutant of BRCA1 and a mutant BRCA1 BRCT fragment with 
three residues localized in the dimer interface mutated (F1662S/M1663K/R1670E). 
and performed both Myc-IP and reciprocal HA-IP experiments to confirm if 
dimerization in impaired when these critical residues in the dimer interface are 
mutated. Findings from these experiments showed that while the WT BRCA1 and 
BRCT can efficiently interact, the interaction/dimerization of BRCA1 and BRCT 
fragment was decreased significantly when these residues were mutated. The band 
intensity was quantified by densitometric analysis using NIH ImageJ software. The 
normalized value (IP over Input) was shown in the bar graph (Figure 17). 
Collectively, these findings suggest that F1662S and M1663K germline mutations 
interfere with stable dimer formation in vivo highlighting the importance of these 
critical residues in BRCA1 dimerization. 
2.4 Discussion 
 BRCA1 accumulation to DNA damage sites is essential for its function in DNA 
repair and cell cycle regulation and thereby maintaining genomic integrity. Although 
phosphorylated S406 residue in the pSPxF motif of Abraxas has been shown to be 
crucial in interaction with BRCA1, a detailed molecular understanding of Abraxas-
BRCA1 BRCT interaction still remained to be determined. In this light, our study 
provides evidence for DNA damage-induced ATM-dependent mechanism for 
Abraxas-mediated BRCA1 accumulation to DNA damage sites. In this, IR-induced 
ATM-dependent phosphorylation of S404 residue adjacent to pSPxF motif acts as a 
regulatory switch inducing stable dimerization of BRCA1 BRCT-Abraxas complex 
that is essential for efficient recruitment of BRCA1 to damaged chromatin (Figure 18)  
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Figure 6. Abraxas Promotes BRCA1 BRCT Dimerization In Vivo
(A) Abraxas-dependent BRCA1 dimerization in vivo. The differentially Myc- and FLAG-tagged BRCA1 full-length constructs were transiently transfected into
parental 293T (Ctrl) or Abraxas KO cells. The lysates from cells treatedwith 10Gy IR followed by 1 hr incubation at 37!Cwere used for FLAG-immunoprecipitation.
The intensity of individual bands was quantified by densitometric analysis using NIH ImageJ software. The normalized value (IPed_mycBRCA1/In-
put_mycBRCA1) was shown in the bar graph.
(B) Abraxas-dependent BRCA1-BRCT domains dimerization in vivo. The differentially Myc- and HA-tagged BRCA1-BRCT domains constructs were transiently
transfected into parental 293T (Ctrl) or Abraxas KO cells. The lysates from cells treated with 10 Gy IR followed by 1 hr incubation at 37!C were used for
HA-immunoprecipitation. The band intensity was quantified with NIH imageJ software. The normalized value (IPed_mycBRCT/Input_mycBRCT) was shown in
the bar graph.
(legend continued on next page)
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Figure 16.  Abraxas-dependent BRCA1 BRCT dimerization. A. Abraxas-
dependent BRCA1 dimerization in vivo. The differentially tagged (myc or Flag) 
full-length BRCA1 constructs were transiently transfected into parental and 
Abraxas KO 293T cells. The lysates from cells treated with 10 Gy IR followed by 
1 hour incubation at 370C were used for Flag immunoprecipitated followed by 
detection with indicated antibodies. The intensity of individual band was 
quantified by densitometric analysis using ImageJ software and normalized 
value (IPed_mycBRCA1/Input_mycBRCA1) was shown in the bar graph. B. 
Abraxas-dependent BRCA1-BRCT dimerization in vivo. The differentially tagged 
BRCA1 BRCT domain const ucts were tr n ie tly transfect d parental or 
Ab axas KO 293Tcells and BRCA1 BRCT dim riza ion was analyzed similarly 
as in A. The band intensity was measured by ImageJ and normalize  values 
were plotted in the bar graph. 
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Our crystal structure data revealed that while phosphorylated S406 phosphopeptide 
of Abraxas interacts with BRCT fragment forming a monomeric complex similar to 
other pSPxF motif containing proteins, doubly phosphorylated Abraxas 
phosphopeptide (pS04pS406) induces stable dimerization of the BRCT domain, 
mediated through the BRCT1 domain. The dimerization interface formed by two 
BRCT1 domains does not interfere with pSPxF motif binding that binds to BRCT 
domain as “two-anchor mode” where S406 and F409 interact with BRCT1 and 
BRCT2 domains, respectively. However, the interaction between two BRCT1 
domains is not sufficient to form a stable dimer in solution as observed with BRCT 
domain only or BRCT domain with pS406 Abraxas, BACH1 and CtIP 
phosphopeptides. On the other hand, under the same condition, in presence of 
doubly phosphorylated Abraxas phosphopeptide (pS404pS406), BRCT undergoes 
stable dimerization indicating that residues adjacent to pSPxF motif confer specificity 
for BRCA1-Abraxas complex dimerization. Consistent with this, we found that along 
with pS404, the N-terminal region of pSPxF motif (GFGE402Y403pS404RpSPVF) also 
contributes to stability of the BRCT-Abraxas complex. Therefore, the unique amino 
acid sequence at the C-terminus of Abraxas allows stable dimerization of BRCT-
Abraxas complex but not with pSPxF motif containing BACH1, and CtIP proteins. 
Because of the symmetric pairing among F1662, M1663, and Y1666 residues of two 
BRCT1 domains, we refer this interaction as ”pair-hugging” mode, where the 
pS404pS406 phosphopeptide stabilizes the interaction. Consistent with these in vitro 
data, compared to WT Abraxas, expression of S404A and S406A mutants of 
Abraxas in Abraxas-deficient cells showed decreased BRCA1 accumulation to DSB  
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Figure 17. BRCA1 germline mutations at the BRCT dimerization interface 
disrupt dimerization in vivo. BRCA1 germline mutations F1662S and M1663K 
decrease BRCA1 dimerization in vivo. Myc-tagged BRCA1 full-length (WT-FL) 
and HA-tagged BRCA1 BRCT (WT-BRCT) or Myc-tagged mutant full-length 
(F1662S or M1663K) and HA-tagged BRCT triple mutant (TM, 
F1662S/M1663K/R1670E) were co-expressed in cells. The lysates from cells 
treated with 10 Gy IR followed by 1 hour incubation at 37 C were prepared for 
either Myc- immunoprecipitation (A) or reciprocal IP with HA- 
immunoprecipitation (B). The band intensity was quantified using ImageJ 
software and normalized value was shown in the bar graph.  
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Figure 6. Abraxas Promotes BRCA1 BRCT Dimerization In Vivo
(A) Abraxas-dependent BRCA1 dimerization in vivo. The differentially Myc- and FLAG-tagged BRCA1 full-length constructs were transiently transfected into
parental 293T (Ctrl) or Abraxas KO cells. The lysates from cells treatedwith 10Gy IR followed by 1 hr incubation at 37!Cwere used for FLAG-immunoprecipitation.
The intensity of individual bands was quantified by densitometric analysis using NIH ImageJ software. The normalized value (IPed_mycBRCA1/In-
put_mycBRCA1) was shown in the bar graph.
(B) Abraxas-dependent BRCA1-BRCT domains dimerization in vivo. The differentially Myc- and HA-tagged BRCA1-BRCT domains constructs were transiently
transfected into parental 293T (Ctrl) or Abraxas KO cells. The lysates from cells treated with 10 Gy IR followed by 1 hr incubation at 37!C were used for
HA-immunoprecipitation. The band intensity was quantified with NIH imageJ software. The normalized value (IPed_mycBRCT/Input_mycBRCT) was shown in
the bar graph.
(legend continued on next page)
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sites at IR-induced foci as well as decreased accumulation of BRCA1 to damaged 
chromatin. With these findings, it is tempting to speculate that S404 phosphorylation-
induced BRCA1 BRCT dimerization may lead to increased concentration of BRCA1 
at the sites of DNA damage, which is likely essential for efficient DNA damage 
signaling and repair.  
In an attempt to examine how this dimerization takes place in vivo, we found 
that Abraxas forms homodimer through its coiled-coiled domain at the C-terminus. 
This likely brings two BRCT domains interacting through the pS406 of the pSPxF 
motif of Abraxas in close proximity and therefore forming an unstable dimer. Since 
S404 is phosphorylated only in presence of DNA damage in an ATM-dependent 
manner, IR-induced DNA damage promotes a much more stable dimerization of the 
BRCT1-Abraxas complex. Of note, Abraxas coiled-coil domain has been shown to 
form a heterodimer with BRCC36 coiled-coil domain (41). Therefore it appears that 
in the A complex, BRCC36 and Abraxas form an oligomeric bundle through the 
coiled-coil domain present in each of them. Detail structural and cellular analysis of 
the oligomeric complex in future will provide valuable insights into how BRCA1-A 
complex is assembled at the DNA damage sites.  
 What is the functional significance of the BRCA1 BRCT dimerization in terms 
of BRCA1’s role as a tumor suppressor? Our in vitro and in vivo analysis confirmed 
that the germline mutations in the BRCT dimerization interface destabilize the dimer. 
While many tumor-derived mutations have been reported in the BRCA1 BRCT 
domain (72-74), function of large majority of these mutations is still remained to be 
determined. In this light, our analysis revealed that germline mutations, M1663K, 
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and F1662S, disrupt the BRCA1 BRCT dimerization and provide an explanation of 
how these residues play a crucial role in the tumor suppressor function of BRCA1. 
Future studies examining whether these mutations in the dimerization interface 
leads to defective DNA repair or inefficient BRCA1 loading onto damaged chromatin 
will provide valuable insights deepening our understanding of how Abraxas and 
BRCA1 function in tumor suppression and maintenance of genome stability. 
 In brief, this study reveals a novel mechanistic view of DNA damage-induced 
Abraxas phosphorylation-dependent BRCA1 accumulation to DNA damage sites. 
The structural insights of the BRCA1-Abraxas interaction will aid in designing small 
molecules in future modulating this interaction for potential therapeutic intervention. 
2.5 Future direction 
 Although BRCA1 was identified as a tumor suppressor almost 20 years ago, 
the full spectrum of its functional significance is still being elucidated. While 
mutations in the BRCA1 gene predisposes women to breast and ovarian cancer 
along with higher risk of developing other types of cancers, the exact role of BRCA1 
in tumor suppression still remains a mystery. Solving this mystery has been a 
challenge given BRCA1 associates with multiple protein complexes that are involved 
in various biological processes. Our findings of Abraxas phosphorylation-mediated 
BRCA1 dimerization at DNA damage sites provides key mechanistic insights into its 
efficient accumulation to damaged chromatin to repair DNA. However, several 
important questions still remain to be addressed to understand how BRCA1 
dimerization plays an essential role in its tumor suppressor function. Is BRCA1 
dimerization important for efficient DNA repair function of BRCA1 and thereby 
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Figure 18. Proposed model showing IR-induced ATM-dependent 
phosphorylation of Abraxas induces BRCA1 dimerization at sites of DNA 
damage for efficient BRCA1 accumulation to damaged chromatin. Abraxas C-
terminal S404 is phosphorylated in DNA damage dependent manner that promotes 
stable dimerization of BRCA1 BRCT-Abraxas complex at the sites of damage. S404 
phosphorylation is essential for efficient BRCA1 accumulation to damaged 
chromatin and germline mutations in the BRCA1-BRCT dimerization interface 
disrupts the dimer formation. 
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maintaining genome stability? Although I have examined that germline mutations in 
the BRCT dimerization interface disrupt dimer formation, future study is needed to 
further examine whether these germline mutations impair BRCA1’s role in DNA 
repair or DNA damage signaling. In addition, whether the dimerization is essential 
for accumulation of BRCA1 to damaged chromatin and thereby triggering efficient 
DDR signaling demands further investigation. Another important question that needs 
to be addressed is identification of the kinase that directly phosphorylates S404 in 
response to DNA damage. Our findings indicate S404 is phosphorylated ATM-
dependent manner. However, proteomic analysis identified more than 700 proteins, 
including many downstream kinases, as substrates for ATM and ATR (18). 
Identification of the kinase responsible for S404 phosphorylation will, therefore, 
broaden our understanding of the damage-induced phosphorylation signaling 
cascade at the damage site. Answers to these questions will shed light into how 
Abraxas phosphorylation-mediated dimerization of BRCA1 plays an essential role at 
the DSB sites to exert its function in the DDR signaling and thereby functioning as a 
‘master regulator’ for maintaining genomic integrity.  
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CHAPTER 3 
INTRODUCTION: ROLE OF LYSINE11-LINKAGE-SPECIFIC UBIQUITINATION IN 
THE DNA DAMAGE RESPONSE PATHWAY 
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3.1 Introduction 
 Ubiquitin is a 76 amino acid long polypeptide that is highly conserved among 
eukaryotic kingdom identified initially as ATP-dependent protein degradation 
component in reticulocytes (100-102). However, recent years have witnessed an 
unprecedented growth in our understanding of the non-proteolytic functions of 
ubiquitination in cellular signaling (103). Covalent conjugation of ubiquitin molecule 
to substrate proteins governs a wide range of cellular processes including protein 
degradation, transcription, cell cycle progression, immune response, and receptor 
trafficking as well as viral infection. Protein ubiquitination is a three-step enzymatic 
process mediated by E1 activating enzyme, E2 conjugating enzyme and E3 ligase 
enzyme (104). Ubiquitin is activated by an E1 activating enzyme in an ATP-
dependent manner forming thioester bond between the C-terminal carboxyl group of 
Gly residue of ubiquitin and the active cysteine residue of the E1 enzyme (105). In 
the following step, the ubiquitin is transferred to the cysteine residue of the cognate 
E2 enzyme (106) and subsequently transferred to the ε-amino group of a lysine 
residue of the substrate forming an isopeptide linkage in presence of an E3 ligase 
(107). Monoubiquitination of substrates in one or more than one lysine residues 
(multi-mono ubiquitination) is highly abundant in eukaryotic cells suggesting the 
functional significance of this modification in cellular signaling (108). For example, 
(multi) mono-ubiquitination of cell surface receptor proteins plays a crucial role in 
endocytosis and subsequent degradation of these receptors in lysosomes or 
recycling back to the cell surface (109).   
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Figure 19: Schematic of ubiquitin system. Ubiquitination is an enzymatic 
process that involves covalent attachment of ubiquitin to target protein catalyzed 
by E1 activating, E2 conjugating and E3 ligase enzymes. These enzymes not 
only transfer ubiquitin to protein substrates at single or multiple lysine residues, 
but also promote the formation of long polyubiquitin chains through one of seven 
lysine residues of ubiquitin as shown here in blue forming polyubiquitin chain of 
distinct linkages. 	
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Interestingly, unlike phosphorylation, ubiquitin machinery can also add further 
ubiquitin molecules through one of the seven lysine residues in substrate-conjugated 
ubiquitin molecule synthesizing polyubiquitin chain of distinct lineages forming 
polyubiquitin chain of distinct linkages (110, 111). In addition, recent findings indicate 
the existence of an eighth kind of ubiquitin chain formed through the N-terminus of 
ubiquitin, also known as ‘Met1-linked’ or linear chains, demonstrating the magnitude 
of complexity of the ‘ubiquitin code’ (112). Proteomic approaches have shown the 
existence of all seven lysine residue-linked as well as Met1-linked linear 
ubiquitination in cells (108, 113-115). Since different ubiquitin chains adopt a distinct 
structure that can be recognized by specific ubiquitin-binding domain (UBD) 
containing proteins, ubiquitin chain with different length and topology trigger vastly 
different molecular signals in vivo (116, 117). Chain specificity is an intrinsic property 
of E2 enzymes; and E3 ligases interact with different E2 enzymes generating 
different linkage-specific ubiquitin chains on substrate proteins (106, 118). In 
eukaryotes, there are approximately 35 E2s and more than 500 E3 enzymes have 
been reported to date. Given the vast number of different E2-E3 combinations, this 
provides an additional layer of regulation for assembly of linkage-specific 
ubiquitination. Furthermore, similar to other post-translational modifications, cellular 
ubiquitination is also reversible process, in which enzymes known as 
deubiquitinases or DUBs cleave the polyubiquitin chain on substrates, thereby 
recycling and maintain free ubiquitin pool in the cell. There are around 100 DUB 
enzymes encoded by the human genome that oppose the function of E3 ligases and 
thereby regulating the ubiquitin signaling in cells (89). Therefore, precise balance 
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and coordination among ‘writer’, ‘reader’ and ‘eraser’ for the ‘ubiquitin code’ 
propagates specific cellular signaling in vivo essential for cellular homeostasis.  
3.1.1 Linkage-specific ubiquitination: 
Among different lysine residue-linked ubiquitination, canonical Lys48-linked 
ubiquitination was first identified and assumed to be the only linkage type targeting 
proteins for degradation (119, 120). Over the following years, Lys63-linked 
ubiquitination was identified as a non-proteolytic signal involved in DNA repair in 
yeast Saccharomyces cerevisiae (121). Since then Lys63-linked ubiquitination has 
been extensively studied in the DNA damage response pathway as well as other 
non-proteolytic pathways including vesicular traffic, endocytosis, and NF-kB 
pathways (122-125). However, our knowledge of the role of other linkage-specific 
ubiquitination in cellular signaling pathways remained limited. One of the major 
challenges in the field of linkage-specific ubiquitination is the detection of different 
lysine residue-linked ubiquitin conjugation in cells due to varying degree of chain 
abundance and rapid turnover of ubiquitin chains by different DUB enzymes. 
Nonetheless, advancement in mass-spectrometry-based proteomic approaches 
such as Absolute QUantitative Analysis (AQUA) as well as Protein Standard 
Absolute Quantification (PSAQ), paves the way to gain further insights into the 
unexplored world of different linkage-specific ubiquitination in cells (108, 111, 113, 
114, 126-129). Although different groups have reported a varying abundance of 
linkage-specific ubiquitin chains, findings from these studies suggest the presence of 
all different chain types in yeast and mammalian cells.  
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3.1.2 Linkage-specific polyubiquitination in the DNA damage response 
pathway: 
Although mass-spec analysis identified the existence of all seven lysine 
residue-linked ubiquitination in cells, the functional significance of these different 
chain types in various cellular signaling pathways in cells still remains to be 
determined. Given the heterogeneity of ubiquitin code and complexity of the DNA 
damage response signaling, it is not tempting to speculate that many of these 
ubiquitin chains exist at the damaged chromatin. Indeed seminal studies done by 
different groups had conclusively shown that Lys63-linked ubiquitin conjugation is 
predominant at DNA damage sites modifying histone proteins at damaged chromatin 
and regulating downstream DDR factor recruitment such as 53BP1 and components 
of the BRCA1-A complex (37-39, 41, 43-45). Along with Lys63-linked ubiquitination, 
several biochemical studies and mass-spec analysis identified existence of other Lys 
residue-linked ubiquitination including Lys6, 27, 29, 33 and 48 at damaged 
chromatin and the abundance of this ubiquitin chains can alter dramatically in 
response to DNA damage. Together these findings indicate that ubiquitin signaling 
at the damage sites is much more complex than anticipated before.  
3.1.3 Lys63-linked ubiquitin chain: 
 DNA damage-induced Lys63-linked ubiquitin conjugation is the most well 
characterized linkage-specific ubiquitination involved in the DNA damage response 
pathway. In one of the seminal articles, Finley and colleagues first reported 
existence of the Lys63-linked ubiquitin conjugates in yeast Saccharomyces 
cerevisiae (121). Although yeast strains carrying K63R mutant ubiquitin were 
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proficient in growth and efficient in turning over of cellular proteins, K63R mutation 
conferred hypersensitivity to DNA damaging agents such as methyl 
methanesulfonate (MMS), UV, X-rays providing key evidence that nonproteolytic 
Lys63-linked ubiquitination is involved in the DDR signaling pathway. Subsequent 
studies identified Ubc13/Mms2 heterodimer assembles Lys63-linked polyubiquitin 
chain in vitro and in yeast (122, 130). To identify the E3 ubiquitin ligase involved in 
the Lys63-linked ubiquitination, Plans et al performed yeast two-hybrid screening 
using Ubc13 (also known as Ube2N) as bait and identified human Ring finger protein 
8 (RNF8) as an E3 ligase that interacts and co-localizes with human Ubc13 in cells. 
Further analysis demonstrated that RNF8 functions as a self-ubiquitin ligase that is 
polyubiquitinated in Lys63-linked manner mediated by Ubc13 (131).  
Although these early findings provided the key insights into the enzymatic 
machinery catalyzing non-proteolytic Lys63-linked ubiquitination, the functional role 
of this ubiquitination in the DDR signaling was still missing until 2007 when 
independent studies demonstrated Lys63-linked polyubiquitin conjugate enrichment 
at damaged chromatin by elegant biochemical approaches (37-39, 41). These 
studies have conclusively shown that a phosphorylation-dependent ubiquitin 
signaling cascade at the DSB sites orchestrates the DNA damage response 
signaling by functioning as a molecular scaffold to recruit downstream DDR factors. 
Upon DNA damage, ATM-mediated phosphorylation of adaptor protein MDC1 
recruits RNF8 to DSBs flanking chromatin. Once recruited, RNF8, in association with 
Ubc13, initiates non-proteolytic Lys63-linked ubiquitination of histones H2A and 
H2A.X. The assembly of the Ubc13-RNF8 complex is further facilitated by another 
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E3 ligase, HERC2, which is phosphorylated by ATM upon DNA damage and 
interacts with RNF8 FHA domain (40). Later studies demonstrated that initial Lys63-
linked ubiquitin polymer generated by Ubc13-RNF8 enzymes is recognized by 
ubiquitin binding domain of another E3 ligase, RNF168 that functions in concert with 
Ubc13 and amplifies the Lys63-linked ubiquitin chain on H2A and H2A.X generating 
polyubiquitin chain of Lys63 lineage (43-45).  Ubc13-RNF8-RNF168-mediated 
Lys63-linked ubiquitination of core histones and other unidentified non-histone 
proteins at damaged chromosomes is crucial to transduce the DDR signal by 
recruiting the DDR mediator proteins, BRCA1 and 53BP1 to DSB sites. As shown by 
our lab and several other groups, Lys63-linked polyubiquitin conjugates at DSB sites 
is recognized by ubiquitin interacting motif (UIM) of Rap80 protein that recruits 
Abraxas and subsequently the entire BRCA1-A complex, which includes Abraxas, 
Rap80, NBA1, BRE and BRCC36 (41, 47, 49, 51, 132, 133). Recruitment of these 
factors to DNA damage sites is essential for efficient DNA repair and checkpoint 
signaling indicating the functional significance of these enzymes in the DDR 
pathway. Although these studies showed core histone proteins, H2A and H2A.X are 
modified by Lys63-linked ubiquitination; it is likely that other non-histone proteins at 
damaged chromatin are also modified by this modification. Identification and 
characterization of these proteins will broaden our understanding of the complexity 
of the DDR signaling.  
In addition to BRCA1, Lys63-linked ubiquitination on nucleosome also recruits 
another mediator protein 53BP1 to the sites of DNA damage. Earlier studies have 
demonstrated that 53BP1 localization to damaged chromatin is mediated by 
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recognition of dimethylated histone H4K20 (H4K20me2) by tandem Tudor domain of 
53BP1 (134). However, impaired recruitment of 53BP1 in RNF8 and RNF168 
depleted cells raised the possibility that Ubc13-RNF168 catalyzed Lys63-linked 
ubiquitination at damaged chromatin may also promote its recruitment to IR-induced 
foci (37-39, 43). Consistent with this idea, recent experimental evidence by Durocher 
group have shown that in addition to its Tudor domain, 53BP1 also harbors a C-
terminal extension, termed as ubiquitination-dependent recruitment (UDR) motif that 
specifically recognizes ubiquitinated histone H2A on lys15 (H2AK15ub) (135). 
Together these findings propose a model of 53BP1 recruitment to DNA damage 
sites as a bivalent reader recognizing both H4K20me2 and Ubc13-RNF8-RNF168 
mediated H2AK15ub.  
Although the seminal studies provided key evidence of histones H2A and 
H2A.X as major substrates for Lys63-linked ubiquitination, the full-spectrum of 
substrates modified by Lys63-linked ubiquitination still remained largely unknown. In 
this light, it is of interest that a recent study identified H1-type linker histone as a key 
substrate modified by the Ubc13-RNF8 complex in DNA damage-dependent manner 
forming Lys63-linked ubiquitin chain. The lys63-linked chain functions as an 
interacting module for RNF168 through its N-terminal ubiquitin-dependent DSB 
recruitment module 1 (UDM1). Once recruited, the Ubc13-RNF8-RNF168 enzymatic 
machinery then catalyzes Lys63-linked ubiquitination of core histone proteins. 
Consistently, depletion of linker histone impairs Lys63-linked ubiquitin conjugation 
and accumulation of DDR factors at damage sites including BRCA1. These findings 
propose a model where Ubc13-RNF8 complex and RNF168 function as writer and 
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reader, respectively of the Lys63 ubiquitinated linker histone H1 protein expanding 
the ‘histone code’ in the DNA damage response pathway (136). 
3.1.4 Lys6-linked ubiquitin chain: 
In the DNA damage response pathway, Lys6-linked ubiquitination was initially 
identified as polyubiquitin chain catalyzed by heterodimeric BRCA1/BARD1 E3 
ubiquitin ligase complex. Both in vitro and in vivo analysis have shown that 
BRCA1/BARD1 ligase complex catalyzes autoubiquitination of BRCA1 in Lys6-
linked polyubiquitin chain that is recognized but not degraded by the 26S 
proteasome (81-84). In addition to BRCA1 autoubiquitination, BRCA1/BRAD1 ligase 
complex has been shown to ubiquitinates RPB8, a subunit of RNA polymerase 
holoenzyme, upon UV-induced DNA damage. While retaining its function as a 
subunit of RNA polymerase complex, the Lys6-linked polyubiquitin-resistant RPB8 
mutant showed UV hypersensitivity in cells emphasizing the role of Lys6-linked 
ubiquitination in the DDR pathway (137).  These findings have been validated further 
by recent global profiling of the ubiquitin species in cells showing that enrichment of 
Lys6-linked polyubiquitin conjugates after UV treatment but not irradiation (IR)-
induced DNA damages (138). BRCA1 has been shown to localize to UV-induced 
foci and functions in a DNA replication-dependent manner to facilitate post-
replicative repair (139).  
In addition to BRCA/BARD1, another RING domain E3 ligase, RNF8, has 
been shown to catalyze Lys6-linked ubiquitination of Nbs1, a component of the MRN 
(MRE11-Rad50-Nbs1) protein complex that senses the DNA double-strand breaks. 
The E2 conjugating enzyme UbcH5c and E3 ligase RNF8-mediated Lys6-linked 
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ubiquitination of Nbs1 is essential for efficient recruitment of Nbs1 to damaged 
chromatin to promote HR repair (140). Consistent with these findings mass-
spectrometry analysis have confirmed no significant enrichment of Lys6-linked 
polyubiquitin conjugates upon treatment with proteasomal inhibitor MG132 indicating 
unlike Lys48-linked ubiquitination, Lys6 polyubiquitin chain is involved in non-
proteolytic functions in cells (141, 142).  
3.1.5 Lys27-linked ubiquitin chain: 
 Lys27-linked ubiquitination has emerged recently as another ‘atypical 
ubiquitination’ involved in the DNA damage response pathway. In their recent 
findings Penengo  and colleagues have analyzed different lysine residue-linked 
ubiquitination in cells overexpressing RING E3 ligase, RNF168, which has been 
shown previously to catalyze Lys63-linked ubiquitination at the damage sites (43-45, 
143). Selected reaction-monitoring mass spectrometry (SRM) analysis revealed that 
overexpression of RNF168 leads to Lys27-linked polyubiquitin conjugation in cells. 
In addition their findings indicate histone proteins, H2A and H2A.X, were modified by 
RNF168-mediated Lys27-linked polyubiquitination. Furthermore, Lys27-linked 
chromatin ubiquitination is essential for efficient recruitment of DDR mediators such 
as BRCA1, 53BP1, Rap80, RNF168, RNF169 to DSB sites and therefore is required 
for optimal activation of the DDR signaling (56). Taken together, these findings 
revealed new roles of linkage-specific ubiquitination induced by genotoxic stress 
providing insights into the complexity of ‘ubiquitin code’ at the DNA damage site. 
3.1.6 Lys29 and Lys33-linked ubiquitin chain: 
 While functions of Lys29-and Lys33-linked ubiquitination in DNA damage 
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response still remain largely elusive, findings from recent studies provide evidence 
of these linkage-specific ubiquitination in various other signaling pathways such as 
Wnt/β-catenin signaling and protein trafficking, respectively (110, 111). Both these 
modifications have been shown to be enriched upon treating the cells with 
proteasomal inhibitor MG132 suggesting proteolytic functions of these chain types in 
cells (113, 142). Interestingly recent quantitative proteomic analysis of global 
ubiquitination profile in mammalian cells by Elledge and colleagues showed a 
marked increase (about 2 fold) in endogenous Lys33-linked ubiquitination upon UV-
induced but not IR-induced DNA damages (138). Although functional significance of 
these preliminary findings demand further investigation, given the complexity of the 
DDR signaling and ‘ubiquitin code’, it is tempting to speculate that these 
modifications play potential roles in the DNA damage response pathway.  
3.1.7 Lys48-linked ubiquitin chain: 
 Although degradation-linked Lys48 ubiquitination has been extensively 
studied in various cellular signaling, its role is obscured in the DDR pathway. Since 
DDR factor retention at the sites of DNA damage needs to be tightly regulated, it is 
likely that many of the DDR factors are modified with Lys48 ubiquitin chain to ensure 
removal of these factors from sites of DNA damage in a timely manner. In one of the 
earliest studies using Xenopus egg extract coupled to tandem Mass-spectrometry, 
Funabiki and colleagues showed that among different DDR factors, Ku80, a crucial 
factors in the NHEJ repair pathway, is modified with Lys48-linked ubiquitin chain 
upon binding to DBS containing DNA by Skp1–Cul1–F-box (SCF) E3 ligase 
complex. Strikingly, although proteasome targets for lys48 ubiquitin decorated Ku80 
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once it is released from DSB, the proteasome activity is not required for Ku80 
removal from DSBs (144, 145). Another study by Shi et al showed that MDC1 is 
heavily ubiquitinated with the Lys48-linked chain in DNA damage-dependent manner 
and subsequently degraded by the proteasome that is essential for disassembly of 
MDC1 protein from the sites of DNA damage (146). Similar to MDC1, BRCA1 has 
also been shown to be ubiquitinated and degraded following a high dose of 
irradiation (IR)-induced DNA damage, independent of its autoubiquitination E3 ligase 
activity and is required for IR-induced apoptosis (147, 148). More recently, RNF8 E3 
ligase, which has been identified as an E3 ligase catalyzing Lys63-linked 
ubiquitination in concert with the Ubc13 E2 enzyme at damaged chromatin, has 
shown to function with another E2 conjugating enzyme, UbcH8, to catalyze Lys48-
linked ubiquitin chain at the damage sites. RNF8-mediated Lys48-linked 
ubiquitination of Ku80 regulates its turnover at the sites of DNA damage regulating 
NHEJ-mediated DNA repair (57, 58). Kinetic analysis of Lys48 and Ly63-linked 
ubiquitination at the sites of DNA damage using linkage-specific antibody showed 
that Lys48-linked ubiquitin chain is assembled at the DSBs immediately after DNA 
damage, while Lys63-linked ubiquitin conjugation occurs at much slower rate at the 
damaged chromatin facilitating coordinated recruitment of DDR factors (57, 149). 
These observations suggest that Lys48-linked ubiquitin conjugation and proteasome 
are the essential elements of the DDR signaling that regulate orchestration of DDR 
factors. 
3.1.8 Lys11-linked ubiquitination: 
 Lys11-linked ubiquitination was first identified as novel ubiquitin chain type 
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catalyzed by Ube2S (also known as E2-EPF) in 1996 (150). Later studies identified 
another E2 conjugating enzyme Ube2C (also known as UbcH10) that along with 
Ube2S catalyze Lys11-linked ubiquitin chain on substrates in presence of APC/C E3 
ubiquitin ligase (151-155). APC/C is a large multisubunit E3 ligase complex that in 
association with Ube2S and Ube2C modifies mitotic and G1 phase cell cycle 
proteins including CyclinB1 and securin, with Lys11-linked ubiquitin chain and target 
proteasomal degradation (156). In recent years, Ube2S/Ube2C and APC/C-
mediated Lys11-linked ubiquitin chain assembly has emerged as a major regulatory 
player in proper cell cycle progression. Importantly, recent studies identified an OUT 
family deubiquitinase (DUB), Cezanne (also known as OTUD7B), which 
preferentially cleaves Lys11 ubiquitin chain (157, 158). Interestingly, although a 
proteomic study identified Lys11-linked ubiquitination as one of most abundant 
ubiquitin chain types in cells (114), the role of Lys11-linked ubiquitination in the DDR 
pathway still remains to be elucidated. 
3.1.9 Objective:  
 Chromatin modification at DNA damage sites constitutes an immediate 
component of the cellular response to DNA damage for signaling and repair. While 
proteomic analysis of global ubiquitination profiling revealed assembly of all seven 
lysine residue-linked ubiquitination in a varying degree of abundance in both yeast 
and mammalian cells (113, 114, 159), function and characterization of non Lys63-
linked ubiquitin conjugation at the DSB sites still demands further investigation. 
Since the DNA damage response signaling encompasses a vast number of 
molecules, depending on the type of DNA lesions experienced by the cell, it is not 
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surprising that DDR factors are modified with non Lys63-linked ubiquitin chains as 
well to regulate the DDR signaling and facilitate efficient repair. Although recent 
findings by above-mentioned studies showed promising evidence of the existence of 
different types of ubiquitin linkages in UV- and IR-induced DNA damage sites, much 
is still missing for understanding the role of linkage-specific ubiquitin chains in the 
regulation of DNA damage response and repair. Therefore, in this study, I aim to 
explore existence and functional significance of non-lys63-linked ubiquitin 
conjugation at the DNA damage sites. Findings from this study will broaden our 
understanding of the complexity of ubiquitin signaling at the damage sites. 
3.2. Materials and Methods  
3.2.1 Cell Culture, Transfection, Antibodies and Reagents 
U2OS and HEK293T cells were grown in McCoy’s 5A and DMEM medium 
respectively with 10% fetal bovine serum (FBS) and maintained at 37°C with 5% 
CO2. For generation of stable knockdown cell lines, cells were infected with 
retrovirus containing shRNAs against Ube2S, Ube2C or CDH1 followed by selection 
with puromycin (0.8 µg/ml) or blasticidin (9 µg/ml) according to the selection marker 
of the construct. For generation of Ube2S/Ube2C double knockdown cell line, 
Ube2S-knockdown cells were further infected with retrovirus containing Ube2C 
shRNA followed by selection with blasticidin. For transient transfection, cells were 
transfected with PEI (polyethylenimine) or Lipofectamine 2000 (Invitrogen). 
Antibodies used in this study are listed in Table 1. Other regents used are listed in 
Table 2. 
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3.2.2 Plasmids, shRNAs and siRNAs 
Retroviral constructs expressing GFP-Ube2S, GFP-Ube2C, Flag-RNF8 were 
generated using MSCV vector. Flag-tagged histone plasmids were kindly provided 
by Dr. Yuzuru Shiio (160), University of Texas Health Science Center at San 
Antonio. HA-tagged WT and K0 ubiquitin plasmids (pRK5-HA-ubiquitin) were 
obtained from Addgene (161) and lysine-only ubiquitin mutants were generated by 
site-directed mutagenesis. His-Biotin (HBT)-WT ubiquitin (pQCXIP HB-Ubiquitin) 
was used to generate His-biotin-K11 ubiquitin mutant through site-directed 
mutagenesis. The shRNAs and siRNAs used in this study are listed in Table 3. GFP-
tagged siRNA1-resistant Ube2S clone was generated by inserting three nucleotide 
mismatches underlined (TCTTCCCAAATGAGG) into Ube2S sequence by site-
directed mutagenesis using the primers described in the Table for resources and 
subsequently recombining into pDEST-MSCV-GFP vector. 
3.2.3 Immunofluorescence 
Immunofluorescence was carried out as described previously (55). Briefly, 
cells were fixed with 2% formaldehyde for 10 min at room temperature, 
permeabilized with 0.5% Triton X-100 solution (25 mM HEPES pH 7.4, 50 mM NaCl, 
1 mM EDTA, 3 mM MgCl2, 300 mM Sucrose, 0.5% triton-X) at 4°C for 5 min and 
incubated with primary antibodies at 37°C for 1 hr. Appropriate secondary antibodies 
conjugated with Alexa 488-conjugated (green; Invitrogen) and Alexa 555-conjugated 
(red; Invitrogen) were used. For endogenous Ube2S immunostaining following laser 
micro-irradiation, cells were pre-extracted with ice-cold pre-extraction buffer (10 mM 
PIPES, pH 7, 100 mM NaCl, 300 mM Sucrose, 3 mM MgCl2, 0.2% Triton-X100) for 
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5 min at room temperature before fixation and permeabilization. Images were 
obtained by Nikon confocal microscope. 
3.2.4 Cell Lysis and Immunoprecipitation  
Cells were lysed in NETN buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 
mM EDTA, 0.5% Nonidet P-40, 1 mM DTT) with protease inhibitors, 1 mM PMSF,1 
mM NaF, 1 mM Na3VO4 and 20 mM N-Ethylmaleimide (NEM) (freshly prepared). For 
Flag immunoprecipitation, Flag beads (98) were added to cell lysates and incubated 
overnight with gentle agitation at 4°C. The beads were washed four times with NETN 
lysis buffer before elution with 2X sample loading buffer. For Flag- 
immunoprecipitation under denaturing condition, cells were harvested and washed 
with PBS, cell pellets were resuspended in denaturing lysis buffer (20 mM Tris, pH 
7.4, 50 mM NaCl, 0.5% NP-40, 0.5% sodium deoxycholate, 0.5% SDS, 1 mM EDTA, 
20 mM N-Ethylmaleimide (NEM) and protease inhibitors). The lysates were 
sonicated, centrifuged and immunoprecipitated with Flag-beads overnight at 4°C 
with gentle agitation. The beads were then washed with denaturing lysis buffer four 
times before elution with 2X sample buffer. 
3.2.5 Chromatin fractionation  
Chromatin fractionation was carries out as described previously (87). The 
chromatin fraction pellet was resuspended in NETN lysis buffer containing 20 mM 
NEM and protease inhibitors. After sonication and centrifugation at 15000 rpm for 10 
min, the supernatant was collected as chromatin fraction and protein concentration 
was measured by Bradford assay. 10 µg of total chromatin fraction protein was used 
for western blot analysis. 
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3.2.6 Laser-induced DNA Damage and Live Cell Imaging 
U2OS cells were cultured in glass-bottomed dish or 8-well chambers (Mattek 
Cultureware). BrdU (BD Biosciences) was added to medium with a final 
concentration 10 µM 24 hour prior to laser irradiation. Nikon TE2000 inverted 
microscope coupled with a MicroPoint laser system with a UV laser (364 nm) and 
60X water lens was used with laser energy output set to 20-30% and number of 
pulses set to five (total of 335 ms).  Following laser ablation, cells were either fixed 
for immunostaining at indicated time points or monitored by live cell imaging with 
images captured at 30 seconds intervals. Live-cell imaging was taken and analyzed 
with Metamorph software. 
3.2.7 Clonogenic survival assay 
The assay was performed as described previously (87). Briefly, U2OS cells 
were plated at low density and treated with 4 or 6 Gy IR (or left untreated). The cells 
were then incubated at 370C for two weeks to form colonies. Colonies were fixed 
and stained with 2% methylene blue and 50% ethanol. Colonies with 50 or more 
cells were counted as positive. 
3.2.8 Nascent transcript detection at DNA damage sites 
U2OS cells were transfected with control or Ube2S/Ube2C siRNAs. 48 hr 
post-transfection, cells were subjected to laser-microirradiation. 5-ethynyl uridine (5-
EU) was added to the media immediately after laser treatment to a final 
concentration of 1 mM followed by incubation at 370C for 1 hr. Cells were then fixed, 
permeabilized and incorporation of 5-EU was detected by Click-iT RNA imaging kit 
(Invitrogen) following manufacturer’s instruction and IF staining of γH2AX was 
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carried out after Click-it reaction. Relative 5-EU intensity along the laser track was 
quantified using Nikon Elements software and normalized to γH2A.X mean intensity 
along the same region.  
3.2.9 Histone acid extraction 
U2OS cells harvested and washed with 1X PBS were resuspended in freshly 
prepared cytosolic extraction buffer (10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM 
MgCl2, 0.34 M sucrose, 10% glycerol, 5 mM NaF, 1 mM Na3VO4 , 1 mM dithiothreitol 
(DTT), 0.5% Triton-X, 20 mM NEM) with protease inhibitors at a concentration of 107 
cells/ml and incubated on ice for 10 min followed by centrifugation at 4000 rpm for 5 
min at 4°C. Cell pellet was washed once with cytosolic extraction buffer and then 
resuspended in 0.25N HCl at a cell density of 4X107/ml and incubated at 4°C for 3 hr 
followed by centrifugation at 12,000 rpm for 5 min at 4°C. The supernatant was then 
collected and 1 ml ice-cold acetone was added for overnight at -20°C. Following 
centrifugation at 12,000 rpm for 5 min at 4°C, the pellet was rinsed with acetone 
once, air-dried at room temperature, and dissolved in 25 µl 50 mM Tris, pH 7.4 
buffer. 5-10 µg of acid-extracted histones was used for western blot analysis.  
3.2.10 Streptavidin beads pull-down 
HeLa cells stably expressing His-Biotin-K11 ubiquitin were grown in media 
supplemented with 2 µg/ml Biotin for 36 hr before treatment with 10 Gy IR. After 
irradiation, cells were incubated at 37°C for 30 min, then lysed in denaturing buffer 
(8M Urea, 300 mM NaCl, 0.5% NP-40, 50 mM Na2HPO4, 50 mM Tris, pH 8, 1 mM 
PMSF, 20 mM NEM). Lysates were sonicated and pull-down with Streptavidin beads 
was carried out overnight at room temperature. Beads were washed 4 times with 
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denaturing buffer and bound proteins were eluted with sample buffer and analyzed 
by SDS-PAGE and western blot using ubH2A antibody. 
2.2.11 In vitro ubiquitination assay 
For in vitro ubiquitination assay, 1 µg histone H2A (New England Biolabs) or 2 
µg mononucleosome or 1 µg  H2A/H2B dimer was incubated with 50 ng E1 (Boston 
Biochem), 50 or 100 ng of each of Ube2S and Ube2C (Abcam), 2 µg ubiquitin 
(Boston Biochem) and purified Flag-RNF8 in 20 µl reaction mixture buffer (50 mM 
Tris, 5 mM KCl, 5 mM MgCl2, 0.5 mM DTT, 200 mM Creatine phosphate 
(Calbiochem), 2 µg/µl Creatine Phosphokinase (Calbiochem), 2 mM ATP(New 
England Biolabs) at 32°C for 2 hr. The reaction was stopped by addition of sample 
buffer and resolved by SDS-PAGE. Flag-RNF8 was purified from HEK293T cells 
expressing Flag-tagged RNF8. Flag immunoprecipitation was carried out by 
incubating Flag-beads with cell lysates overnight at 4°C with gentle agitation. The 
beads were then washed by NETN buffer followed by elution with 3X Flag peptide 
(98). For RNF8 autoubiquitination assay, Flag-RNF8 was incubated with purified 
ubiquitin (2 µg), E1 activating enzyme (50 ng), 50 or 100 ng of each of Ube2S and 
Ube2C in the reaction mixture buffer at 32°C for 2 hr. For recombinant GST-RNF8 in 
vitro autoubiquitination assay, 500-1000 ng of purified GST-RNF8 was used. 
Reaction was stopped by addition of 2X sample loading buffer and analyzed by 
western blot with FK2 antibody. 
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Table 1: List of Antibodies: 
Antibody Company/Source Catalogue number 
BRCA1 Santa Cruz Cat#sc-6954 
γ-tubulin Sigma Aldrich Cat#T3559 
HA Cell Signaling Cat#C29F4 
Ube2S  Cell Signaling Cat#9630 
Ube2C Sigma Aldrich Cat#WH0011065M1 
Flag  Sigma Aldrich Cat#F7425 
H2A Abcam Cat#Ab13923 
H2AX Abcam Cat#Ab11175 
H3 Abcam Cat#ab1791 
H2B Abcam Cat#ab1790 
phospho H3 Millipore Cat#06-570 
53BP1 Upstate Cat#05-726 
γ-H2A.X  Upstate Cat#05-636 
γ-H2A.X Millipore Cat#07-164 
ubH2A Millipore Cat#05-678 (lot 22424) 
GFP Invitrogen Cat#A11122 
FK2 Biomol Cat#PW8810 
Cyclin B1  Santa Cruz Cat#SC245 
ATM Cell Signaling Cat#2873S 
ATR SantaCruz  Cat#sc-1887 
Ubc13 Zymed Laboratories Cat#37-1100 
Rap80 Bethyl  Cat#A300-763A 
Rpb1 Santa Cruz Cat#sc-899 
PCNA Santa Cruz Cat#sc-56 
OTUD7B Santa Cruz  Cat#sc-514402 
Abraxas Wang et al., 2007 N/A 
Cdh1 NeoMarkers Cat# MS-1116-P0 
MDC1 Stuart et al., 2003 N/A 
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Table 2: List of chemicals, recombinant proteins and reagents: 
 
Chemicals (Inhibitors), Purified protein, 
reagents 
Company Catalogue number 
MG132 Thermo Scientific Cat#NC9819784 
NEM Thermo Scientific Cat#128-53-0 
proTAME Boston Biochem Cat#I-440 
Purified GST-RNF8 Ubiquigent Cat#63-0021-025 
Purified Ube2S Abcam Cat#ab87756 
Purified Ube2C Abcam Cat#ab151891 
Recombinant Human Mononucleosome  EpiCypher Cat#16-0009 
Recombinant Human H2A/H2B dimer EpiCypher Cat#15-0311 
Recombinant Human histone H2A NEB Cat#M2502S 
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Table 3: List of shRNA and siRNA sequences: 
 
 
 
Ube2S shRNA - TGGAGGTCTGTTCCGCATG   
Ube2C shRNA - GGAGCAGCTGGAACAGTAT   
Cdh1 shRNA  - GGGAAGAAGCTGTCCATGT   
Ube2S siRNAs                                                        
(siRNA1-GGUCUUUCCCAACGAGGAG,                 
siRNA2-CAAGGAGGUGACGACACUG,                 
siRNA3-CAUGCUGGCGAGCGCGAUA) 
Invitrogen  
Ube2C  siRNAs                                                      
(siRNA1-CCUACUCAAAGCAGGUCAC,                 
siRNA2-GUGUCGUCUUUUUAAUUUU) 
Invitrogen  
ATM siRNAs                                                            
(siRNA1-GCGCAGTGTAGCTACTTCTTCTATT, 
siRNA2- GGGCCTTTGTTCTTCGAGACGTTAT, 
siRNA3-GCAACATTTGCCTATATCAGCAATT) 
Invitrogen              
(Stealth siRNA) 
 
ATR siRNAs Invitrogen             
(Stealth siRNA) 
HSS100876, 
HSS100877, 
HSS100878 
MDC1 siRNAs Invitrogen           
(Stealth siRNA) 
HSS114445, 
HSS114446, 
HSS114447 
RNF8 siRNAs                                                          
(siRNA1-GGGUUUGGAGAUAGCCCAAGGAGAA,  
siRNA2-GCAGCAAGAAGGACUUUGAAGCAAU, 
siRNA3-GGAGAAUGCGGA- GUAUGAAUAUGAA) 
Invitrogen             
(Stealth siRNAs 
 
Ubc13 siRNAs                                                          
(siRNA1-UUCUGGAAGGAAUAGUUCAAGUUUA,  
siRNA2-UUCCCAACUUGUCUACAUUAGGAUG, 
siRNA3-AUUGGGAGCACUUAACAAGGCCUGG) 
Invitrogen            
(Stealth siRNAs 
 
Cezanne (OTUD7B) siRNAs                                                      
(siRNA1 – AGGUCUCUCUCUAUGAAGC,                 
siRNA2 – CUUCUGUGUAUACCAGCCC) 
Invitrogen  
H2AX siRNAs Invitrogen stealth 
siRNAs 
HSS142372, 
HSS142373, 
HSS142374 
Apc2 siRNAs                                                                 
(siRNA1 – GAGAUGAUCCAGCGUCUGUUU,  
siRNA2 –GACAUCAUCACCCUCUAUAUU) 
Dhamrmacon  
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3.3. Results  
3.3.1 Analysis of linkage-specific ubiquitin mutant conjugation at DNA damage 
sites 
As described in section 3.1, all seven lysine residues in ubiquitin molecule 
can serve as conjugate sites for additional ubiquitin molecules forming polyubiquitin 
chain of distinct lineages. To test whether different linkage-specific ubiquitin 
conjugation occurs at the site, GFP-tagged single lysine only ubiquitin mutants (K6-, 
K11-, K27-, K29-, K33-, K48- and K63-), in which all lysine residues except one were 
mutated to arginine, as well as a lysine-less mutant with all lysine residues mutated 
(K0) were generated (Figure 20A). Stable U2OS cells expressing GFP-tagged WT or 
lysine only and K0 ubiquitin mutants were generated by infecting WT U2OS cells 
with retroviral constructs expressing WT or abovementioned ubiquitin mutants. 
Western blot analysis confirmed GFP-WT or mutant Ub was expressed at a similar 
level and was able to form polyubiquitin conjugates indicated by higher molecular 
weight bands in the western blot with GFP antibody. (Figure 20B). To test 
conjugation of different lysine only ubiquitin mutants at the DNA damage sites, a 
laser ablation system equipped with live-cell imaging was utilized to induce DNA 
damage at a particular region in the nucleus and conjugation of different ubiquitin 
mutants as the damage sites were monitored by time-lapse microscopy. As shown in 
Figure 21A, GFP-WT and GFP Lys63 Ub were deposited at laser-induced DNA 
damage tracks immediately after laser treatment, in consistent with an established 
role of ubiquitin conjugation occurring at DNA damage 
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Figure 20 :Generation of lysine only ubiquitin mutants. A Schematic 
representation of different lysine only ubiquitin mutants. 
linkages. B. Western blot analysis of cell lysates from U2OS cells stably 
overexpressing GFP-tagged WT or lysine only ubiquitin mutants. Expression of GFP-
ubiquitin was detected by GFP antibody. (*) indicates a non-specific band used as 
loading control. 
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sites (37-39, 41, 43-45, 162). Interestingly, GFP-K11 Ub was observed accumulating 
at laser-irradiated tracks robustly with similar kinetics as that of GFP-K63 Ub or K48 
Ub (Figure 21A and B). Compared to WT, GFP-K63, -K48, and -K11; accumulation 
of GFP-K6, K27, K29, K33, and K0 Ub to laser tracks were mild during the time 
frame of imaging. These findings suggest that mono-ubiquitination or polyubiquitin 
conjugation with linkages other than Lys11, 48 and 63 does not occur as robustly at 
least in the early time points in response to laser-induced DNA damage. Since GFP-
Ub can be incorporated into chains of endogenous Ub, it is also possible that GFP-
Ub K11/K48/K63 mutant are more efficient than other mutants to be incorporated 
into endogenous Ub chain. Nevertheless, the accumulation of GFP-K11 Ub to laser 
tracks suggests that Lys11-linkage ubiquitination may occur at DNA damage sites. 
This led us to characterize Lys11-linked ubiquitination in the DNA damage response 
pathway. 
3.3.2 Recruitment of ubiquitin Lys11-linkage-catalyzing E2 conjugating 
enzymes to DNA damage site 
 Conjugation of Lys11-linkage ubiquitination at DNA damage sites indicates 
that the corresponding E2 conjugating enzyme and E3 ligase may also accumulate 
to DNA damage sites for assembly of the Lys11-linkage ubiquitin chains. Lys11-
linked polyubiquitination was first identified as a product of an E2-conjugating 
enzyme Ube2S (also known as E2-EPF) (150). Ube2S and Ube2C (also known as 
UbcH10) works in concert with the anaphase promoting complex/cyclosome 
(APC/C) to assemble Lys11-linked ubiquitin chain, in which Ube2C initiates and 
Ube2S elongates Lys11-linked polyubiquitin chain on APC/C 
	 84	
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Figure 21: Linkage specific ubiquitin conjugation in response to DNA 
damage. A U2OS cells stably overexpressing either GFP-tagged-WT or Lys only 
ubiquitin mutants were subject to laser micro irradiation with a UV laser. Live-cell 
imaging was performed immediately after laser damage for 6 minutes with 30 
seconds interval. Dotted line in the first image indicates laser micro irradiated 
regions across the cell nuclei. Shown here are t=0 and t=3 minutes post-laser 
micro irradiation. B. Lys11-linked ubiquitin conjugation at DNA damage sites. 
Live-cell imaging of GFP-WT or -Lys63, Lys11 or Lys0 ubiquitin mutants at 
indicated time-points post-laser micro irradiation. U2OS cells expressing GFP was 
used as negative control.		
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Figure 22 : Lysine11 ubiquitin conjugation enzymes localize to DNA damage 
sites. A. Ube2S and Ube2C are associated with chromatin. Cell fraction analysis 
was carried out with U2OS cells treated or not treated with 10 Gy IR followed by 
30 min incubation at 37°C. B. Ube2S and Ube2C accumulate to DNA damage 
sites. Images of U2OS cells stably expressing GFP-Ube2S or GFP-Ube2C were 
laser microirradiated and live cell imaging was performed at indicated time points. 
Western blot analysis of GFP-Ube2S or Ube2C expression levels was shown with 
tubulin expression as a loading control. C. Ube2S co-localizes with γH2AX at DNA 
damage sites. U2OS cells 5-10 min after laser-micro-irradiation were treated with 
pre-extraction buffer and immunostained with antibodies to Ube2S and γH2AX. D. 
Cdc20 and Cdh1 localization to DNA damage sites. U2OS cells stably expressing 
GFP-Cdc20 or Cdh1 were subjected for laser micro-irradiation followed by live cell 
imaging. Images at indicated times are shown. 
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substrates (151-154, 163). APC/C is a large multisubunit RING-finger E3 ligase 
complex including a catalytic core along with two additional co-activators Cdc20 and 
Cdh1 that recruit substrates to the APC/C ligase complex during mitosis and G1 
phases respectively. It plays a major function during cell cycle progression targeting 
mitotic and G1 cell cycle specific regulators for proteasomal degradation (164, 165). 
More recently studies done by Komander group identified an OTU family 
deubiquitinase (DUB), Cezanne (also known as OTUD7B), which preferentially 
cleaves Lys11-linked ubiquitin chain (157, 158). I first determined whether 
Ube2S/Ube2C or the APC/C E3 ligase components accumulate to DNA damage 
sites. Cell fractionation analysis showed that Ube2S and a portion of Ube2C are 
associated with chromatin (Figure 22A). In addition, using live-cell imaging following 
laser ablation in cells stably expressing GFP-tagged Ube2S and Ube2C, I observed 
that GFP-Ube2S and to a lesser extent GFP-Ube2C were recruited to laser-induced 
DNA damage tracks immediately after damage (Figure 22B). To further confirm 
recruitment of Ube2S, I used a Ube2S-specific antibody to detect localization of 
endogenous Ube2S to laser-induced DNA damage sites in U2OS cells and found 
that endogenous Ube2S accumulates to damage sites marked with the DNA 
damage marker γH2AX (Figure 22C). APC/C coactivators, CDC20 and CDH1 were 
also appeared to be recruited to damage tracks after laser treatment (Figure 22D).  
3.3.3 Ube2S/Ube2C dependent Lys11-linkage ubiquitin conjugation of 
chromatin-bound proteins 
 Next, I examined whether Lys11-linkage ubiquitination occurs to chromatin-
bound proteins on damaged chromatin. To test this, I utilized biochemical approach 
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by isolating chromatin fraction from cells transiently expressing HA-K11 Ub. Analysis 
of chromatin-enriched fraction isolated from these cells showed that chromatin 
ubiquitination by K11 Ub increased significantly upon IR-induced DNA damage and 
was further enhanced by treatment with a proteasomal inhibitor, MG132 (Figure 
23A). In addition, by comparing cells expressing HA-WT or mutant (K63, K48, and 
K11) Ub, I found that ubiquitin modification by K11 Ub was at a level similar to that of 
K63 or K48 Ub (Figure 23B). These findings confirm live-cell imaging data indicating 
that Lys11-linked ubiquitination at damaged chromatin is as abundant as Lys63 and 
Lys48-linked ubiquitination. A ubiquitin K0G76V mutant that cannot be conjugated to 
substrates was included in the experiment as a negative control and showed no 
conjugation of chromatin-bound proteins with this mutant ubiquitin (Figure 23B).  
 To determine whether Lys11-linkage chromatin ubiquitination is mediated by 
Ube2S/Ube2C conjugating enzymes at DNA damage sites, I depleted endogenous 
Ube2S and Ube2C using siRNAs from cells expressing HA-K11 Ub. Analysis of 
chromatin fraction isolated from these cells showed significant impairment of K11-
linked ubiquitination of chromatin-bound proteins in Ube2S/Ube2C siRNAs (Figure 
24A). Additionally, I found depletion of Ube2S alone impaired Lys11-linked 
chromatin ubiquitination to a large extent (Figure 24B), suggesting that Ube2S 
catalyzes K11-linkage ubiquitin chain formation on damaged chromatin. In order to 
exclude any possibility of siRNA off-target effects, these results were further 
confirmed with three different Ube2S siRNAs and as shown in Figure 24C, all three 
Ube2S siRNAs impaired Lys11-linked chromatin ubiquitination. Moreover, to validate 
Ube2S–mediated chromatin ubiquitination by K11 ubiquitin chain, I used siRNA- 
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Figure 23 : IR-induced Lys11-linkage ubiquitination at damaged chromatin A 
IR-induced Lys11-linkage chromatin ubiquitination. U2OS cells expressing HA-K11 
Ub were either treated or not treated with 10 Gy IR followed by 1hr incubation at 
37°C. MG132 (10 µM) was added 5 hr before IR.  
B. Linkage-specific ubiquitination on chromatin in response to IR. U2OS cells 
expressing HA-Ub WT or mutant were treated with IR similarly as in (A). 
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Figure  24: IR-induced Lys11-linkage chromatin ubiquitination depends on 
Ube2S/Ube2C enzyme A Ube2S/Ube2C are required for Lys11-linkage chromatin 
ubiquitination. Cells expressing HA-K11 Ub were treated with control or 
Ube2S/Ube2C siRNAs. 48 hours post transfection, cells were treated with MG132 
and IR and chromatin fraction was isolated for HA antibody analysis. Whole cell 
lysate (WCE) was used for western blot for assessing knockdown efficiency. B. 
Ube2S depletion alone impairs Lys11-linked chromatin ubiquitination. U2OS cells 
expressing HA-K11 Ub were transfected with siRNA targeting Ube2S. Chromatin 
fraction was analyzed as in A. C. Three independent Ube2S siRNAs decreases 
Lys11-linked chromatin ubiquitination. D. Ube2S catalyzes Lys11-linkage chromatin  
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ubiquitination. Cells expressing HA-K11 Ub were transfected with control or 
Ube2S siRNA along with GFP vector or GFP-tagged siRNA-resistant Ube2S, as 
indicated. Chromatin fraction was isolated and analyzed with HA antibody. Whole 
cell extract was used to detect knockdown efficiency. 
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resistant Ube2S construct in the Ube2S-depleted cells and found that expression of 
siRNA-resistant GFP-Ube2S can restore Lys11-linked chromatin ubiquitination in 
Ube2S-depleted cells (Figure 24D). Together, these results indicate that chromatin-
bound proteins are modified with Lys11-linked ubiquitin modification in Ube2S-
dependent manner. 
3.3.4 APC/C E3 ligase-independent Lys11-linked chromatin ubiquitination 
 Since Ube2S/Ube2C functions with APC/C E3 ligase to catalyze Lys11-linked 
ubiquitination on substrates that regulate cell cycle progression such as cyclin B, I 
tested whether APC/C is required for Lys11-linkage modification on chromatin in 
response to DNA damage. To test this, I depleted Apc2, a core component of the 
APC/C E3 complex, in cells expressing HA-K11 Ub. While depletion of Apc2 
abrogated APC/C’s E3 ligase function leading to stabilization of Cyclin B1 and an 
increase of mitotic cells as marked by increased phospho-histone H3, this had 
minimal effect on K11-linked chromatin ubiquitination in response to IR (Figure 25A). 
Inhibition of APC/C by proTAME, an inhibitor to APC (166), also did not decrease 
K11 Ub modification on damaged chromatin (Figure 25B). Moreover, knockdown of 
the APC/C co-activator Cdh1 also did not result in a decrease of chromatin-level 
K11-linked ubiquitin conjugation (Figure 25C). Together, these findings indicate that 
Ube2S-catalyzed Lys11-linkage chromatin ubiquitination in response to DNA 
damage is independent of APC/C E3 ubiquitin ligase. 
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Figure 25 : APC/C-independent Lys11-linkage chromatin ubiquitination.                
A. U2OS cells expressing HA-K11 Ub were transfected with control or Apc2 
siRNAs. 48 hours post-transfection, cells were treated with MG132, irradiated and 
chromatin fraction was isolated for western blot analysis with HA antibody. Total 
cell lysates were blotted with indicated antibodies to confirm abrogation of APC/C’s 
function in Apc2 knockdown cells. B. U2OS expressing HA-K11 Ub were treated 
with APC/C inhibitor (proTAME 25 µM) for 18 hours before treatment with MG132 
(or untreated) and IR. Chromatin fraction was isolated and analyzed with HA 
antibody. H3 was used as loading control. C. Knockdown of Cdh1 does not  
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decrease Lys11-linkage chromatin ubiquitination. U2OS cells stably expressing 
control shRNA or shRNA targeting Cdh1 were transfected with HA-K11 Ub. 48 hr 
post-transfection, chromatin fraction was isolated and analyzed by western blot 
with HA antibody. Total cell lysates were analyzed to confirm knockdown 
efficiency. 
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3.3.5 Lys11-linked chromatin ubiquitination is dependent on ATM kinase and 
upstream DDR factors 
 In response to IR-induced DNA damage, ATM-mediated phosphorylation of 
histone H2AX (γH2AX) recruits MDC1 to DNA damage sites that initiates the 
subsequent recruitment of RNF8 and RNF168 E3 ubiquitin ligases and Ubc13 E2 
conjugating enzyme for Lys63-linkage ubiquitin chain assembly on histones H2A 
and H2AX (37-39, 41, 43, 45, 143). Given the pivotal role of ATM kinase in triggering 
DDR response immediately after DNA damage, I investigated whether the Lys11-
linkage ubiquitin modification on damaged chromatin is also regulated by ATM 
signaling. Cells treated with siRNAs to ATM but not ATR greatly impaired K11-linked 
ubiquitination on damaged chromatin to levels resembling those of Ube2S/Ube2C 
depleted cells (Figure 26A), indicating that Lys11-linkage ubiquitin modification 
occurs on damaged chromatin in an ATM-dependent manner. I further tested 
whether depletion of other upstream DDR factors such as MDC1 as well H2A.X had 
any effect in Lys11-linked chromatin ubiquitination. Interestingly, I found that 
knockdown of MDC1 and H2AX also led to significant impairment of K11-linked 
chromatin ubiquitination (Figure 26A and B).  
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Figure 26 : Lys11-linkage chromatin ubiquitination is regulated by ATM, 
MDC1 and RNF8 A. ATM and MDC1, but not ATR is required for Lys11-linkage 
ubiquitination on chromatin in response to IR. U2OS cells treated with control or 
Ube2S/Ube2C, ATM, ATR or MDC1 were transfected with HA-K11 Ub. 48 hours 
post-transfection, chromatin fractions were extracted and analyzed with HA 
antibody. Histone H3 was used as a loading control. Whole cell extracts were 
analyzed with indicated antibodies to confirm knockdown efficiency B. H2AX is  
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required for Lys11-linkage ubiquitination on damaged chromatin. Chromatin 
fraction was isolated from cells transfected with control or H2A.X siRNAs and HA 
K11 Ub and treated similarly as in A C. RNF8 regulates Lys11-linkage 
ubiquitination on chromatin. Cells transfected with indicated siRNAs and HA K11 
Ub were treated and analyzed similarly as in A. RNF8 knockdown efficiency is 
measured by decrease of Abraxas IRIF. U2OS cells transfected with control or 
RNF8 siRNAs treated with IR at 10 Gy followed by 2 hours incubation at 37°C 
were analyzed by IF with Abraxas and γH2AX antibodies. More than 500 cells 
were counted for quantification and cells containing more than 10 foci were 
counted as positive. The data represents means± SD.  	
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3.3.6 RNF8 functions as an E3 ligase catalyzing Lys11 ubiquitin chain that is 
deubiquitnated by the DUB Cezanne 
 Since my findings indicate that Lys11-linked chromatin ubiquitination occurs 
in a manner independent of APC/C E3 ligase, I examined other enzymes known to 
play role in catalyzing ubiquitination at damaged chromatin. To this end, I examined 
whether Ubc13 and RNF8, enzymes known to catalyze Lys63-linked ubiquitination 
at DNA damage sites, also regulate K11-linked ubiquitin conjugation on damaged 
chromatin. Interestingly while depletion of Ubc13 appeared to have minimal effects 
on Lys11-linked chromatin ubiquitination, I found that depletion of RNF8 completely 
abrogated K11-linked chromatin ubiquitination to a level similar to that of the 
Ube2S/Ube2C knockdown cells (Figure 26C), indicating that RNF8 may function as 
an E3 ligase in catalyzing Lys11-linkage ubiquitination at DNA damage sites 
independent of Ubc13. Of note, as described in sections 3.1.2 and 3.1.6, RNF8 has 
been shown to catalyze both Lys63 and Lys48-linked ubiquitination by interacting 
with distinct of E2 enzymes, Ubc13, and UbcH8, respectively. RNF8 is a RING 
domain E3 ligase and one characteristic feature of many of the RING domain E3 
ligases is to catalyze substrate-independent autoubiquitination (167). RNF8 has 
been shown to undergo substrate-independent autoubiquitination synthesizing both 
Lys63 and Lys48-linked chains by interacting with distinct E2 enzymes, Ubc13 and 
UbcH8, respectively (57, 58). I hypothesized that if RNF8 indeed catalyzes Lys11-
linked ubiquitin chain in concert with Ube2S, it might also undergo Lys11-linked 
autoubiquitination. To test this, I co-expressed Flag-RNF8 along with HA-K11, 
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Figure 27: RNF8 functions as an E3 ligase for Lys11-linked ubiquitination.             
A. RNF8 autoubiquitination by Lys11-linkage modification. HEK293T cells were co-
transfected with Flag-RNF8 and HA-K63, -K48 or -K11 Ub. 48 hours post-
transfection, cells were irradiated with 10 Gy IR (or left untreated) followed by 30 
min incubation at 37°C. Flag-immunoprecipitation was carried out under denaturing 
condition. B. Lys11-linkage autoubiquitination of RNF8 in vitro. Purified HA-Flag-
RNF8 was eluted from Flag-beads after immunoprecipitation from lysates of 
HEK293T cells expressing HA-Flag-RNF8. Equal amount of eluted Flag-RNF8 was 
incubated in  
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reaction mixtures containing purified ubiquitin, E1 and increasing amount of purified 
Ube2S and Ube2C as indicated. C. Lys11-linkage autoubiquitination of RNF8 in vitro 
using recombinant GST-RNF8. D. Ube2S alone can promote RNF8 
autoubiquitination in vitro. In vitro autoubiquitination assay was performed in 
presence of recombinant Ube2C (lane 4) or Ube2S (lane 5) or both (lane 6) and 
GST-RNF8 similarly as in C. E. RNF8 interacts with Ube2S. HEK293T cells were co-
transfected with Flag-RNF8 and GFP-Ube2S before treatment with IR.  	
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K63, K48 or K0 Ub in cells and examined linkage-specific RNF8 self-ubiquitination 
under denaturing condition. This analysis revealed that in addition to previously 
reported K63- and K48-linked autoubiquitination; RNF8 is also modified by Lys11-
linked polyubiquitin chain, suggesting that RNF8 may act as an E3 ligase for Lys11-
linked ubiquitination (Figure 27A). To validate RNF8’s role as an E3 ligase that in 
concert with Ube2S/Ube2C catalyzes Lys11-linkage ubiquitination, I tested whether 
Ube2S/Ube2C assist in autoubiquitination of RNF8 in vitro. Purified RNF8 eluted 
from Flag-immunoprecipitates from cell lysates (Figure 27B) or recombinant GST-
RNF8 was incubated in vitro with ubiquitin in the presence of purified E1 and 
Ube2S/Ube2C E2 enzymes (Figure 27C). The findings obtained from this in vitro 
ubiquitination assays showed that Ube2S/Ube2C facilitated self-ubiquitination of 
RNF8 in vitro. Moreover, I tested whether Ube2S alone can facilitate RNF8 
autoubiquitination. As shown in Figure 27D, in vitro RNF8 autoubiquitination assay in 
presence of Ube2S or Ube2C or both confirmed that Ube2S alone can catalyze 
RNF8 autoubiquitination under this condition. Furthermore, I reason that if Ube2S 
and RNF8 coordinate with each other to catalyze Lys11-linked ubiquitination, they 
might also interact with each other. Since endogenous E2-E3 interaction is difficult to 
detect due to transient nature of this interaction (106, 168), I co-expressed Flag-
RNF8 with GFP-Ube2S or GFP-Ube2C in HEK293T cells. Co-immunoprecipitation 
analysis showed that Flag-tagged RNF8 interacted with GFP-tagged Ube2S (Figure 
27E) but not Ube2C (data not shown) in the presence of IR; consistent with the idea 
that RNF8 E3 ligase works with Ube2S to assemble Lys11-linked chains. 
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Figure 28 : RNF8-dependent Lys11-linkage ubiquitination is antagonized by 
Cezanne. U2OS cells were transfected with indicated siRNAs individually or in 
combination, followed by transient transfection of HA-K11 Ub. 48 hours post-
transfection, cells were treated with MG132, irradiated and chromatin fraction was 
isolated for western blot analysis with HA antibody. Knockdown efficiency of 
individual gene was confirmed by western blot analysis of whole cell lysate with 
indicated antibodies (right panel). 
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Finally, to further confirm that RNF8 promotes Lys11-linkage ubiquitin 
modification, I examined whether Cezanne, a DUB that specifically cleaves the 
Lys11-linkage ubiquitin conjugates (157), antagonizes the activity of RNF8 in Lys11-
linkage ubiquitin modification of chromatin-bound proteins. Indeed, while knockdown 
of RNF8 decreased the Lys11-linkage ubiquitin modification, depletion of Cezanne in 
RNF8-deficient cells significantly reversed the decrease of Lys11-linkage 
ubiquitination, indicating that RNF8 and Cezanne function in the same pathway to 
modify Lys11-linkage ubiquitin conjugation on damaged chromatin (Figure 28). 
Taken together, these findings conclusively suggest that RNF8 acts as an E3 ligase 
that in association Ube2S E2 conjugating enzyme catalyzes Lys11-linked chromatin 
ubiquitination at the damaged chromatin.  
3.3.7 Histone H2A/H2A.X are modified with Lys11-linked ubiquitin conjugates 
in DNA damage-dependent manner 
My findings indicate that chromatin-bound proteins undergo Lys11-linked 
ubiquitination by Ube2S-RNF8 enzymes in DNA damage-dependent manner. 
Because histone proteins are the fundamental unit of chromatin structure and are 
subjected to extensive post-translational modifications including ubiquitination, I 
examined whether histones are modified by Lys11-linkage ubiquitin conjugates. To 
test this, I undertook multiple biochemical approaches. First, I used acid extraction to 
isolate all histone proteins from cells expressing HA-tagged WT or Lys only mutant 
Ub. Acid extraction of highly basic histone proteins is a standard procedure to isolate 
histone proteins from chromatin. Robust ubiquitination of acid-extracted proteins,  
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Figure 29 : Histone proteins are modified with Lys11-linked ubiquitination. 
Linkage-specific ubiquitination of acid-extracted histone faction. U2OS cells 
expressing HA-WT or mutant Ub were treated with MG132, irradiated followed by 
acid extraction to isolate highly basic histone proteins. Histone H3 was used as 
loading control. Bottom panel: Ponceau staining of acid-extracted histones is 
shown. B. DNA damage-induced Lys11-linkage ubiquitination of histone 
H2A/H2AX. HEK293T cells co-transfected with Flag-H2A or -H2AX and HA-K11 Ub 
were irradiated at 12 Gy and incubated at 37°C for 1 hour. Flag- 
immunoprecipitation was carried out under denaturing condition as described in 
material and methods. Bottom panel: Flag immunoblot showing immunoprecipitated 
Flag-tagged histone proteins. 
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presumably mainly histones, by HA-WT Ub could be seen with western blot. 
Interestingly, the level of ubiquitin modification by K11 Ub was similar to that of K63 
and K48 Ub, suggesting that Lys11-linkage formation occurs as extensively as the 
Lys63- or Lys48-linkage formation on histones (Figure 29A). These findings again 
corroborate my live-cell imaging data of Lys11-linked ubiquitination at damaged 
chromatin (Figure 21). Second, to examine which histone protein(s) is modified with 
Lys11-linked ubiquitination, I co-expressed Flag-tagged individual histone proteins, 
including H2A, H2AX, H2B, H3, and H4 along with HA-K11 Ub in HEK293T cells and 
treated the cells with IR to induce DNA damage. Analysis of Flag-
immunoprecipitation done under denaturing condition revealed that among all 
histone proteins, histone H2A and H2AX were modified with K11 Ub in a DNA 
damage-dependent manner. Analysis of Lys11-linkage ubiquitin modification on 
other histone proteins showed that H2B was also modified by K11-linked ubiquitin 
but the modification was independent of IR and that H3 and H4, on the other hand, 
did not show modification by K11-linked ubiquitin (Figure 29B). 
I then set out to confirm whether endogenous histone H2A/H2A.X are modified 
by Lys11-linkage ubiquitination upon DNA damage. Utilizing a previously published 
system expressing a tandem hexahistidine-biotin tag (HBT-tag) fused to ubiquitin for 
purification of ubiquitinated proteins under fully denaturing conditions (113), I 
generated HeLa cells stably expressing HBT-K11 Ub. Analysis of streptavidin beads 
pull-down proteins under complete denaturing condition (8M Urea) and by western 
blot with antibodies to ubH2A, H2A or γH2A.X revealed that  
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Figure 30 : Endogenous histone H2A/H2A.X are modified with Lys11-linked 
ubiquitination. A. Left panel: Schematic for detection of endogenous histone H2A 
modification with Lys11-linked ubiquitin conjugates under denaturing condition. 
Right panel: Streptavidin pulldown proteins were analyzed with western blot using 
antibodies to ubiquitinated H2A (ubH2A). B and C. Hela cells expressing His-
Biotin-K11 Ub were subjected to treatment as described in Figure A and were 
analyzed with antibodies again H2A (B) and γH2A.X (C). 
	 107	
 
Figure 31: RNF8 and Ube2S/Ube2C catalyze histone H2A ubiquitination in 
vitro. A. Recombinant histone H2A was incubated with a reaction mixture 
containing purified ubiquitin, E1, increasing amount of Ube2S/Ube2C (lanes 3-4 
and 5-6), in the presence (lane 5 & 6) or absence (lanes 1-4) of purified HA-Flag-
RNF8. Reaction mixtures were analyzed by western blot with FK2 antibody. B. H2A 
ubiquitination in vitro. H2A/H2B dimer was used in the reaction as described in (A). 
The western blot was carried out with ubH2A antibody. C. In vitro ubiquitination by 
RNF8 and Ube2C/Ube2S using nucleosome as substrates. 
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endogenous histone H2A/H2AX could be modified by K11-Ub conjugates and this 
modification was somewhat enhanced in response to IR (Figure 30). Finally, I tested 
whether histone H2A is a substrate directly modified by RNF8 and Ube2S/Ube2C 
using in vitro ubiquitination assay. I incubated purified H2A with ubiquitin, E1, 
Ube2S/Ube2C and HA-Flag-RNF8 and examined the conjugation of ubiquitin on 
H2A by the FK2 antibody or ubH2A antibody. It showed that polyubiquitination of 
H2A was triggered when purified RNF8 was present, suggesting that H2A is a direct 
substrate of RNF8 (Figure 31A). Ubiquitination of H2A recognized by ubH2A 
antibody was also shown when histone H2A/H2B dimer was used in the reaction 
(Figure 31B). Similar findings were also observed when I used nucleosome as 
substrate for in vitro ubiquitination reaction (Figure 31C). Together, these findings 
confirm that RNF8 functions with Ube2S to assemble Lys11-linkage ubiquitin chains 
on substrates including H2A. 
3.3.8 RNF8 and Ube2S catalyze Lys11-linked H2A ubiquitination in DNA 
damage-dependent manner 
 Next, I tested whether Ube2S and RNF8 are required for Lys11-linkage 
ubiquitin modification of H2A. I depleted Ube2S or RNF8 in HEK293T cells 
expressing Flag-tagged H2A and HA-K11 Ub. My findings indicate that depletion of 
Ube2S or RNF8 by siRNAs led to a marked decrease of K11-linked 
polyubiquitination of H2A, indicating that Ube2S and RNF8 are required for 
catalyzing Lys11-linkage ubiquitination of H2A in response to IR (Figure 32A). Since 
Lys11-linked ubiquitination was identified as a proteolytic signal for mitotic proteins, I 
tested whether modification of histones H2A and H2A.X triggers degradation of  
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Figure 32: Ube2S and RNF8-dependent Lys11-linkage ubiquitination of 
histone H2A/H2AX in response to DNA damage. A. HEK293T cells depleted of 
Ube2S or RNF8 were co-transfected with Flag-H2A and HA-K11 Ub. 48 hours post-
transfection, cells were treated with MG132 (or left untreated), irradiated at 12 Gy 
(or untreated) followed by lysis and Flag-immunoprecipitation under denaturing 
condition and western blot analysis with indicated antibodies. Whole cell extracts 
were immunoblotted with indicated antibodies to confirm knockdown efficiency. 
Right panel: Confirmation of RNF8 knockdown efficiency. U2OS cells transfected 
with control or RNF8 siRNAs were analyzed by IF for Abraxas IRIF formation. Cells 
containing 10 or more foci were counted as positive and the data represents 
means± SD. B. Endogenous H2A/H2AX protein levels are not affected in Ube2S-
deficient cells. Chromatin fraction from U2OS cells transfected with control or 
Ube2S siRNAs was analyzed by western blot with indicated histone antibodies. 
PCNA protein level was used as a loading control. Total cell lysates were analyzed 
by western blot for knockdown efficiency. 
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these proteins. Analysis of endogenous histones H2A and H2A.X in presence or 
absence of DNA damage and/or proteasomal inhibitor MG132 revealed no alteration 
in chromatin-bound histone protein level in control and Ube2S depleted cells 
indicating Lys11-linked ubiquitination of histone is not a proteolytic signal (Figure 
32B). 
3.3.9 Lys11-linkage ubiquitination does not interfere with Lys63-linked 
ubiquitination-dependent recruitment of 53BP1 and BRCA1 
We reason that, if RNF8 functions with Ube2S/Ube2C, but not Ubc13, in 
regulating Lys11-linkage ubiquitin modification, knocking down Ube2S/Ube2C 
should not interfere with the Ubc13-dependent Lys63-linkage ubiquitin conjugation at 
damaged chromatin that recruits 53BP1 and BRCA1 to DNA damage sites. To test 
this, I utilized multiple approaches. First, I examined whether depletion of 
endogenous Ube2S impairs chromatin-bound proteins modification by Lys63-linked 
ubiquitin. Isolating chromatin fraction from Ube2S depleted cells showed that Ube2S 
depletion had minimal effect on Lys63-linked chromatin ubiquitination (Figure 33). In 
addition, I tested IR-induced foci formation (IRIF) of 53BP1 and Abraxas/BRCA1-A 
complex (41, 47) components in Ube2S/Ube2C depleted cells. Consistent with a role 
of Ube2S in forming DNA damage-induced ubiquitin conjugates at DNA damage 
sites, IF staining with the FK2 antibody that detects ubiquitin chains showed a 
significant decrease of ubiquitin foci formation in Ube2S/Ube2C (Figure 34). 
However, knockdown of Ube2S/Ube2C did not appear to have a major effect on 
affecting IRIF of 53BP1, BRCA1, Abraxas, or Rap80 (Figure 35), indicating that 
Lys11-linkage ubiquitin modification does not directly interfere with the Lys63-linkage 
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F   Figure 33: Ube2S knockdown effect on chromatin ubiquitination modified by 
HA-WT, K63 or K0 Ub. U2OS cells treated with control or Ibe2S siRNAs were 
transfected with HA-K11 Ub. 48 hours post-transfection, chromatin fractions were 
extracted and analyzed with HA antibody. Histone H3 was used as a loading 
control. Whole cell extracts were analyzed with indicated antibodies to confirm 
knockdown efficiency. 
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F   Figure 34 : Lys11-linkage ubiquitination is dispensable for recruitment of DNA 
damage repair proteins 53BP1 and BRCA1-A complex proteins. 
U2OS cells were transfected with control siRNA or siRNAs targeting 
Ube2S/Ube2C. 48 hr post-transfection, cells were irradiated with 10 Gy IR, 
incubated for 2 hr at 37°C followed by immunostaining with antibodies to 
conjugated ubiquitin (FK2 antibody) (A), 53BP1 (B), BRCA1 (C), Abraxas (D), or 
Rap80 (E). Percentage of foci-positive cells (cells containing more than 10 foci) was 
quantified and indicated as means± SD with p-value indicated. The experiments 
were repeated three times with more than 500 cells counted each time, and 
representative images are shown.  
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 Figure 35: Lys11-linkage ubiquitination is dispensable for recruitment of DNA 
damage repair proteins 53BP1 and BRCA1 in Ube2S depleted cells. U2OS 
cells were transfected with control or siRNAs targeting Ube2S (siRNA#1). 48 hr 
post-transfection, cells were irradiated with 10 Gy IR followed by 2 hr incubation at 
37°C followed by immunostaining with antibodies to conjugated ubiquitin (FK2 
antibody) (A), 53BP1 (B), BRCA1 (C), Abraxas (D). Percentage of foci-positive 
cells (cells containing more than 10 foci) was quantified and indicated as means± 
SD with p-value indicated. E. Whole cell extracts were analyzed for Ube2S 
knockdown efficiency. Tubulin was used as a control. 
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ubiquitin conjugation-mediated recruitment of 53BP1 and Abraxas/BRCA1-A 
complex. Since Ube2C has been shown to catalyze Lys63, Lys48 and Lys11-linked 
ubiquitination, while Ube2S is Lys11-Ub specific E2 conjugating enzyme, I further 
confirmed the IRIF of 53BP1 and of BRCA1-A complex components in Ube2S only 
depleted cells. And as shown in Figure 35, depletion of Ube2S alone appeared to 
have a similar phenotype as dual depletion of Ube2S and Ube2C. Taken together, 
these data, suggest that the role of RNF8 in regulating Lys11-linkage modification is 
independent of its role in catalyzing Lys63-linkage ubiquitin conjugation at DNA 
damage sites. 
3.3.10 Lys11-linked ubiquitination at damaged chromatin is required for 
regulation of DNA damage-induced transcription silencing 
Histone ubiquitination is often associated with transcription regulation (169-
172). In addition, a recent study by Greenberg and colleague showed that RNF8 
plays an essential role in inducing transcription inhibition at DSBs (67). To find out 
the functional significance of Ube2S-RNF8-mediated Lys11-linked chromatin 
ubiquitination, I tested whether Lys11-linkage ubiquitination is involved in regulating 
transcriptional silencing at the sites of DNA damage. To examine this, I utilized the 
Click chemistry-based imaging to measure the nascent transcript production at the 
sites of DNA damage induced by laser micro irradiation as described by Gong et al, 
2015 and depicted in Figure 36A.  In this assay system, I monitored nascent RNA 
transcript production at laser micro irradiated DNA damage sites using 5-ethynyl 
uridine (EU), a nucleoside analog of uracil, which is incorporated into nascent RNA 
during active transcription (173). Using this system I first confirmed whether RNF8 
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Figure 36: Lys11-linkage ubiquitination regulates DNA damage-induced 
transcription silencing. A. A scheme for examining DNA damage-induced 
transcription inhibition as described in materials and method section. B. Detection 
of 5-EU labeling and gH2AX staining 1 hr post laser-microirradiation in control and 
RNF8 siRNA-transfected U2OS cells. C. Ube2S/Ube2C-deficient cells are defective  
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in DNA damage-induced transcription inhibition. D. Quantification of 5-EU 
intensity normalized by γH2AX intensity in the laser-damaged region. E. Ube2S-
deficient cells are defective in DNA damage-induced transcription inhibition. EU 
labeling and γH2AX staining was performed similarly as in B and C. F. 
Quantification of E. 5-EU intensity was measured along the laser tracks and 
normalized by γH2AX intensity along the same laser-damaged region. 
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depletion had any effects in transcription silencing as reported by Shanbhag et al, 
2012. Consistent with previous findings, I found compared to control siRNA 
transfected cells, transcription silencing was significantly impaired in RNF8 depleted 
cells as indicated by enrichment of EU intensity along the γH2A.X marked damaged 
region Figure 36B. These findings corroborate previous findings of RNF8’s role in 
transcription silencing at the sites of DNA damage. Interestingly compared to that in 
control cells in which nascent transcript production was inhibited at laser micro 
irradiation-induced DNA damage sites, in Ube2S/Ube2C depleted cells, 
transcriptional silencing after DNA damage is significantly reduced (Figure 36C). 
Quantification of EU intensity normalized over γH2AX intensity showed significant 
enrichment of EU labeling along the damage region of the chromatin in 
Ube2S/Ube2C siRNA transfected cells (Figure 36D). Moreover, to test whether 
depletion of Ube2S alone can impair transcription silencing at damaged chromatin, I 
measured nascent transcript production in Ube2S depleted cells. Quantification of 
EU intensity normalized to γH2AX intensity showed that Ube2S deficiency alone can 
affect transcription silencing at DNA damage sites (Figure 36E and F). 
To further validate these findings, I tested RNAPII phosphorylation status. 
RNAPII transcribing activity correlates with the phosphorylation status of RNA 
polymerase II carboxy-terminal domain (CTD) in hepta-repeats YSPTSPS. Active 
transcription is associated with hyperphosphorylation of the C-terminal domain 
(CTD) of RNA polymerase II (RNAPII), whereas it remains hypophosphorylated in 
non-elongating RNAPII complexes (174-177). To test the effect of Ube2S/Ube2C 
depletion in RNAPII phosphorylation status, I monitored the phosphorylation state of 
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Figure 37: Increased RNAPII phosphorylation and IR sensitivity in 
Ube2S/Ube2C depleted cells in response to IR. A. Increased RNAPol II 
hyperphosphorylation in Ube2S/Ube2C-deficient cells. U2OS cells stably 
expressing indicated shRNAs were irradiated with 10 Gy IR, harvested at indicated 
time-points and nuclear fractions were isolated for western blot analysis.  IIo and IIa 
designate hyperphosphorylated and hypophosphorylated forms of the large subunit 
Rpb1 of RNA Pol II respectively. B. Quantification of Rpb1 hyperphosphorylation 
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in Ube2S/Ube2C-deficient cells. Hyperphosphorylated Rpb1 and 
hypophosphorylated Rpb1 (IIa) band intensities were measured by ImageJ and 
normalized to untreated samples. C. Chromatin fraction analysis of increased 
RNAPII hyperphosphorylation in control and Ube2S/Ube2C deficient cells. D. 
Quantification of C. E. Increased cellular sensitivity of Ube2/Ube2C-deficient cells 
to IR. Percentage of survival in the clonogenic survival assay is quantified and 
presented as means ± SD.  
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RNAPII by using an antibody that recognizes both hyperphosphorylated and 
Hypophosphorylated (IIa) forms of RNAPII. As shown in Figure 37A analysis of 
nuclear fraction showed that hyperphosphorylation of RNAPII decreased significantly 
in control cells after 1 hour post-IR-induced DNA damage followed by recovery at 
later time points, indicating silencing of active transcription at damaged chromatin 
after DNA damage. Interestingly, compared to control cells, hyperphosphorylation 
status of RNAPII in Ube2S/Ube2C-deficient cells did not decrease particularly at 1 
hour after IR treatment, indicating that active transcription is not efficiently inhibited 
in Ube2S/Ube2C-deficient cells in response to IR (Figure 37A and B). This was also 
confirmed when chromatin fraction was analyzed for RNAPII phosphorylation state 
(Figure 37C and D). Collectively, these data indicate that Ube2S/Ube2C-mediated 
Lys11-linkage ubiquitination plays a crucial role in promoting transcriptional silencing 
on the damaged chromatin. In consistent with a role of Lys11-linkage ubiquitination 
in the DDR, I also found that depletion of Ube2S/Ube2C led to a marked increase in 
cellular sensitivity to IR (Figure 37E). Thus Lys11-linkage ubiquitination is likely to 
play a critical role in the cellular response to DNA damage.  
 Collectively, in this study, we report ubiquitin Lys11-linkage conjugation as a 
new platform of ubiquitin landscape on damaged chromatin in the cellular response 
to DNA damage. I show that Lys11-linkage ubiquitination occurs on damaged 
chromatin and is regulated by ATM-dependent signaling. I identify the corresponding 
ubiquitin modifying enzymes responsible for the Lys11-linkage ubiquitin events at 
DNA damage sites including Ube2S/Ube2C E2 conjugating enzymes, RNF8 E3 
ligase and Cezanne deubiquitinating enzyme. Moreover, I find that histone 
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H2A/H2AX is a target of this modification on damaged chromatin. Importantly, I 
show that Lys11-linkage ubiquitin conjugation plays a critical role in the regulation of 
DNA damage-induced transcription silencing, distinct from the role of Lys63-linkage 
ubiquitin in the recruitment of 53BP1 and BRCA1 DNA damage repair proteins. 
3.4 Discussion  
Chromatin modification at DNA damages sites constitutes an immediate 
component of the cellular response to DNA damage for signaling and repair. 
Proteomic analysis of global ubiquitination profiling reveals assembly of all seven 
lysine residue-linked ubiquitination in a varying degree of abundance in both yeast 
and mammalian cells (113, 114, 159). However, much is still missing for 
understanding the role of linkage-specific ubiquitin chains in the regulation of DNA 
damage response and repair. My findings in this study, for the first time, reveals a 
connection between Lys11-linkage ubiquitination, one of the most abundant ubiquitin 
linkages (114), to DNA damage response. It provides evidence that Lys11-linkage 
ubiquitin chains occur extensively at DNA damage sites in an ATM-dependent 
manner with kinetics and degree of conjugation similar to that of Lys63- and Lys48-
linkages, putting Lys11-linkage ubiquitin modification as a yet another important 
aspect of the ubiquitin landscape at sites of DNA damage (Figure 38).  
 In this study, I have identified the ubiquitin enzymatic machinery that 
assembles and disassembles Lys11-linkage ubiquitin modification at the DNA 
damage sites. I found that E2 conjugating enzyme Ube2S and E3 ligase RNF8 
catalyze Lys11-linked Ub modification at damaged chromatin. Ube2S was identified 
as a bona fide E2 enzyme that functions in concert with APC/C E3 ligase complex to 
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elongate the Lys11-linked ubiquitin chain initiated by Ube2C, another cognate E2 
conjugating enzyme that can also assemble Lys63 and Lys48-linked ubiquitin chains 
substrates (129, 151-154, 163, 178). Although APC/C has been extensively shown 
to partner with Ube2S and Ube2C in catalyzing Lys11-linked ubiquitination during 
mitosis and G1 phases of the cell cycle, in our analysis I found Ube2S does not 
partner with APC/C to assemble Lys11-linked polyubiquitin conjugates. While 
depletion of Ube2S alone abrogates Lys11-linked chromatin ubiquitination, it is 
largely unaffected by APC/C inactivation. Instead, my findings identify RNF8 as a 
new partner E3 ligase that works with Ube2S for the DNA damage-induced Lys11-
linkage ubiquitin conjugation on chromatin-bound proteins including histone H2A 
both in vitro and in vivo. RNF8-deficient cells abolish both Lys11-linked chromatin 
and histone H2A ubiquitination to the same degree as Ube2S depleted cells 
indicating that these two enzymes work in concert to catalyze Lys11-linked 
polyubiquitin conjugates at damaged chromatin. In addition, I found that Ube2S and 
RNF8 interact with each other and RNF8 is self-ubiquitinated in Ube2S-dependent 
manner. Since Ube2S has specificity to assemble only Lys11 ubiquitin chain, these 
findings confirm that RNF8 is autoubiquitinated by Lys11 ubiquitin. Interestingly, it 
has been shown that RNF8 is capable of interacting with several different E2 
conjugating enzymes in response to DNA damage, including Ubc13 for Lys63-
linkage (37-39, 41), UbcH5C for Lys6-linkage (140) and UbcH8 for Lys48-linkage 
(57, 58) ubiquitination. This is consistent with the notion that chain specificity is an 
intrinsic property of E2 enzymes and E3 ligases interact with different E2s 
generating linkage-specific ubiquitin chains (106, 118). Therefore, RNF8 appears to 
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function as a ‘master E3 ligase’ at the DNA damage sites generating different Lys 
residue-linked ubiquitination by interacting with different E2 conjugating enzymes. 
One question that arises from these observations is “how these different types of 
ubiquitin chains are coordinated at the DNA damage sites?” Although we are still 
away from understanding the full spectrum of the complexity of ubiquitin signaling at 
the damage sites, it is tempting to speculate that many of the E3 ligases, previously 
known to catalyze single type of ubiquitin chain, may interact with other E2 enzymes 
at the damage sites to assemble different linkage-specific ubiquitination. Along with 
RNF8’s role to generate multiple different chain types, as discussed in section 3.1.4, 
recent findings from Penengo and colleague showed that RNF168 is also involved in 
catalyzing Lys27-linked ubiquitination at DNA damage sites (56). Together, E3 ligase 
interaction with the distinct E2 enzyme is likely to be a central mechanism for 
coordination of linkage-specific ubiquitination at sites of DNA damage. 
Ubiquitin conjugation is a dynamic enzymatic activity that is regulated by the 
precise balance between enzymatic activities of the ligase and DUB that cleaves the 
polyubiquitin chain and thereby regulates downstream signaling (89). Ubc13-
mediated Lys63-linked polyubiquitin chain at damage sites is disassembled by 
BRCC36, a DUB present in the BRCA1-A complex (41, 54, 88, 91). In this study, we 
identify that Cezanne, a DUB that has been shown to preferentially deubiquitinate 
Lys11-linked ubiquitin chain (157), regulates DNA damage-induced Lys11-linkage 
ubiquitination, antagonizing the RNF8- and Ube2S-dependent assembly of Lys11-
linkage chains. Thus, our data illustrates Lys11-linkage modification as an 
independent posttranslational modification utilizing distinct E2 conjugating enzyme, 
	 124	
E3 ligase and DUB for assembly and disassembly of ubiquitin chains at DNA 
damage sites. 
Chromatin ubiquitination plays a crucial role in the DNA damage response (4, 
162). Functional significance of linkage-specific ubiquitination at DSBs has just 
begun to emerge.  The best-illustrated example is Lys63-linkage ubiquitination in 
response to DNA damage and activation of ATM. The RNF8/RNF168- and Ubc13-
catalyzed Lys63-linkage ubiquitin chains assembled on damaged chromatin provide 
docking sites for the recruitment of 53BP1 and BRCA1-A complex (4, 162). The 
study done by Penengo group indicates that Lys27-linked ubiquitination of 
H2A/H2AX generated by RNF168 adds an additional layer of regulation by linkage-
specific ubiquitination facilitating the accumulation of 53BP1 and BRCA1 forming 
IRIF (56). Lys48-linkage formation, on the other hand, modifies Ku80 and regulates 
its abundance at DNA damage sites for modulation of non-homologous end joining 
repair (57). Thus, the type of ubiquitin linkage is likely to determine the functional 
outcome of the modification. In this report, I found that although disruption of Lys11-
linkage formation significantly decreased the ubiquitin conjugates detected by the 
FK2 antibody at DNA damage-induced foci, it has minimal effect on the recruitment 
of 53BP1 or BRCA1, distinct from the role of Lys63- or Lys27-linkage ubiquitin 
chains. Rather, Ube2S- and RNF8- mediated Lys11-linkage formation plays an 
important role in regulating DNA damage- induced transcriptional silencing. 
Transcription in regions near DNA damage site is temporarily inhibited in an ATM- 
and DNAPK-dependent manner for proper DNA repair and transcription activities to 
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maintain genome stability (67, 179). However, how the transcriptional silencing is 
achieved at DSB sites still remains elusive. Our study uncovers a novel role of 
Lys11-linked chromatin ubiquitination in promoting transcriptional repression at 
DSBs. It is possible that Lys11-linked ubiquitin modification of H2A/H2AX directly 
contributes to the recruitment of transcriptional repressor complexes or adopting a 
chromatin environment that enhances repression of transcription locally at sites of 
damage. In fact, histone ubiquitination has been implicated extensively in 
transcriptional regulation (180). Ubiquitination of histone H2A (uH2A) accumulates at 
DNA damage sites and is correlated with transcriptional repression (169-172). It is 
also indicated that ATM- and RNF8-dependent ubiquitination of H2A promotes DNA 
damage-induced transcription repression (67). Our study expands this knowledge 
and suggests that RNF8 may regulate the DNA damage-induced transcriptional 
silencing through catalyzing Lys11-linkage ubiquitin modification of H2A/H2AX. 
Alternatively, additional substrates of Lys11-linkage modification may be involved in 
promoting transcriptional silencing through additional mechanisms such as 
influencing the phosphorylation of RNA polymerase II.   
Lys11-linked chain type has been considered as a degradative chain type, 
along with Lys48-linked ubiquitin polymers, promoting proteasome-dependent 
degradation of substrates. The Lys11-linkage ubiquitin chain assembly on APC/C 
substrates Cyclin B1 and Securin during mitosis and G1 phases leads to their 
degradation and regulating cell cycle progression (151-154). Although the study of 
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Figure 38: A proposed model for the Lys11-linkage ubiquitination at sites of 
DNA damage.  DNA damage induces an ATM-MDC1-dependent Lys11-linked 
ubiquitination at damaged chromatin mediated by Ube2S conjugating enzyme and 
RNF8 ligase and is deubiquitinated by the DUB Cezanne. Lys11-linked chromatin 
ubiquitination modifies histone H2A and H2A.X at damaged chromatin along with 
other unidentified chromatin-bound proteins and while Lys11-linked chromatin 
ubiquitination does not regulate DDR factor recruitment to DSB sites, it plays an 
essential role in regulating transcription silencing.  
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aiming to examine the role of Lys11-linkage ubiquitin modification in various cellular 
processes is still limited, Lys11-linked ubiquitin chain conjugation also has been 
implicated in non-proteolytic pathways such as NF-κB activation (181-183). In our 
study, we didn’t observe any changes in the steady-state level of chromatin-bound 
H2A/H2AX in cells depleted with Ube2S in presence or absence of DNA damage, 
indicating that Lys11-linked ubiquitination of histone H2A/H2AX is less likely to 
represent a proteolytic signal for protein degradation. However, we could not exclude 
the possibility that other yet unknown substrates of Lys11-linkage modification on 
damaged chromatin undergo proteasome-dependent degradation due to this 
modification. Recent crystallographic and NMR analysis showed that Lys11-linked 
di-ubiquitin adopts a compact structure distinct from the Lys48- and Lys63-linked 
ubiquitin chains (157, 184, 185), suggesting that Lys11-linked chains are capable of 
representing an independent signaling entity within cells.  
In summary, this study demonstrates that Lys11-linkage ubiquitin modification 
is an important aspect of the complex ubiquitin landscape that exists in the vicinity of 
DNA damage regulating DNA damage-induced transcriptional silencing. My findings 
emphasize the complexity of ubiquitin signaling at the sites of damage involving 
different E2-E3 pair to assemble different ubiquitin linkages. It highlights the 
importance of linkage-specific ubiquitination in the DDR and supports the notion that 
polyubiquitin chains with different linkages should be regarded as independent 
posttranslational modification. 
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3.5 Future directions: 
 This study provides evidence for the first time that damaged chromatin is 
modified with Lys11-linked ubiquitin chain in an ATM-dependent manner by Ube2S 
and RNF8 enzymes and Lys11-linked chromatin ubiquitination is essential for 
inducing transcriptional silencing in the vicinity of the DNA damage. Although these 
findings expand our understanding of the linkage-specific ubiquitination at the DNA 
damage sites, this study also raises several important questions that require further 
investigation. First, I found that Ube2S/Ube2C depleted cells become sensitive to IR-
induced DNA damage indicating these enzymes may involve in cellular resistance to 
IR and likely to play a role in DNA repair. However, the exact role of this enzymes 
and Lys11-linked ubiquitination in DNA repair still remains to be determined. 
Transcriptionally active regions have been shown to favor HR repair (186). Given I 
found that active transcription is not efficiently inhibited at the damage sites in 
Ube2S/Ube2C depleted cells, it will be interesting to examine whether depletion of 
Ube2S/Ube2C have any effects on HR repair. Second, my findings indicate that 
histone H2A/H2A.X are modified with Lys11-linked ubiquitin chain in DNA damage-
dependent manner. However, the identity of the lysine residue(s) on histone H2A 
that is modified with Lys11 ubiquitin chain still requires further examination. H2A is 
known to be modified with Lys63-linked ubiquitin chain at Lys13 and Lys15 residue 
on H2A (143). A proteomic analysis of in vivo ubiquitination sites identified novel 
sites for ubiquitination on different histone proteins (142). Therefore, site-directed 
mutagenesis analysis should be performed to identify and characterize the H2A 
lysine residue(s) that is modified with Lys11 ubiquitin chain. Third, it is possible that 
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other non-histone proteins are also modified with Lys11-linked ubiquitin chain at the 
damage sites. Identification and characterization of these substrates will further our 
understanding of the role of Lys11-linked chromatin ubiquitination at the DNA 
damage sites. Fourth, does Lys11-linked ubiquitin chain trigger proteolytic signal at 
the damage sites? The chromatin fraction analysis showed that chromatin-bound 
protein modification with Lys11 ubiquitin chain is enhanced dramatically upon 
treating the cells with MG132. This raises the possibility that a fraction of the Lys11 
ubiquitin-modified proteins is likely to be targeted by the proteasome. Although I 
could not detect any alteration in histone protein levels, it is possible that other non-
histone proteins may undergo proteasomal degradation by Lys11-linked 
ubiquitination in DNA damage-dependent manner. Fifth, although my study uncovers 
a novel role of Lys11-linked chromatin ubiquitination in inducing transcriptional 
silencing at the DNA damage sites, the mechanism of this silencing event requires 
further investigation. There are several possibilities that can be tested to figure out 
the mechanism of transcription silencing at damaged chromatin. It is possible that 
histone H2A ubiquitination in the Lys11-linked manner directly recruits transcriptional 
repressor complex. Another possibility is, components of the RNAPII holoenzyme 
may be modified and degraded by Lys11 ubiquitin chain and thereby inducing 
transcription stalling until the damage is repaired. These possibilities should be 
tested in future studies. And lastly, given recognition of different ubiquitin chain by 
specific ubiquitin binding domain (UBD) containing proteins contributes to a diverse 
set of functional outcome, it will be interesting to examine specific UBDs that can 
bind to Lys11 ubiquitin chain. Identification of UBDs that recognize Lys11 ubiquitin 
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chain will, therefore, likely to reveal novel function this modification at the DNA 
damage sites as well as other signaling events in the cell. 
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CHAPTER 4 
DISCUSSION AND FINAL WORDS 
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4.1 Discussion 
 Since the discovery of DNA structure, a remarkable amount of effort has been 
dedicated to understanding how cells preserve its genetic material to maintain 
genetic integrity. It is the largest molecule that is subject for numerous lesions. It is 
estimated that cells experience around 104 to 106 DNA lesions per cell per day. 
Nevertheless, the cells must keep the DNA intact by deploying a repertoire of repair 
mechanisms in proliferating cells as well as in germ cells to ensure faithful 
transmission across generations (3, 4). Given injury to DNA interferes with DNA 
replication and transcription, resulting in genome instability, the DNA damage 
response signaling has evolved as the “sentinel of the genome” to repair DNA injury 
in a timely manner. Of note, DNA is wrapped in around histones forming the 
nucleosome, the fundamental unit of chromatin (187, 188). The nucleosome is 
further compacted into higher order chromatin structure with linker histone protein as 
well as non-histone proteins (189, 190). Although this higher order chromatin 
structure appears to be functioning as a barrier to DNA-associated processes such 
as replication, transcription as well as DNA repair; the highly dynamic chromatin 
structure is modulated by various ways such as DNA methylation (191), post-
translational modifications of histones and non-histone proteins (10, 192), 
nucleosome/chromatin remodeling complexes (193). Among these different factors, 
post-translational modification of chromatin that can be dynamically added or 
removed by enzymatic reactions has emerged as a key regulatory player in 
modulating nucleosome in response to DNA damage. While phosphorylation, 
ubiquitination, acetylation, methylation, ubiquitination, SUMOylation and ADP-
	 133	
ribosylation are among the best-studied modifications, recent studies indicate the 
existence of additional PTMS such as crotonylation, succinylation, and malonylation 
of histone and non-histone proteins (194). In addition to altering nucleosome 
dynamics, these above-mentioned PTMs recruit reader proteins that further 
modulate chromatin remodeling during events such as DNA repair and transcription. 
Although each of this modification entails a distinct set of enzymes that catalyze and 
disassemble chromatin PTMs, recent studies from different groups indicate that 
potential cross talks exist among different post-translational modifications that 
function in a coordinated fashion at the damaged chromatin to execute efficient DDR 
signaling. One classic example of this potential cross talk is γH2A.X and MDC1 
phosphorylation-dependent H2A/H2A.X ubiquitination by the RNF8/RNF168-Ubc13 
enzymatic machinery at the DNA double-strand break sites that function 
synergistically to activate the DDR signal and facilitates downstream DDR factors 
recruitment such as 53BP1 and components of the BRCA1-A complex (37-39, 41, 
43-45). While this represents only a small fraction of crosstalk at the damaged 
chromatin, emerging evidence support a more complex picture of the crosstalk 
among different PTMs to induce efficient DSB response. This potential crosstalk not 
only transduce the damage signal, but also regulates recruitment of effector proteins 
at damage sites, transcriptional silencing as well as coordination with DNA 
replication (16, 195, 196), emphasizing the functional significance of different post-
translational modifications at damaged chromatin.  
 In this study, I investigated the role of phosphorylation and ubiquitination, two 
of the most well studied post-translational modifications at damaged chromatin. The 
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novel findings obtained from this study highlight the significance of cross talk among 
phosphorylation and ubiquitination at DSB sites. In addition to γH2A.X and MDC1 
phosphorylation and Lys63-linked ubiquitination-dependent BRCA1 localization at 
DBSs, I showed that DNA damage-induced Abraxas phosphorylation at the S404 
site is crucial for efficient BRCA1 dimerization and efficient accumulation to damage 
sites to initiate DNA repair (87). Also, I showed that along with Lys63-linked 
ubiquitination, damage chromatin is modified with Lys11-linked ubiquitination in 
phosphorylation-dependent manner to induce transcriptional silencing at the vicinity 
of the DSB sites. These findings not only deepen our understanding of 
spatiotemporal regulation of DDR factors at the damage sites but also provide 
mechanistic insights into how damaged chromatin is orchestrated in response to 
DNA damage to inhibit transcription. While these studies reveal a regulatory role of 
post-translational modifications at the damage sites, they also open up new areas of 
research to understand the role PTMs in regulating the DDR pathway. Future 
studies aiming to understand PTMs in the DDR will likely identify novel molecules in 
the DNA damage response pathway and will provide potential therapeutic 
opportunities to diseases associated with defective DDR signaling. 
4.2  Final words 
 The DNA damage response is absolutely essential for maintaining the 
genomic stability and defective DDR signaling has been characterized as one of the 
hallmarks of cancer (7) and has been attributed to many different types of cancer 
(197). While defects in the DDR signaling has been the major factor in tumorigenesis 
as well as other diseases, this provides a unique opportunity to exploit the DDR 
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system as a potential therapy of cancer with radiotherapy and chemotherapy 
regimens. This is best exemplified by the synthetic lethality approach with the 
PARP1 inhibitor to induce cell death in tumor cells defective in BRCA1 or BRCA2 
genes. Olaparib, the PARP1 inhibitor, has recently been approved by the FDA for 
treatment of women with ovarian cancer. Recent analysis indicate that there are at 
least 450 genes integral to the DDR and choice of drug target depends on the type 
of DNA damage repair to be inhibited given multiple repair mechanisms exist in cells 
to repair damaged DNA. While many of the compounds for DDR targets are already 
approved or under clinical trials, a large number are still in the discovery phase, 
potentially representing next generation DDR targets (198). Interestingly, among 
different PTMs involved in the DDR pathway, phosphorylation and ubiquitin-modified 
proteome and corresponding enzymatic machinery have emerged as a highly 
druggable class of proteins that include protein kinases such as ATM, ATR, DNA-
PK, Chk1, as well as many of the E3 ubiquitin ligases (24 total) involved in various 
DDR pathways (198). The promising results from these studies emphasize how 
post-translational modifications such as phosphorylation and ubiquitination and 
crosstalk among these PTMs in the DDR signaling can potentially be harnessed as a 
viable therapeutic approach in cancer cells. Therefore, detail understanding of PTMs 
in the DDR pathway will likely to identify new molecules in the near future that can 
be targeted for cancer therapy. In this light, my study provides crucial mechanistic 
insights into the DDR pathway. Although there remain questions that require further 
investigation, findings from this study will broaden our understanding of the 
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complexity of the DDR signaling as well as expand the list of DDR factors in DSB 
repair pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 137	
Bibliography: 1.	 Blanpain,	C.,	M.	Mohrin,	P.	A.	Sotiropoulou,	and	E.	Passegue.	2011.	DNA-damage	response	in	tissue-specific	and	cancer	stem	cells.	Cell	Stem	Cell	8:	16-29.	2.	 Lindahl,	 T.,	 and	 D.	 E.	 Barnes.	 2000.	 Repair	 of	 endogenous	 DNA	 damage.	 Cold	
Spring	Harbor	symposia	on	quantitative	biology	65:	127-133.	3.	 Hoeijmakers,	 J.	 H.	 2009.	 DNA	 damage,	 aging,	 and	 cancer.	 The	 New	 England	
journal	of	medicine	361:	1475-1485.	4.	 Ciccia,	A.,	 and	S.	 J.	Elledge.	2010.	The	DNA	damage	 response:	making	 it	 safe	 to	play	with	knives.	Mol	Cell	40:	179-204.	5.	 Jackson,	S.	P.,	and	J.	Bartek.	2009.	The	DNA-damage	response	in	human	biology	and	disease.	Nature	461:	1071-1078.	6.	 Bartek,	J.,	J.	Bartkova,	and	J.	Lukas.	2007.	DNA	damage	signalling	guards	against	activated	oncogenes	and	tumour	progression.	Oncogene	26:	7773-7779.	7.	 Hanahan,	D.,	and	R.	A.	Weinberg.	2011.	Hallmarks	of	cancer:	the	next	generation.	
Cell	144:	646-674.	8.	 Hoeijmakers,	 J.	 H.	 2001.	 Genome	 maintenance	 mechanisms	 for	 preventing	cancer.	Nature	411:	366-374.	9.	 Harper,	J.	W.,	and	S.	J.	Elledge.	2007.	The	DNA	damage	response:	ten	years	after.	
Mol	Cell	28:	739-745.	10.	 Polo,	S.	E.,	and	S.	P.	Jackson.	2011.	Dynamics	of	DNA	damage	response	proteins	at	DNA	breaks:	a	focus	on	protein	modifications.	Genes	Dev	25:	409-433.	11.	 Huen,	 M.	 S.,	 and	 J.	 Chen.	 2008.	 The	 DNA	 damage	 response	 pathways:	 at	 the	crossroad	of	protein	modifications.	Cell	Res	18:	8-16.	
	 138	
12.	 Dantuma,	 N.	 P.,	 and	 H.	 van	 Attikum.	 2016.	 Spatiotemporal	 regulation	 of	posttranslational	modifications	in	the	DNA	damage	response.	EMBO	J	35:	6-23.	13.	 Lukas,	 J.,	 C.	 Lukas,	 and	 J.	 Bartek.	 2011.	More	 than	 just	 a	 focus:	 The	 chromatin	response	to	DNA	damage	and	its	role	in	genome	integrity	maintenance.	Nat	Cell	
Biol	13:	1161-1169.	14.	 Sancar,	 A.,	 L.	 A.	 Lindsey-Boltz,	 K.	 Unsal-Kacmaz,	 and	 S.	 Linn.	 2004.	 Molecular	mechanisms	 of	 mammalian	 DNA	 repair	 and	 the	 DNA	 damage	 checkpoints.	
Annual	review	of	biochemistry	73:	39-85.	15.	 Kim,	J.	S.,	T.	B.	Krasieva,	H.	Kurumizaka,	D.	J.	Chen,	A.	M.	Taylor,	and	K.	Yokomori.	2005.	 Independent	and	sequential	 recruitment	of	NHEJ	and	HR	 factors	 to	DNA	damage	sites	in	mammalian	cells.	J	Cell	Biol	170:	341-347.	16.	 Kuo,	C.	Y.,	C.	Shieh,	F.	Cai,	and	D.	K.	Ann.	2011.	Coordinate	to	guard:	crosstalk	of	phosphorylation,	 sumoylation,	 and	 ubiquitylation	 in	 DNA	 damage	 response.	
Front	Oncol	1:	61.	17.	 Pellegrino,	 S.,	 and	M.	Altmeyer.	 2016.	 Interplay	 between	Ubiquitin,	 SUMO,	 and	Poly(ADP-Ribose)	 in	 the	 Cellular	 Response	 to	 Genotoxic	 Stress.	Front	Genet	7:	63.	18.	 Matsuoka,	 S.,	B.	A.	Ballif,	A.	 Smogorzewska,	E.	R.	McDonald,	3rd,	K.	E.	Hurov,	 J.	Luo,	C.	E.	Bakalarski,	Z.	Zhao,	N.	Solimini,	Y.	Lerenthal,	Y.	Shiloh,	S.	P.	Gygi,	and	S.	J.	 Elledge.	 2007.	 ATM	 and	 ATR	 substrate	 analysis	 reveals	 extensive	 protein	networks	responsive	to	DNA	damage.	Science	316:	1160-1166.	19.	 Cimprich,	 K.	 A.,	 and	 D.	 Cortez.	 2008.	 ATR:	 an	 essential	 regulator	 of	 genome	integrity.	Nat	Rev	Mol	Cell	Biol	9:	616-627.	
	 139	
20.	 Bakkenist,	C.	 J.,	and	M.	B.	Kastan.	2004.	 Initiating	cellular	stress	responses.	Cell	118:	9-17.	21.	 Lee,	J.	H.,	and	T.	T.	Paull.	2004.	Direct	activation	of	the	ATM	protein	kinase	by	the	Mre11/Rad50/Nbs1	complex.	Science	304:	93-96.	22.	 Lee,	 J.	 H.,	 and	 T.	 T.	 Paull.	 2005.	 ATM	 activation	 by	 DNA	 double-strand	 breaks	through	the	Mre11-Rad50-Nbs1	complex.	Science	308:	551-554.	23.	 Shiloh,	 Y.,	 and	 Y.	 Ziv.	 2013.	 The	 ATM	 protein	 kinase:	 regulating	 the	 cellular	response	to	genotoxic	stress,	and	more.	Nat	Rev	Mol	Cell	Biol	14:	197-210.	24.	 Falck,	 J.,	 J.	 Coates,	 and	 S.	 P.	 Jackson.	 2005.	 Conserved	modes	 of	 recruitment	 of	ATM,	ATR	and	DNA-PKcs	to	sites	of	DNA	damage.	Nature	434:	605-611.	25.	 Stracker,	 T.	H.,	M.	Morales,	 S.	 S.	 Couto,	H.	Hussein,	 and	 J.	H.	 Petrini.	 2007.	 The	carboxy	terminus	of	NBS1	is	required	for	 induction	of	apoptosis	by	the	MRE11	complex.	Nature	447:	218-221.	26.	 Paull,	T.	T.	2015.	Mechanisms	of	ATM	Activation.	Annual	review	of	biochemistry	84:	711-738.	27.	 Uziel,	T.,	Y.	Lerenthal,	L.	Moyal,	Y.	Andegeko,	L.	Mittelman,	and	Y.	Shiloh.	2003.	Requirement	of	 the	MRN	complex	 for	ATM	activation	by	DNA	damage.	EMBO	J	22:	5612-5621.	28.	 Bensimon,	A.,	A.	Schmidt,	Y.	Ziv,	R.	Elkon,	S.	Y.	Wang,	D.	J.	Chen,	R.	Aebersold,	and	Y.	 Shiloh.	 2010.	 ATM-dependent	 and	 -independent	 dynamics	 of	 the	 nuclear	phosphoproteome	after	DNA	damage.	Sci	Signal	3:	rs3.	
	 140	
29.	 Meier,	 A.,	 H.	 Fiegler,	 P.	 Munoz,	 P.	 Ellis,	 D.	 Rigler,	 C.	 Langford,	 M.	 A.	 Blasco,	 N.	Carter,	and	S.	P.	Jackson.	2007.	Spreading	of	mammalian	DNA-damage	response	factors	studied	by	ChIP-chip	at	damaged	telomeres.	EMBO	J	26:	2707-2718.	30.	 Savic,	V.,	B.	Yin,	N.	L.	Maas,	A.	L.	Bredemeyer,	A.	C.	Carpenter,	B.	A.	Helmink,	K.	S.	Yang-Iott,	B.	P.	Sleckman,	and	C.	H.	Bassing.	2009.	Formation	of	dynamic	gamma-H2AX	 domains	 along	 broken	 DNA	 strands	 is	 distinctly	 regulated	 by	 ATM	 and	MDC1	and	dependent	upon	H2AX	densities	in	chromatin.	Mol	Cell	34:	298-310.	31.	 Fernandez-Capetillo,	 O.,	 A.	 Lee,	 M.	 Nussenzweig,	 and	 A.	 Nussenzweig.	 2004.	H2AX:	the	histone	guardian	of	the	genome.	DNA	Repair	(Amst)	3:	959-967.	32.	 Lee,	M.	 S.,	 R.	 A.	 Edwards,	 G.	 L.	 Thede,	 and	 J.	 N.	 Glover.	 2005.	 Structure	 of	 the	BRCT	repeat	domain	of	MDC1	and	its	specificity	for	the	free	COOH-terminal	end	of	the	gamma-H2AX	histone	tail.	J	Biol	Chem	280:	32053-32056.	33.	 Stucki,	M.,	 J.	 A.	 Clapperton,	D.	Mohammad,	M.	 B.	 Yaffe,	 S.	 J.	 Smerdon,	 and	 S.	 P.	Jackson.	 2005.	 MDC1	 directly	 binds	 phosphorylated	 histone	 H2AX	 to	 regulate	cellular	responses	to	DNA	double-strand	breaks.	Cell	123:	1213-1226.	34.	 Stucki,	M.,	and	S.	P.	Jackson.	2006.	gammaH2AX	and	MDC1:	anchoring	the	DNA-damage-response	 machinery	 to	 broken	 chromosomes.	 DNA	 Repair	 (Amst)	 5:	534-543.	35.	 Lou,	Z.,	K.	Minter-Dykhouse,	S.	Franco,	M.	Gostissa,	M.	A.	Rivera,	A.	Celeste,	 J.	P.	Manis,	 J.	 van	Deursen,	A.	Nussenzweig,	T.	T.	Paull,	F.	W.	Alt,	 and	 J.	Chen.	2006.	MDC1	maintains	genomic	stability	by	participating	in	the	amplification	of	ATM-dependent	DNA	damage	signals.	Mol	Cell	21:	187-200.	
	 141	
36.	 Stewart,	G.	S.,	B.	Wang,	C.	R.	Bignell,	A.	M.	Taylor,	and	S.	J.	Elledge.	2003.	MDC1	is	a	mediator	of	the	mammalian	DNA	damage	checkpoint.	Nature	421:	961-966.	37.	 Huen,	M.	S.,	R.	Grant,	I.	Manke,	K.	Minn,	X.	Yu,	M.	B.	Yaffe,	and	J.	Chen.	2007.	RNF8	transduces	 the	 DNA-damage	 signal	 via	 histone	 ubiquitylation	 and	 checkpoint	protein	assembly.	Cell	131:	901-914.	38.	 Kolas,	N.	K.,	 J.	 R.	 Chapman,	 S.	Nakada,	 J.	 Ylanko,	R.	 Chahwan,	 F.	D.	 Sweeney,	 S.	Panier,	M.	Mendez,	J.	Wildenhain,	T.	M.	Thomson,	L.	Pelletier,	S.	P.	Jackson,	and	D.	Durocher.	 2007.	 Orchestration	 of	 the	 DNA-damage	 response	 by	 the	 RNF8	ubiquitin	ligase.	Science	318:	1637-1640.	39.	 Mailand,	N.,	S.	Bekker-Jensen,	H.	Faustrup,	F.	Melander,	J.	Bartek,	C.	Lukas,	and	J.	Lukas.	 2007.	 RNF8	 ubiquitylates	 histones	 at	 DNA	 double-strand	 breaks	 and	promotes	assembly	of	repair	proteins.	Cell	131:	887-900.	40.	 Bekker-Jensen,	 S.,	 J.	 Rendtlew	Danielsen,	 K.	 Fugger,	 I.	 Gromova,	 A.	Nerstedt,	 C.	Lukas,	 J.	 Bartek,	 J.	 Lukas,	 and	N.	Mailand.	 2010.	 HERC2	 coordinates	 ubiquitin-dependent	assembly	of	DNA	repair	 factors	on	damaged	chromosomes.	Nat	Cell	
Biol	12:	80-86;	sup	pp	81-12.	41.	 Wang,	 B.,	 and	 S.	 J.	 Elledge.	 2007.	 Ubc13/Rnf8	 ubiquitin	 ligases	 control	 foci	formation	 of	 the	 Rap80/Abraxas/Brca1/Brcc36	 complex	 in	 response	 to	 DNA	damage.	Proc	Natl	Acad	Sci	U	S	A	104:	20759-20763.	42.	 Christensen,	 D.	 E.,	 P.	 S.	 Brzovic,	 and	 R.	 E.	 Klevit.	 2007.	 E2-BRCA1	 RING	interactions	dictate	synthesis	of	mono-	or	specific	polyubiquitin	chain	linkages.	
Nat	Struct	Mol	Biol	14:	941-948.	
	 142	
43.	 Doil,	 C.,	N.	Mailand,	 S.	 Bekker-Jensen,	 P.	Menard,	D.	H.	 Larsen,	R.	 Pepperkok,	 J.	Ellenberg,	S.	Panier,	D.	Durocher,	J.	Bartek,	J.	Lukas,	and	C.	Lukas.	2009.	RNF168	binds	 and	 amplifies	 ubiquitin	 conjugates	 on	 damaged	 chromosomes	 to	 allow	accumulation	of	repair	proteins.	Cell	136:	435-446.	44.	 Pinato,	 S.,	 C.	 Scandiuzzi,	 N.	 Arnaudo,	 E.	 Citterio,	 G.	 Gaudino,	 and	 L.	 Penengo.	2009.	 RNF168,	 a	 new	 RING	 finger,	 MIU-containing	 protein	 that	 modifies	chromatin	by	ubiquitination	of	histones	H2A	and	H2AX.	BMC	Mol	Biol	10:	55.	45.	 Stewart,	G.	S.,	S.	Panier,	K.	Townsend,	A.	K.	Al-Hakim,	N.	K.	Kolas,	E.	S.	Miller,	S.	Nakada,	 J.	 Ylanko,	 S.	 Olivarius,	 M.	 Mendez,	 C.	 Oldreive,	 J.	 Wildenhain,	 A.	Tagliaferro,	L.	Pelletier,	N.	Taubenheim,	A.	Durandy,	P.	J.	Byrd,	T.	Stankovic,	A.	M.	Taylor,	 and	 D.	 Durocher.	 2009.	 The	 RIDDLE	 syndrome	 protein	 mediates	 a	ubiquitin-dependent	 signaling	 cascade	 at	 sites	 of	 DNA	 damage.	 Cell	136:	 420-434.	46.	 Thorslund,	T.,	A.	Ripplinger,	S.	Hoffmann,	T.	Wild,	M.	Uckelmann,	B.	Villumsen,	T.	Narita,	 T.	 K.	 Sixma,	 C.	 Choudhary,	 S.	 Bekker-Jensen,	 and	 N.	 Mailand.	 2015.	Histone	H1	couples	initiation	and	amplification	of	ubiquitin	signalling	after	DNA	damage.	Nature	527:	389-393.	47.	 Wang,	B.,	S.	Matsuoka,	B.	A.	Ballif,	D.	Zhang,	A.	Smogorzewska,	S.	P.	Gygi,	and	S.	J.	Elledge.	2007.	Abraxas	and	RAP80	form	a	BRCA1	protein	complex	required	for	the	DNA	damage	response.	Science	316:	1194-1198.	48.	 Kim,	 H.,	 J.	 Chen,	 and	 X.	 Yu.	 2007.	 Ubiquitin-binding	 protein	 RAP80	 mediates	BRCA1-dependent	DNA	damage	response.	Science	316:	1202-1205.	
	 143	
49.	 Kim,	H.,	 J.	Huang,	and	 J.	Chen.	2007.	CCDC98	 is	a	BRCA1-BRCT	domain-binding	protein	involved	in	the	DNA	damage	response.	Nat	Struct	Mol	Biol	14:	710-715.	50.	 Liu,	Z.,	J.	Wu,	and	X.	Yu.	2007.	CCDC98	targets	BRCA1	to	DNA	damage	sites.	Nat	
Struct	Mol	Biol	14:	716-720.	51.	 Sobhian,	B.,	G.	Shao,	D.	R.	Lilli,	A.	C.	Culhane,	L.	A.	Moreau,	B.	Xia,	D.	M.	Livingston,	and	R.	A.	Greenberg.	2007.	RAP80	targets	BRCA1	to	specific	ubiquitin	structures	at	DNA	damage	sites.	Science	316:	1198-1202.	52.	 Feng,	L.,	J.	Huang,	and	J.	Chen.	2009.	MERIT40	facilitates	BRCA1	localization	and	DNA	damage	repair.	Genes	Dev	23:	719-728.	53.	 Wang,	B.,	K.	Hurov,	K.	Hofmann,	and	S.	J.	Elledge.	2009.	NBA1,	a	new	player	in	the	Brca1	A	complex,	is	required	for	DNA	damage	resistance	and	checkpoint	control.	
Genes	Dev	23:	729-739.	54.	 Patterson-Fortin,	 J.,	 G.	 Shao,	 H.	 Bretscher,	 T.	 E.	 Messick,	 and	 R.	 A.	 Greenberg.	2010.	Differential	regulation	of	 JAMM	domain	deubiquitinating	enzyme	activity	within	the	RAP80	complex.	J	Biol	Chem	285:	30971-30981.	55.	 llo,	A.,	A.	Paul,	B.	Sun,	T.	H.	Huang,	Y.	Wang,	S.	A.	Yazinski,	J.	Tyler,	L.	Li,	M.	J.	You,	L.	 Zou,	 J.	 Yao,	 and	 B.	 Wang.	 2014.	 The	 BRCA1-interacting	 protein	 Abraxas	 is	required	for	genomic	stability	and	tumor	suppression.	Cell	reports	8:	807-817.	56.	 Gatti,	 M.,	 S.	 Pinato,	 A.	 Maiolica,	 F.	 Rocchio,	 M.	 G.	 Prato,	 R.	 Aebersold,	 and	 L.	Penengo.	 2015.	 RNF168	 promotes	 noncanonical	 K27	 ubiquitination	 to	 signal	DNA	damage.	Cell	reports	10:	226-238.	57.	 Feng,	 L.,	 and	 J.	 Chen.	 2012.	 The	 E3	 ligase	 RNF8	 regulates	 KU80	 removal	 and	NHEJ	repair.	Nat	Struct	Mol	Biol	19:	201-206.	
	 144	
58.	 Lok,	G.	T.,	S.	M.	Sy,	S.	S.	Dong,	Y.	P.	Ching,	S.	W.	Tsao,	T.	M.	Thomson,	and	M.	S.	Huen.	 2012.	Differential	 regulation	of	RNF8-mediated	Lys48-	 and	Lys63-based	poly-ubiquitylation.	Nucleic	acids	research	40:	196-205.	59.	 Adam,	 S.,	 and	 S.	 E.	 Polo.	 2014.	 Blurring	 the	 line	 between	 the	 DNA	 damage	response	and	transcription:	the	importance	of	chromatin	dynamics.	Exp	Cell	Res	329:	148-153.	60.	 Mayne,	L.	V.,	and	A.	R.	Lehmann.	1982.	Failure	of	RNA	synthesis	to	recover	after	UV	 irradiation:	 an	 early	 defect	 in	 cells	 from	 individuals	 with	 Cockayne's	syndrome	and	xeroderma	pigmentosum.	Cancer	research	42:	1473-1478.	61.	 Mone,	 M.	 J.,	 M.	 Volker,	 O.	 Nikaido,	 L.	 H.	 Mullenders,	 A.	 A.	 van	 Zeeland,	 P.	 J.	Verschure,	E.	M.	Manders,	and	R.	van	Driel.	2001.	Local	UV-induced	DNA	damage	in	cell	nuclei	results	in	local	transcription	inhibition.	EMBO	Rep	2:	1013-1017.	62.	 Solovjeva,	L.	V.,	M.	P.	Svetlova,	V.	O.	Chagin,	and	N.	V.	Tomilin.	2007.	Inhibition	of	transcription	at	radiation-induced	nuclear	foci	of	phosphorylated	histone	H2AX	in	mammalian	cells.	Chromosome	Res	15:	787-797.	63.	 Seiler,	D.	M.,	J.	Rouquette,	V.	J.	Schmid,	H.	Strickfaden,	C.	Ottmann,	G.	A.	Drexler,	B.	Mazurek,	 C.	 Greubel,	 V.	 Hable,	 G.	 Dollinger,	 T.	 Cremer,	 and	 A.	 A.	 Friedl.	 2011.	Double-strand	break-induced	transcriptional	silencing	is	associated	with	loss	of	tri-methylation	at	H3K4.	Chromosome	Res	19:	883-899.	64.	 Vissers,	 J.	 H.,	 M.	 van	 Lohuizen,	 and	 E.	 Citterio.	 2012.	 The	 emerging	 role	 of	Polycomb	repressors	in	the	response	to	DNA	damage.	J	Cell	Sci	125:	3939-3948.	65.	 Ayrapetov,	M.	K.,	O.	Gursoy-Yuzugullu,	C.	Xu,	Y.	Xu,	 and	B.	D.	Price.	 2014.	DNA	double-strand	 breaks	 promote	 methylation	 of	 histone	 H3	 on	 lysine	 9	 and	
	 145	
transient	formation	of	repressive	chromatin.	Proc	Natl	Acad	Sci	U	S	A	111:	9169-9174.	66.	 Chou,	D.	M.,	B.	Adamson,	N.	E.	Dephoure,	X.	Tan,	A.	C.	Nottke,	K.	E.	Hurov,	S.	P.	Gygi,	M.	 P.	 Colaiacovo,	 and	 S.	 J.	 Elledge.	 2010.	 A	 chromatin	 localization	 screen	reveals	poly	(ADP	ribose)-regulated	recruitment	of	the	repressive	polycomb	and	NuRD	complexes	 to	sites	of	DNA	damage.	Proc	Natl	Acad	Sci	U	S	A	107:	18475-18480.	67.	 Shanbhag,	N.	M.,	I.	U.	Rafalska-Metcalf,	C.	Balane-Bolivar,	S.	M.	Janicki,	and	R.	A.	Greenberg.	2010.	ATM-dependent	chromatin	changes	silence	transcription	in	cis	to	DNA	double-strand	breaks.	Cell	141:	970-981.	68.	 Wang,	B.	2012.	BRCA1	tumor	suppressor	network:	focusing	on	its	tail.	Cell	Biosci	2:	6.	69.	 Huen,	 M.	 S.,	 S.	 M.	 Sy,	 and	 J.	 Chen.	 2010.	 BRCA1	 and	 its	 toolbox	 for	 the	maintenance	of	genome	integrity.	Nat	Rev	Mol	Cell	Biol	11:	138-148.	70.	 Venkitaraman,	A.	R.	2002.	Cancer	susceptibility	and	the	functions	of	BRCA1	and	BRCA2.	Cell	108:	171-182.	71.	 Kobayashi,	H.,	S.	Ohno,	Y.	Sasaki,	and	M.	Matsuura.	2013.	Hereditary	breast	and	ovarian	cancer	susceptibility	genes	(review).	Oncology	reports	30:	1019-1029.	72.	 Savage,	K.	I.,	and	D.	P.	Harkin.	2015.	BRCA1,	a	'complex'	protein	involved	in	the	maintenance	of	genomic	stability.	FEBS	J	282:	630-646.	73.	 Futreal,	P.	A.,	Q.	Liu,	D.	Shattuck-Eidens,	C.	Cochran,	K.	Harshman,	S.	Tavtigian,	L.	M.	 Bennett,	 A.	 Haugen-Strano,	 J.	 Swensen,	 Y.	 Miki,	 and	 et	 al.	 1994.	 BRCA1	mutations	in	primary	breast	and	ovarian	carcinomas.	Science	266:	120-122.	
	 146	
74.	 Miki,	Y.,	J.	Swensen,	D.	Shattuck-Eidens,	P.	A.	Futreal,	K.	Harshman,	S.	Tavtigian,	Q.	Liu,	C.	Cochran,	L.	M.	Bennett,	W.	Ding,	and	et	al.	1994.	A	strong	candidate	for	the	breast	and	ovarian	cancer	susceptibility	gene	BRCA1.	Science	266:	66-71.	75.	 Jiang,	Q.,	and	R.	A.	Greenberg.	2015.	Deciphering	the	BRCA1	Tumor	Suppressor	Network.	J	Biol	Chem	290:	17724-17732.	76.	 Huen,	 M.	 S.	 Y.,	 S.	 M.	 H.	 Sy,	 and	 J.	 Chen.	 2009.	 BRCA1	 and	 its	 toolbox	 for	 the	maintenance	of	genome	integrity.	Nature	Reviews	Molecular	Cell	Biology	11:	138-148.	77.	 Deng,	C.	X.	2006.	BRCA1:	cell	cycle	checkpoint,	genetic	 instability,	DNA	damage	response	and	cancer	evolution.	Nucleic	acids	research	34:	1416-1426.	78.	 Tirkkonen,	M.,	O.	Johannsson,	B.	A.	Agnarsson,	H.	Olsson,	S.	Ingvarsson,	R.	Karhu,	M.	 Tanner,	 J.	 Isola,	 R.	 B.	 Barkardottir,	 A.	 Borg,	 and	 O.	 P.	 Kallioniemi.	 1997.	Distinct	somatic	genetic	changes	associated	with	 tumor	progression	 in	carriers	of	BRCA1	and	BRCA2	germ-line	mutations.	Cancer	research	57:	1222-1227.	79.	 Weaver,	Z.,	C.	Montagna,	X.	Xu,	T.	Howard,	M.	Gadina,	S.	G.	Brodie,	C.	X.	Deng,	and	T.	Ried.	2002.	Mammary	tumors	in	mice	conditionally	mutant	for	Brca1	exhibit	gross	genomic	 instability	and	centrosome	amplification	yet	display	a	 recurring	distribution	 of	 genomic	 imbalances	 that	 is	 similar	 to	 human	 breast	 cancer.	
Oncogene	21:	5097-5107.	80.	 Meza,	J.	E.,	P.	S.	Brzovic,	M.	C.	King,	and	R.	E.	Klevit.	1999.	Mapping	the	functional	domains	of	BRCA1.	Interaction	of	the	ring	finger	domains	of	BRCA1	and	BARD1.	J	
Biol	Chem	274:	5659-5665.	
	 147	
81.	 Mallery,	D.	 L.,	 C.	 J.	 Vandenberg,	 and	K.	Hiom.	 2002.	Activation	 of	 the	E3	 ligase	function	 of	 the	 BRCA1/BARD1	 complex	 by	 polyubiquitin	 chains.	 EMBO	 J	 21:	6755-6762.	82.	 Wu-Baer,	 F.,	 K.	 Lagrazon,	 W.	 Yuan,	 and	 R.	 Baer.	 2003.	 The	 BRCA1/BARD1	heterodimer	assembles	polyubiquitin	chains	through	an	unconventional	linkage	involving	lysine	residue	K6	of	ubiquitin.	J	Biol	Chem	278:	34743-34746.	83.	 Morris,	 J.	 R.,	 and	 E.	 Solomon.	 2004.	 BRCA1	 :	 BARD1	 induces	 the	 formation	 of	conjugated	 ubiquitin	 structures,	 dependent	 on	 K6	 of	 ubiquitin,	 in	 cells	 during	DNA	replication	and	repair.	Human	molecular	genetics	13:	807-817.	84.	 Nishikawa,	H.,	S.	Ooka,	K.	Sato,	K.	Arima,	J.	Okamoto,	R.	E.	Klevit,	M.	Fukuda,	and	T.	Ohta.	2004.	Mass	spectrometric	and	mutational	analyses	reveal	Lys-6-linked	polyubiquitin	 chains	 catalyzed	 by	 BRCA1-BARD1	 ubiquitin	 ligase.	 J	 Biol	 Chem	279:	3916-3924.	85.	 Shakya,	R.,	L.	J.	Reid,	C.	R.	Reczek,	F.	Cole,	D.	Egli,	C.	S.	Lin,	D.	G.	deRooij,	S.	Hirsch,	K.	Ravi,	 J.	 B.	Hicks,	M.	 Szabolcs,	M.	 Jasin,	R.	Baer,	 and	T.	 Ludwig.	 2011.	BRCA1	tumor	 suppression	 depends	 on	 BRCT	 phosphoprotein	 binding,	 but	 not	 its	 E3	ligase	activity.	Science	334:	525-528.	86.	 Williams,	 R.	 S.,	 R.	 Green,	 and	 J.	 N.	 Glover.	 2001.	 Crystal	 structure	 of	 the	 BRCT	repeat	region	from	the	breast	cancer-associated	protein	BRCA1.	Nat	Struct	Biol	8:	838-842.	87.	 Wu,	Q.,	A.	Paul,	D.	Su,	S.	Mehmood,	T.	K.	Foo,	T.	Ochi,	E.	L.	Bunting,	B.	Xia,	C.	V.	Robinson,	B.	Wang,	and	T.	L.	Blundell.	2016.	Structure	of	BRCA1-BRCT/Abraxas	
	 148	
Complex	 Reveals	 Phosphorylation-Dependent	 BRCT	 Dimerization	 at	 DNA	Damage	Sites.	Mol	Cell	61:	434-448.	88.	 Hu,	X.,	J.	A.	Kim,	A.	Castillo,	M.	Huang,	J.	Liu,	and	B.	Wang.	2011.	NBA1/MERIT40	and	BRE	interaction	is	required	for	the	integrity	of	two	distinct	deubiquitinating	enzyme	BRCC36-containing	complexes.	J	Biol	Chem	286:	11734-11745.	89.	 Komander,	D.,	M.	J.	Clague,	and	S.	Urbe.	2009.	Breaking	the	chains:	structure	and	function	of	the	deubiquitinases.	Nat	Rev	Mol	Cell	Biol	10:	550-563.	90.	 Cooper,	 E.	M.,	 C.	 Cutcliffe,	 T.	 Z.	 Kristiansen,	 A.	 Pandey,	 C.	M.	 Pickart,	 and	 R.	 E.	Cohen.	 2009.	 K63-specific	 deubiquitination	 by	 two	 JAMM/MPN+	 complexes:	BRISC-associated	Brcc36	and	proteasomal	Poh1.	EMBO	J	28:	621-631.	91.	 Feng,	L.,	J.	Wang,	and	J.	Chen.	2010.	The	Lys63-specific	deubiquitinating	enzyme	BRCC36	 is	 regulated	by	 two	scaffold	proteins	 localizing	 in	different	subcellular	compartments.	J	Biol	Chem	285:	30982-30988.	92.	 Szabo,	 C.,	 A.	 Masiello,	 J.	 F.	 Ryan,	 and	 L.	 C.	 Brody.	 2000.	 The	 breast	 cancer	information	 core:	 database	 design,	 structure,	 and	 scope.	Human	mutation	16:	123-131.	93.	 Wang,	B.	2012.	BRCA1	tumor	suppressor	network:	focusing	on	its	tail.	Cell	Biosci	2:	6.	94.	 Clapperton,	J.	A.,	I.	A.	Manke,	D.	M.	Lowery,	T.	Ho,	L.	F.	Haire,	M.	B.	Yaffe,	and	S.	J.	Smerdon.	2004.	Structure	and	mechanism	of	BRCA1	BRCT	domain	recognition	of	phosphorylated	BACH1	with	implications	for	cancer.	Nat	Struct	Mol	Biol	11:	512-518.	
	 149	
95.	 Williams,	 R.	 S.,	M.	 S.	 Lee,	 D.	 D.	 Hau,	 and	 J.	 N.	 Glover.	 2004.	 Structural	 basis	 of	phosphopeptide	recognition	by	the	BRCT	domain	of	BRCA1.	Nat	Struct	Mol	Biol	11:	519-525.	96.	 Shiozaki,	E.	N.,	L.	Gu,	N.	Yan,	and	Y.	Shi.	2004.	Structure	of	the	BRCT	repeats	of	BRCA1	bound	 to	 a	BACH1	phosphopeptide:	 implications	 for	 signaling.	Mol	Cell	14:	405-412.	97.	 Varma,	A.	K.,	R.	S.	Brown,	G.	Birrane,	and	J.	A.	Ladias.	2005.	Structural	basis	for	cell	 cycle	 checkpoint	 control	 by	 the	 BRCA1-CtIP	 complex.	 Biochemistry	 44:	10941-10946.	98.	 Neeley,	W.	L.,	and	J.	M.	Essigmann.	2006.	Mechanisms	of	formation,	genotoxicity,	and	mutation	of	guanine	oxidation	products.	Chem	Res	Toxicol	19:	491-505.	99.	 Stock,	 J.	 K.,	 S.	 Giadrossi,	 M.	 Casanova,	 E.	 Brookes,	 M.	 Vidal,	 H.	 Koseki,	 N.	Brockdorff,	A.	G.	Fisher,	and	A.	Pombo.	2007.	Ring1-mediated	ubiquitination	of	H2A	restrains	poised	RNA	polymerase	II	at	bivalent	genes	in	mouse	ES	cells.	Nat	
Cell	Biol	9:	1428-1435.	100.	 Ciehanover,	 A.,	 Y.	 Hod,	 and	 A.	 Hershko.	 1978.	 A	 heat-stable	 polypeptide	component	 of	 an	 ATP-dependent	 proteolytic	 system	 from	 reticulocytes.	
Biochemical	and	biophysical	research	communications	81:	1100-1105.	101.	 Hershko,	A.,	A.	Ciechanover,	H.	Heller,	A.	L.	Haas,	and	I.	A.	Rose.	1980.	Proposed	role	of	ATP	in	protein	breakdown:	conjugation	of	protein	with	multiple	chains	of	the	polypeptide	of	ATP-dependent	proteolysis.	Proc	Natl	Acad	Sci	U	S	A	77:	1783-1786.	
	 150	
102.	 Wilkinson,	 K.	 D.,	 M.	 K.	 Urban,	 and	 A.	 L.	 Haas.	 1980.	 Ubiquitin	 is	 the	 ATP-dependent	 proteolysis	 factor	 I	 of	 rabbit	 reticulocytes.	 J	 Biol	 Chem	255:	 7529-7532.	103.	 Chen,	 Z.	 J.,	 and	 L.	 J.	 Sun.	 2009.	 Nonproteolytic	 functions	 of	 ubiquitin	 in	 cell	signaling.	Mol	Cell	33:	275-286.	104.	 Pickart,	 C.	 M.	 2001.	 Mechanisms	 underlying	 ubiquitination.	 Annual	 review	 of	
biochemistry	70:	503-533.	105.	 Schulman,	B.	A.,	and	J.	W.	Harper.	2009.	Ubiquitin-like	protein	activation	by	E1	enzymes:	the	apex	for	downstream	signalling	pathways.	Nat	Rev	Mol	Cell	Biol	10:	319-331.	106.	 Ye,	Y.,	and	M.	Rape.	2009.	Building	ubiquitin	chains:	E2	enzymes	at	work.	Nat	Rev	
Mol	Cell	Biol	10:	755-764.	107.	 Welchman,	R.	L.,	C.	Gordon,	 and	R.	 J.	Mayer.	2005.	Ubiquitin	and	ubiquitin-like	proteins	as	multifunctional	signals.	Nat	Rev	Mol	Cell	Biol	6:	599-609.	108.	 Kaiser,	S.	E.,	B.	E.	Riley,	T.	A.	Shaler,	R.	S.	Trevino,	C.	H.	Becker,	H.	Schulman,	and	R.	R.	Kopito.	2011.	Protein	standard	absolute	quantification	(PSAQ)	method	for	the	measurement	of	cellular	ubiquitin	pools.	Nature	methods	8:	691-696.	109.	 Haglund,	K.,	S.	Sigismund,	S.	Polo,	I.	Szymkiewicz,	P.	P.	Di	Fiore,	and	I.	Dikic.	2003.	Multiple	 monoubiquitination	 of	 RTKs	 is	 sufficient	 for	 their	 endocytosis	 and	degradation.	Nat	Cell	Biol	5:	461-466.	110.	 Swatek,	K.	N.,	and	D.	Komander.	2016.	Ubiquitin	modifications.	Cell	Res	26:	399-422.	
	 151	
111.	 Akutsu,	M.,	I.	Dikic,	and	A.	Bremm.	2016.	Ubiquitin	chain	diversity	at	a	glance.	J	
Cell	Sci	129:	875-880.	112.	 Iwai,	 K.,	 H.	 Fujita,	 and	 Y.	 Sasaki.	 2014.	 Linear	 ubiquitin	 chains:	 NF-kappaB	signalling,	cell	death	and	beyond.	Nat	Rev	Mol	Cell	Biol	15:	503-508.	113.	 Meierhofer,	D.,	X.	Wang,	L.	Huang,	and	P.	Kaiser.	2008.	Quantitative	analysis	of	global	 ubiquitination	 in	 HeLa	 cells	 by	mass	 spectrometry.	 Journal	 of	 proteome	
research	7:	4566-4576.	114.	 Xu,	 P.,	 D.	 M.	 Duong,	 N.	 T.	 Seyfried,	 D.	 Cheng,	 Y.	 Xie,	 J.	 Robert,	 J.	 Rush,	 M.	Hochstrasser,	D.	 Finley,	 and	 J.	 Peng.	 2009.	Quantitative	proteomics	 reveals	 the	function	 of	 unconventional	 ubiquitin	 chains	 in	 proteasomal	 degradation.	 Cell	137:	133-145.	115.	 Peng,	J.,	D.	Schwartz,	J.	E.	Elias,	C.	C.	Thoreen,	D.	Cheng,	G.	Marsischky,	J.	Roelofs,	D.	Finley,	and	S.	P.	Gygi.	2003.	A	proteomics	approach	to	understanding	protein	ubiquitination.	Nat	Biotechnol	21:	921-926.	116.	 Hurley,	J.	H.,	S.	Lee,	and	G.	Prag.	2006.	Ubiquitin-binding	domains.	Biochem	J	399:	361-372.	117.	 Dikic,	I.,	S.	Wakatsuki,	and	K.	J.	Walters.	2009.	Ubiquitin-binding	domains	-	from	structures	to	functions.	Nat	Rev	Mol	Cell	Biol	10:	659-671.	118.	 Stewart,	M.	 D.,	 T.	 Ritterhoff,	 R.	 E.	 Klevit,	 and	 P.	 S.	 Brzovic.	 2016.	 E2	 enzymes:	more	than	just	middle	men.	Cell	Res	26:	423-440.	119.	 Chau,	V.,	 J.	W.	Tobias,	A.	Bachmair,	D.	Marriott,	D.	 J.	 Ecker,	D.	K.	Gonda,	 and	A.	Varshavsky.	 1989.	 A	 multiubiquitin	 chain	 is	 confined	 to	 specific	 lysine	 in	 a	targeted	short-lived	protein.	Science	243:	1576-1583.	
	 152	
120.	 Hochstrasser,	M.	1996.	Ubiquitin-dependent	protein	degradation.	Annual	review	
of	genetics	30:	405-439.	121.	 Spence,	 J.,	 S.	 Sadis,	 A.	 L.	 Haas,	 and	 D.	 Finley.	 1995.	 A	 ubiquitin	 mutant	 with	specific	 defects	 in	 DNA	 repair	 and	multiubiquitination.	Mol	Cell	Biol	15:	 1265-1273.	122.	 Hofmann,	R.	M.,	and	C.	M.	Pickart.	1999.	Noncanonical	MMS2-encoded	ubiquitin-conjugating	enzyme	functions	in	assembly	of	novel	polyubiquitin	chains	for	DNA	repair.	Cell	96:	645-653.	123.	 Deng,	L.,	 C.	Wang,	E.	 Spencer,	L.	Yang,	A.	Braun,	 J.	You,	C.	 Slaughter,	C.	Pickart,	and	 Z.	 J.	 Chen.	 2000.	 Activation	 of	 the	 IkappaB	 kinase	 complex	 by	 TRAF6	requires	 a	 dimeric	 ubiquitin-conjugating	 enzyme	 complex	 and	 a	 unique	polyubiquitin	chain.	Cell	103:	351-361.	124.	 Zhou,	H.,	I.	Wertz,	K.	O'Rourke,	M.	Ultsch,	S.	Seshagiri,	M.	Eby,	W.	Xiao,	and	V.	M.	Dixit.	 2004.	 Bcl10	 activates	 the	 NF-kappaB	 pathway	 through	 ubiquitination	 of	NEMO.	Nature	427:	167-171.	125.	 Galan,	 J.	 M.,	 and	 R.	 Haguenauer-Tsapis.	 1997.	 Ubiquitin	 lys63	 is	 involved	 in	ubiquitination	of	a	yeast	plasma	membrane	protein.	EMBO	J	16:	5847-5854.	126.	 Jung,	J.	W.,	S.	J.	Bae,	G.	Y.	Kang,	K.	H.	Kim,	W.	S.	Yeo,	S.	H.	Park,	J.	H.	Seol,	E.	C.	Yi,	and	K.	P.	Kim.	2013.	Analysis	of	the	biochemical	role	of	Lys-11	in	polyubiquitin	chain	 formation	 using	 quantitative	 mass	 spectrometry.	 Rapid	 Commun	 Mass	
Spectrom	27:	339-346.	127.	 Ordureau,	A.,	C.	Munch,	and	J.	W.	Harper.	2015.	Quantifying	ubiquitin	signaling.	
Mol	Cell	58:	660-676.	
	 153	
128.	 Phu,	 L.,	 A.	 Izrael-Tomasevic,	 M.	 L.	 Matsumoto,	 D.	 Bustos,	 J.	 N.	 Dynek,	 A.	 V.	Fedorova,	 C.	 E.	 Bakalarski,	 D.	 Arnott,	 K.	 Deshayes,	 V.	 M.	 Dixit,	 R.	 F.	 Kelley,	 D.	Vucic,	 and	 D.	 S.	 Kirkpatrick.	 2011.	 Improved	 quantitative	 mass	 spectrometry	methods	 for	 characterizing	 complex	 ubiquitin	 signals.	 Molecular	 &	 cellular	
proteomics	:	MCP	10:	M110	003756.	129.	 Kirkpatrick,	D.	S.,	N.	A.	Hathaway,	 J.	Hanna,	S.	Elsasser,	 J.	Rush,	D.	Finley,	R.	W.	King,	and	S.	P.	Gygi.	2006.	Quantitative	analysis	of	 in	vitro	ubiquitinated	cyclin	B1	reveals	complex	chain	topology.	Nat	Cell	Biol	8:	700-710.	130.	 Hofmann,	R.	M.,	and	C.	M.	Pickart.	2001.	In	vitro	assembly	and	recognition	of	Lys-63	polyubiquitin	chains.	J	Biol	Chem	276:	27936-27943.	131.	 Plans,	V.,	J.	Scheper,	M.	Soler,	N.	Loukili,	Y.	Okano,	and	T.	M.	Thomson.	2006.	The	RING	 finger	 protein	 RNF8	 recruits	 UBC13	 for	 lysine	 63-based	 self	polyubiquitylation.	J	Cell	Biochem	97:	572-582.	132.	 Sims,	 J.	 J.,	and	R.	E.	Cohen.	2009.	Linkage-specific	avidity	defines	 the	 lysine	63-linked	polyubiquitin-binding	preference	of	rap80.	Mol	Cell	33:	775-783.	133.	 Hu,	 Y.,	 R.	 Scully,	 B.	 Sobhian,	 A.	 Xie,	 E.	 Shestakova,	 and	D.	M.	 Livingston.	 2011.	RAP80-directed	 tuning	 of	 BRCA1	 homologous	 recombination	 function	 at	ionizing	radiation-induced	nuclear	foci.	Genes	Dev	25:	685-700.	134.	 Botuyan,	M.	V.,	 J.	Lee,	 I.	M.	Ward,	 J.	E.	Kim,	 J.	R.	Thompson,	 J.	Chen,	and	G.	Mer.	2006.	 Structural	 basis	 for	 the	methylation	 state-specific	 recognition	 of	 histone	H4-K20	by	53BP1	and	Crb2	in	DNA	repair.	Cell	127:	1361-1373.	135.	 Fradet-Turcotte,	A.,	M.	D.	Canny,	C.	Escribano-Diaz,	A.	Orthwein,	C.	C.	Leung,	H.	Huang,	M.	 C.	 Landry,	 J.	 Kitevski-LeBlanc,	 S.	M.	 Noordermeer,	 F.	 Sicheri,	 and	D.	
	 154	
Durocher.	 2013.	 53BP1	 is	 a	 reader	 of	 the	 DNA-damage-induced	 H2A	 Lys	 15	ubiquitin	mark.	Nature	499:	50-54.	136.	 Thorslund,	T.,	A.	Ripplinger,	S.	Hoffmann,	T.	Wild,	M.	Uckelmann,	B.	Villumsen,	T.	Narita,	 T.	 K.	 Sixma,	 C.	 Choudhary,	 S.	 Bekker-Jensen,	 and	 N.	 Mailand.	 2015.	Histone	H1	couples	initiation	and	amplification	of	ubiquitin	signalling	after	DNA	damage.	Nature.	137.	 Wu,	W.,	H.	Nishikawa,	R.	Hayami,	K.	Sato,	A.	Honda,	S.	Aratani,	T.	Nakajima,	M.	Fukuda,	 and	 T.	 Ohta.	 2007.	 BRCA1	 ubiquitinates	 RPB8	 in	 response	 to	 DNA	damage.	Cancer	research	67:	951-958.	138.	 Elia,	A.	E.,	A.	P.	Boardman,	D.	C.	Wang,	E.	L.	Huttlin,	R.	A.	Everley,	N.	Dephoure,	C.	Zhou,	I.	Koren,	S.	P.	Gygi,	and	S.	J.	Elledge.	2015.	Quantitative	Proteomic	Atlas	of	Ubiquitination	and	Acetylation	 in	the	DNA	Damage	Response.	Mol	Cell	59:	867-881.	139.	 Pathania,	S.,	J.	Nguyen,	S.	J.	Hill,	R.	Scully,	G.	O.	Adelmant,	J.	A.	Marto,	J.	Feunteun,	and	D.	M.	 Livingston.	 2011.	 BRCA1	 is	 required	 for	 postreplication	 repair	 after	UV-induced	DNA	damage.	Mol	Cell	44:	235-251.	140.	 Lu,	C.	S.,	L.	N.	Truong,	A.	Aslanian,	L.	Z.	Shi,	Y.	Li,	P.	Y.	Hwang,	K.	H.	Koh,	T.	Hunter,	J.	 R.	 Yates,	 3rd,	M.	W.	 Berns,	 and	 X.	Wu.	 2012.	 The	 RING	 finger	 protein	 RNF8	ubiquitinates	Nbs1	to	promote	DNA	double-strand	break	repair	by	homologous	recombination.	J	Biol	Chem	287:	43984-43994.	141.	 Kim,	W.,	E.	J.	Bennett,	E.	L.	Huttlin,	A.	Guo,	J.	Li,	A.	Possemato,	M.	E.	Sowa,	R.	Rad,	J.	Rush,	M.	J.	Comb,	J.	W.	Harper,	and	S.	P.	Gygi.	2011.	Systematic	and	quantitative	assessment	of	the	ubiquitin-modified	proteome.	Mol	Cell	44:	325-340.	
	 155	
142.	 Wagner,	 S.	 A.,	 P.	 Beli,	 B.	 T.	 Weinert,	 M.	 L.	 Nielsen,	 J.	 Cox,	 M.	 Mann,	 and	 C.	Choudhary.	2011.	A	proteome-wide,	quantitative	survey	of	in	vivo	ubiquitylation	sites	reveals	widespread	regulatory	roles.	Molecular	&	cellular	proteomics	:	MCP	10:	M111	013284.	143.	 Mattiroli,	F.,	 J.	H.	Vissers,	W.	 J.	 van	Dijk,	P.	 Ikpa,	E.	Citterio,	W.	Vermeulen,	 J.	A.	Marteijn,	and	T.	K.	Sixma.	2012.	RNF168	ubiquitinates	K13-15	on	H2A/H2AX	to	drive	DNA	damage	signaling.	Cell	150:	1182-1195.	144.	 Postow,	L.,	C.	Ghenoiu,	E.	M.	Woo,	A.	N.	Krutchinsky,	B.	T.	Chait,	and	H.	Funabiki.	2008.	 Ku80	 removal	 from	 DNA	 through	 double	 strand	 break-induced	ubiquitylation.	J	Cell	Biol	182:	467-479.	145.	 Postow,	L.,	and	H.	Funabiki.	2013.	An	SCF	complex	containing	Fbxl12	mediates	DNA	damage-induced	Ku80	ubiquitylation.	Cell	Cycle	12:	587-595.	146.	 Shi,	W.,	Z.	Ma,	H.	Willers,	K.	Akhtar,	S.	P.	Scott,	 J.	Zhang,	S.	Powell,	and	J.	Zhang.	2008.	 Disassembly	 of	 MDC1	 foci	 is	 controlled	 by	 ubiquitin-proteasome-dependent	degradation.	J	Biol	Chem	283:	31608-31616.	147.	 Liu,	W.,	W.	 Zong,	G.	Wu,	T.	 Fujita,	W.	 Li,	 J.	Wu,	 and	Y.	Wan.	 2010.	Turnover	 of	BRCA1	involves	in	radiation-induced	apoptosis.	PloS	one	5:	e14484.	148.	 Ramadan,	 K.,	 and	 M.	 Meerang.	 2011.	 Degradation-linked	 ubiquitin	 signal	 and	proteasome	 are	 integral	 components	 of	DNA	double	 strand	 break	 repair:	New	perspectives	for	anti-cancer	therapy.	FEBS	Lett	585:	2868-2875.	149.	 Ramadan,	 K.	 2012.	 p97/VCP-	 and	 Lys48-linked	 polyubiquitination	 form	 a	 new	signaling	pathway	in	DNA	damage	response.	Cell	Cycle	11:	1062-1069.	
	 156	
150.	 Baboshina,	 O.	 V.,	 and	 A.	 L.	 Haas.	 1996.	 Novel	 multiubiquitin	 chain	 linkages	catalyzed	by	the	conjugating	enzymes	E2EPF	and	RAD6	are	recognized	by	26	S	proteasome	subunit	5.	J	Biol	Chem	271:	2823-2831.	151.	 Jin,	 L.,	 A.	Williamson,	 S.	 Banerjee,	 I.	 Philipp,	 and	M.	 Rape.	 2008.	Mechanism	of	ubiquitin-chain	formation	by	the	human	anaphase-promoting	complex.	Cell	133:	653-665.	152.	 Garnett,	M.	J.,	J.	Mansfeld,	C.	Godwin,	T.	Matsusaka,	J.	Wu,	P.	Russell,	J.	Pines,	and	A.	 R.	 Venkitaraman.	 2009.	 UBE2S	 elongates	 ubiquitin	 chains	 on	 APC/C	substrates	to	promote	mitotic	exit.	Nat	Cell	Biol	11:	1363-1369.	153.	 Williamson,	A.,	K.	E.	Wickliffe,	B.	G.	Mellone,	L.	Song,	G.	H.	Karpen,	and	M.	Rape.	2009.	 Identification	 of	 a	 physiological	 E2	 module	 for	 the	 human	 anaphase-promoting	complex.	Proc	Natl	Acad	Sci	U	S	A	106:	18213-18218.	154.	 Wu,	T.,	Y.	Merbl,	Y.	Huo,	J.	L.	Gallop,	A.	Tzur,	and	M.	W.	Kirschner.	2010.	UBE2S	drives	 elongation	 of	 K11-linked	 ubiquitin	 chains	 by	 the	 anaphase-promoting	complex.	Proc	Natl	Acad	Sci	U	S	A	107:	1355-1360.	155.	 Wickliffe,	K.	E.,	A.	Williamson,	H.	J.	Meyer,	A.	Kelly,	and	M.	Rape.	2011.	K11-linked	ubiquitin	chains	as	novel	regulators	of	cell	division.	Trends	Cell	Biol	21:	656-663.	156.	 Pines,	 J.	2011.	Cubism	and	the	cell	cycle:	 the	many	 faces	of	 the	APC/C.	Nat	Rev	
Mol	Cell	Biol	12:	427-438.	157.	 Bremm,	A.,	S.	M.	Freund,	and	D.	Komander.	2010.	Lys11-linked	ubiquitin	chains	adopt	 compact	 conformations	 and	 are	 preferentially	 hydrolyzed	 by	 the	deubiquitinase	Cezanne.	Nat	Struct	Mol	Biol	17:	939-947.	
	 157	
158.	 Bremm,	 A.,	 S.	 Moniz,	 J.	 Mader,	 S.	 Rocha,	 and	 D.	 Komander.	 2014.	 Cezanne	(OTUD7B)	 regulates	 HIF-1alpha	 homeostasis	 in	 a	 proteasome-independent	manner.	EMBO	Rep	15:	1268-1277.	159.	 Bennett,	E.	J.,	T.	A.	Shaler,	B.	Woodman,	K.	Y.	Ryu,	T.	S.	Zaitseva,	C.	H.	Becker,	G.	P.	Bates,	 H.	 Schulman,	 and	 R.	 R.	 Kopito.	 2007.	 Global	 changes	 to	 the	 ubiquitin	system	in	Huntington's	disease.	Nature	448:	704-708.	160.	 Shiio,	 Y.,	 and	 R.	 N.	 Eisenman.	 2003.	 Histone	 sumoylation	 is	 associated	 with	transcriptional	repression.	Proc	Natl	Acad	Sci	U	S	A	100:	13225-13230.	161.	 Lim,	K.	 L.,	 K.	 C.	 Chew,	 J.	M.	 Tan,	 C.	Wang,	K.	 K.	 Chung,	 Y.	 Zhang,	 Y.	 Tanaka,	W.	Smith,	S.	Engelender,	C.	A.	Ross,	V.	L.	Dawson,	and	T.	M.	Dawson.	2005.	Parkin	mediates	 nonclassical,	 proteasomal-independent	 ubiquitination	 of	 synphilin-1:	implications	 for	 Lewy	body	 formation.	The	 Journal	of	neuroscience	 :	 the	official	
journal	of	the	Society	for	Neuroscience	25:	2002-2009.	162.	 Jackson,	S.	P.,	 and	D.	Durocher.	2013.	Regulation	of	DNA	damage	 responses	by	ubiquitin	and	SUMO.	Mol	Cell	49:	795-807.	163.	 Wickliffe,	 K.	 E.,	 S.	 Lorenz,	 D.	 E.	 Wemmer,	 J.	 Kuriyan,	 and	 M.	 Rape.	 2011.	 The	mechanism	of	linkage-specific	ubiquitin	chain	elongation	by	a	single-subunit	E2.	
Cell	144:	769-781.	164.	 Peters,	 J.	 M.	 2006.	 The	 anaphase	 promoting	 complex/cyclosome:	 a	 machine	designed	to	destroy.	Nat	Rev	Mol	Cell	Biol	7:	644-656.	165.	 Rape,	 M.	 2010.	 Assembly	 of	 k11-linked	 ubiquitin	 chains	 by	 the	 anaphase-promoting	complex.	Sub-cellular	biochemistry	54:	107-115.	
	 158	
166.	 Zeng,	X.,	F.	Sigoillot,	S.	Gaur,	S.	Choi,	K.	L.	Pfaff,	D.	C.	Oh,	N.	Hathaway,	N.	Dimova,	G.	 D.	 Cuny,	 and	 R.	 W.	 King.	 2010.	 Pharmacologic	 inhibition	 of	 the	 anaphase-promoting	complex	induces	a	spindle	checkpoint-dependent	mitotic	arrest	in	the	absence	of	spindle	damage.	Cancer	Cell	18:	382-395.	167.	 Lorick,	K.	L.,	J.	P.	Jensen,	S.	Fang,	A.	M.	Ong,	S.	Hatakeyama,	and	A.	M.	Weissman.	1999.	 RING	 fingers	 mediate	 ubiquitin-conjugating	 enzyme	 (E2)-dependent	ubiquitination.	Proc	Natl	Acad	Sci	U	S	A	96:	11364-11369.	168.	 Deshaies,	R.	J.,	and	C.	A.	Joazeiro.	2009.	RING	domain	E3	ubiquitin	ligases.	Annual	
review	of	biochemistry	78:	399-434.	169.	 de	Napoles,	M.,	J.	E.	Mermoud,	R.	Wakao,	Y.	A.	Tang,	M.	Endoh,	R.	Appanah,	T.	B.	Nesterova,	 J.	 Silva,	 A.	 P.	 Otte,	 M.	 Vidal,	 H.	 Koseki,	 and	 N.	 Brockdorff.	 2004.	Polycomb	 group	 proteins	 Ring1A/B	 link	 ubiquitylation	 of	 histone	 H2A	 to	heritable	gene	silencing	and	X	inactivation.	Dev	Cell	7:	663-676.	170.	 Fang,	 J.,	T.	Chen,	B.	Chadwick,	E.	 Li,	 and	Y.	Zhang.	2004.	Ring1b-mediated	H2A	ubiquitination	 associates	 with	 inactive	 X	 chromosomes	 and	 is	 involved	 in	initiation	of	X	inactivation.	The	Journal	of	biological	chemistry	279:	52812-52815.	171.	 Wang,	H.,	L.	Wang,	H.	Erdjument-Bromage,	M.	Vidal,	P.	Tempst,	R.	S.	Jones,	and	Y.	Zhang.	2004.	Role	of	histone	H2A	ubiquitination	 in	Polycomb	silencing.	Nature	431:	873-878.	172.	 Zhou,	W.,	P.	Zhu,	 J.	Wang,	G.	Pascual,	K.	A.	Ohgi,	 J.	Lozach,	C.	K.	Glass,	and	M.	G.	Rosenfeld.	 2008.	 Histone	 H2A	 monoubiquitination	 represses	 transcription	 by	inhibiting	RNA	polymerase	II	transcriptional	elongation.	Mol	Cell	29:	69-80.	
	 159	
173.	 Gong,	F.,	L.	Y.	Chiu,	B.	Cox,	F.	Aymard,	T.	Clouaire,	J.	W.	Leung,	M.	Cammarata,	M.	Perez,	 P.	 Agarwal,	 J.	 S.	 Brodbelt,	 G.	 Legube,	 and	 K.	 M.	 Miller.	 2015.	 Screen	identifies	 bromodomain	 protein	 ZMYND8	 in	 chromatin	 recognition	 of	transcription-associated	 DNA	 damage	 that	 promotes	 homologous	recombination.	Genes	Dev	29:	197-211.	174.	 Palancade,	B.,	and	O.	Bensaude.	2003.	Investigating	RNA	polymerase	II	carboxyl-terminal	 domain	 (CTD)	 phosphorylation.	 European	 journal	 of	 biochemistry	 /	
FEBS	270:	3859-3870.	175.	 Phatnani,	H.	P.,	and	A.	L.	Greenleaf.	2006.	Phosphorylation	and	functions	of	 the	RNA	polymerase	II	CTD.	Genes	Dev	20:	2922-2936.	176.	 Hsin,	 J.	 P.,	 and	 J.	 L.	 Manley.	 2012.	 The	 RNA	 polymerase	 II	 CTD	 coordinates	transcription	and	RNA	processing.	Genes	Dev	26:	2119-2137.	177.	 Komarnitsky,	 P.,	 E.	 J.	 Cho,	 and	 S.	 Buratowski.	 2000.	 Different	 phosphorylated	forms	 of	 RNA	 polymerase	 II	 and	 associated	 mRNA	 processing	 factors	 during	transcription.	Genes	Dev	14:	2452-2460.	178.	 Williamson,	A.,	S.	Banerjee,	X.	Zhu,	I.	Philipp,	A.	T.	Iavarone,	and	M.	Rape.	2011.	Regulation	 of	 ubiquitin	 chain	 initiation	 to	 control	 the	 timing	 of	 substrate	degradation.	Mol	Cell	42:	744-757.	179.	 Pankotai,	 T.,	 C.	 Bonhomme,	 D.	 Chen,	 and	 E.	 Soutoglou.	 2012.	 DNAPKcs-dependent	 arrest	 of	 RNA	 polymerase	 II	 transcription	 in	 the	 presence	 of	 DNA	breaks.	Nat	Struct	Mol	Biol	19:	276-282.	180.	 Weake,	V.	M.,	and	 J.	L.	Workman.	2008.	Histone	ubiquitination:	 triggering	gene	activity.	Mol	Cell	29:	653-663.	
	 160	
181.	 Iwai,	 K.	 2012.	 Diverse	 ubiquitin	 signaling	 in	NF-kappaB	 activation.	Trends	Cell	
Biol	22:	355-364.	182.	 Dynek,	 J.	N.,	T.	Goncharov,	E.	C.	Dueber,	A.	V.	Fedorova,	A.	 Izrael-Tomasevic,	L.	Phu,	E.	Helgason,	W.	 J.	Fairbrother,	K.	Deshayes,	D.	S.	Kirkpatrick,	and	D.	Vucic.	2010.	c-IAP1	and	UbcH5	promote	K11-linked	polyubiquitination	of	RIP1	in	TNF	signalling.	EMBO	J	29:	4198-4209.	183.	 Bremm,	 A.,	 and	 D.	 Komander.	 2011.	 Emerging	 roles	 for	 Lys11-linked	polyubiquitin	in	cellular	regulation.	Trends	Biochem	Sci	36:	355-363.	184.	 Matsumoto,	M.	L.,	K.	E.	Wickliffe,	K.	C.	Dong,	C.	Yu,	I.	Bosanac,	D.	Bustos,	L.	Phu,	D.	S.	Kirkpatrick,	S.	G.	Hymowitz,	M.	Rape,	R.	F.	Kelley,	and	V.	M.	Dixit.	2010.	K11-linked	polyubiquitination	in	cell	cycle	control	revealed	by	a	K11	linkage-specific	antibody.	Mol	Cell	39:	477-484.	185.	 Castaneda,	 C.	 A.,	 T.	 R.	 Kashyap,	 M.	 A.	 Nakasone,	 S.	 Krueger,	 and	 D.	 Fushman.	2013.	 Unique	 structural,	 dynamical,	 and	 functional	 properties	 of	 k11-linked	polyubiquitin	chains.	Structure	21:	1168-1181.	186.	 Aymard,	F.,	B.	Bugler,	C.	K.	Schmidt,	E.	Guillou,	P.	Caron,	S.	Briois,	J.	S.	Iacovoni,	V.	Daburon,	K.	M.	Miller,	S.	P.	Jackson,	and	G.	Legube.	2014.	Transcriptionally	active	chromatin	 recruits	 homologous	 recombination	 at	 DNA	 double-strand	 breaks.	
Nat	Struct	Mol	Biol	21:	366-374.	187.	 Kornberg,	R.	D.	1977.	Structure	of	chromatin.	Annual	review	of	biochemistry	46:	931-954.	
	 161	
188.	 Luger,	K.,	A.	W.	Mader,	R.	K.	Richmond,	D.	F.	Sargent,	and	T.	 J.	Richmond.	1997.	Crystal	structure	of	the	nucleosome	core	particle	at	2.8	A	resolution.	Nature	389:	251-260.	189.	 Tremethick,	D.	J.	2007.	Higher-order	structures	of	chromatin:	the	elusive	30	nm	fiber.	Cell	128:	651-654.	190.	 Luger,	 K.,	 M.	 L.	 Dechassa,	 and	 D.	 J.	 Tremethick.	 2012.	 New	 insights	 into	nucleosome	 and	 chromatin	 structure:	 an	 ordered	 state	 or	 a	 disordered	 affair?	
Nat	Rev	Mol	Cell	Biol	13:	436-447.	191.	 Kulis,	M.,	and	M.	Esteller.	2010.	DNA	methylation	and	cancer.	Adv	Genet	70:	27-56.	192.	 Kouzarides,	T.	2007.	Chromatin	modifications	and	their	function.	Cell	128:	693-705.	193.	 Clapier,	 C.	 R.,	 and	 B.	 R.	 Cairns.	 2009.	 The	 biology	 of	 chromatin	 remodeling	complexes.	Annual	review	of	biochemistry	78:	273-304.	194.	 Olsen,	 C.	 A.	 2012.	 Expansion	 of	 the	 lysine	 acylation	 landscape.	 Angewandte	
Chemie	51:	3755-3756.	195.	 van	Attikum,	H.,	and	S.	M.	Gasser.	2009.	Crosstalk	between	histone	modifications	during	the	DNA	damage	response.	Trends	Cell	Biol	19:	207-217.	196.	 Zhao,	 Y.,	 J.	 R.	 Brickner,	 M.	 C.	 Majid,	 and	 N.	 Mosammaparast.	 2014.	 Crosstalk	between	 ubiquitin	 and	 other	 post-translational	 modifications	 on	 chromatin	during	double-strand	break	repair.	Trends	Cell	Biol	24:	426-434.	197.	 Vogelstein,	B.,	N.	Papadopoulos,	V.	E.	Velculescu,	S.	Zhou,	L.	A.	Diaz,	Jr.,	and	K.	W.	Kinzler.	2013.	Cancer	genome	landscapes.	Science	339:	1546-1558.	
	 162	
198.	 Pearl,	 L.	 H.,	 A.	 C.	 Schierz,	 S.	 E.	 Ward,	 B.	 Al-Lazikani,	 and	 F.	 M.	 Pearl.	 2015.	Therapeutic	opportunities	within	the	DNA	damage	response.	Nat	Rev	Cancer	15:	166-180.	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 163	
VITA 
 
Atanu Paul was born in Kanchrapara in the state of West Bengal, India. He was born 
on 23rd July 1983 to Mr. Bimal Kanti Paul and Mrs. Banani Paul. After completing 
high school at Kanchrapara Harnett High School in Kanchrapara, Atanu, continued 
his college education at West Bengal University of Animal & Fishery Sciences, 
Kolkata, India from 2002-2007. Following his undergraduate training, Atanu moved 
to the United States to pursue Master’s of Science majoring in Biology at the 
University of Texas at El Paso (UTEP). At UTEP, Atanu completed his Master’s 
dissertation project entitled “ A specific regulatory role for SGTα on the maturation 
and activation of steroid hormone receptors” under the supervision of Dr. Marc B. 
Cox. Following his graduation from UTEP, Atanu joined the PhD program at the 
Graduate School of Biomedical Sciences, a joint venture of The University of Texas 
Health Science Center at Houston and The University of Texas MD Anderson 
Cancer Center, Houston in August 2010. Atanu joined the lab of Dr. Bin Wang in the 
Department of Genetics in the Genes & Development graduate program to pursue 
his PhD dissertation. Atanu’s PhD project focuses on examining the role of post-
translational modifications in the DNA damage response pathway.  
 
Permanent Address:  
9, Abdul Jabbar Road, Kanchrapara  
North 24 Pgs, West Bengal, India, 743145  
